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Expert Center for Chronic Fatigue
The studies reported in this thesis are carried out at the Expert Center for Chronic 
Fatigue (ECCF) in the Netherlands. Until December 2016, the ECCF was affiliated 
with the Radboud university medical center (Radboudumc) in Nijmegen. Since 
January 2017, the ECCF is affiliated with the VU University Medical Center (VUmc) 
and the Academic Medical Center (AMC) in Amsterdam. The ECCF originally focused 
on studying chronic fatigue syndrome and successfully developed and tested a 
cognitive-behavioural intervention for patients with chronic fatigue syndrome [1-7]. 
The first studies on cancer-related fatigue (CRF) at the ECCF have been performed in 
1996 in collaboration with the Department of Medical Oncology at the Radboudumc. 
There are various definitions of CRF, but the most frequently used definition is the 
one formulated by the National Comprehensive Cancer Network, which defines 
fatigue as “a distressing, persistent, subjective sense of physical, emotional, and/
or cognitive tiredness or exhaustion related to cancer or cancer treatment that is 
not proportional to recent activity and interferes with usual functioning” [8]. CRF is 
a frequent, almost universal symptom in patients with cancer, yet it is a problem 
that is highly underreported, underrecognized and also undertreated [9-11]. Over the 
past 20 years, the ECCF performed several studies on the prevalence, impact, and 
treatment of CRF in different cancer populations that will be described below. 
Fatigue after cancer treatment with curative intent
The initial CRF studies at the ECCF dealt with the presence and course of CRF in 
disease-free cancer patients and demonstrated that fatigue is a serious and persistent 
problem for at least a quarter of these cancer survivors [12]. Several psychological and 
behavioural factors were associated with the persistence of fatigue complaints in a 
longitudinal study [12]. These findings have led to the development of an explanatory 
model, in which precipitating and perpetuating factors of CRF in disease-free cancer 
survivors were distinguished. The precipitating factors include cancer and its treatment 
and serve as triggers for fatigue. Upon completion of cancer treatment, however, 
other factors are responsible for the persistence of fatigue. These perpetuating 
factors include inappropriate coping skills, fear of cancer recurrence, dysfunctional 
fatigue-related cognitions, deregulated sleep-wake patterns, deregulated activity 
patterns, low social support and negative interactions. Based on this explanatory 
model, a cognitive-behavioural intervention for CRF in disease-free cancer survivors 
was developed and tested in comparison with usual care in a randomised controlled 
trial (RCT) [13]. The intervention proved to be effective in reducing CRF and functional 
impairments and positive intervention effects were sustained up to two-years follow 
up [14]. However, treatment capacity is limited, as delivery of this clinic-based 
intervention requires a significant amount of therapist time. To extend treatment 
options, a web-based version of this intervention requiring less therapist time has been 
developed recently [15]. Efficacy of this web-based intervention has been evaluated 
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in an RCT with 132 severely fatigued breast cancer survivors and the findings have 
been submitted for publication [Abrahams et al., submitted for publication].
Fatigue during adjuvant cancer treatment
Given the positive effects of cognitive behaviour therapy (CBT) for severely fatigued 
disease-free cancer survivors, the subsequent studies by the ECCF aimed to prevent 
the development of long-term CRF by addressing fatigue during or shortly after 
adjuvant cancer treatment. A three-armed RCT was designed to examine the effects 
of CBT and a brief nurse-led intervention focusing on physical activity in comparison 
with usual care. CBT appeared to be effective, the nurse led intervention not [16]. At 
one-year follow up, the positive intervention effect of CBT for fatigue was no longer 
observed [17]. However, it is important to note that participants in this study were not 
selected on the presence of severe fatigue. Thus, the non-significant findings at long-
term follow up might be due to a floor effect. The study authors implied that CBT for 
fatigue should be offered to patients selected on the presence of severe fatigue, who 
have a higher chance to benefit from the intervention. In addition to selecting those 
patients most in need, it seems important to develop interventions that specifically 
target fatigue as these were more effective in reducing fatigue in adult cancer patients 
compared to interventions with a more general approach [18]. 
Fatigue during cancer treatment with palliative intent
The next step in CRF research at the ECCF was to study patients with advanced 
or metastatic cancer receiving cancer treatment with palliative intent. Recently 
conducted studies by the ECCF investigated the prevalence of CRF in these patients 
and reported that almost half of the patients (47%) scored above the threshold for 
severe fatigue [19]. Furthermore, the number of severely fatigued patients increased 
further along the treatment trajectory, with those receiving further lines of systemic 
treatment more frequently experiencing severe fatigue compared to patients on first-
line treatment. A longitudinal study revealed that fatigue levels remained relatively 
stable over 6 months’ time [20]. Lastly, the perpetuating factors from the explanatory 
model of CRF in disease-free cancer survivors were evaluated in the sample of 
patients with incurable cancer. All factors were correlated with fatigue severity [21]. In 
addition, a low level of self-reported physical activity and difficulties in accepting the 
incurable nature of the disease at baseline were predictors of fatigue over time [20].
Fatigue in understudied populations in psychosocial oncology
Fortunately, CRF has received more attention in both research and clinical practice 
in recent years. Yet, the majority of studies on CRF have been performed in patients 
with common cancer types, such as breast cancer, lung cancer, colon cancer, or 
prostate cancer and in cancer survivors or patients undergoing cancer treatment with 
curative intent [22-24]. Comparatively fewer studies have been conducted in samples 
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of patients with a rare cancer diagnosis or patients undergoing cancer treatment 
with palliative intent. Despite increased awareness for CRF, these populations remain 
understudied.
PART I: FATIGUE IN PATIENTS WITH RARE CANCER
Information on the prevalence, impact and correlates of CRF in patients with rare 
cancers is scarce. As background, a cancer is considered to be rare if the incidence is 
less than 6 per 100,000 persons diagnosed with it each year (http://www.rarecare.eu/). 
Despite the rarity of each of the 186 rare cancers, they represent in total about 22% 
of all annual cancer cases in Europe [25]. The first part of this thesis is concerned with 
studying CRF in three different groups of patients with rare cancers: cancers occurring 
in the adolescent and young adult population, gastrointestinal stromal tumors, and 
chronic myeloid leukemia.
Adolescent and young adult cancer 
In the Netherlands, every year approximately 2700 patients are diagnosed with cancer 
between the age of 18 and 35 years. The discipline of adolescent and young adult (AYA) 
oncology is an evolving field that has begun to be defined only since the beginning 
of the new millennium. Historically, these patients, positioned at the intersection of 
paediatric and adult oncology, have not been recognized as a distinct patient group. 
As a result, AYA cancer patients often fall through the cracks of the traditional health 
care system and supportive care services. AYA cancer care is characterized by a 
distinct biology of cancers occurring at this age, differences in treatment response 
from those of other age groups, and the presence of key developmental milestones. 
Examples of these developmental milestones include completing education, finding 
first or pursuing employment, and starting a family [26]. Several studies have reported 
higher levels of distress and worse quality of life in AYA cancer patients compared to 
healthy matched peers or older adult cancer patients [27-29]. Despite the fact that 
overall survival for AYAs continues to lag behind that of children or older adults [30], 
advances in early detection and improvements in cancer treatments have resulted in 
an overall 5-year survival rate exceeding 80% [31]. With the expected further gains in 
overall survival of AYA cancer, persistent disease- and treatment-related symptoms 
that may compromise quality of life warrant early and adequate attention. In 2009, the 
Department of Medical Oncology at Radboudumc launched the first AYA outpatient 
clinic in the Netherlands in collaboration with the Department of Medical Psychology. 
The multidisciplinary team at the AYA clinic is available to all young adults who have 
(or had) cancer, regardless of their treatment status, type and intent of treatment. One 
of the issues experienced by young adults with cancer consulting the AYA outpatient 
clinic is CRF. It is believed that the impact of CRF might be even more pronounced 
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for AYA cancer patients compared to adult patients because it can interrupt with 
several developmental milestones. The prevalence, impact on quality of life, and 
associated factors of severe fatigue in patients with a diagnosis of cancer during 
young adulthood will be studied in the first part of this thesis.
Gastrointestinal stromal tumors
Gastrointestinal stromal tumors (GISTs) represent an extremely rare solid tumor 
with an estimated incidence rate of 250 to 300 cases per year in the Netherlands. 
Following the introduction of imatinib in 2001, a targeted therapy initially designed 
to treat chronic myeloid leukemia [32, 33], the perspective of metastatic GIST 
patients has changed significantly. Based on SEER data, cancer-specific survival of 
metastatic GIST increased from 15.0% (95% CI: 5.3 to 42.6%) in 1998 to 61.9% (95% 
CI: 51.4 to 74.5%) in 2008 (all PTrend < 0.05) [34].  Imatinib is taken orally on a daily 
basis and is generally well tolerated in comparison with traditional chemotherapy. 
However, fatigue is the most common, important and often complained of side effect 
experienced with the use of this drug and other tyrosine kinase inhibitors (TKIs). With 
the dramatically improved survival of patients with GISTs, management of TKI-related 
side effects as well as the impact of side effects on quality of life necessitates more 
attention. In the first part of this thesis, the prevalence, impact and associated factors 
of severe fatigue in a real-life and heterogeneous sample of GIST patients during and 
after TKI treatment will be studied.
Chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a type of cancer that starts in certain blood-
forming cells of the bone marrow. Every year, about 500 patients are diagnosed with 
CML in the Netherlands. It is a fairly slow growing leukemia, but it can change into a 
fast-growing acute leukemia that is hard to treat. A stem cell transplantation including 
high-dose chemotherapy and radiotherapy is the only potential cure for CML. 
However, with the introduction of imatinib and other TKIs it is now often possible 
to control CML for many years in such a way that the life expectancy of patients 
with CML approaches the life expectancy of the general population today [35]. With 
this improved survival and the need to continue lifelong treatment it is important 
to manage the side effects of these lifesaving drugs. Research demonstrated that 
chronic fatigue is the most important factor limiting quality of life in imatinib-treated 
CML patients [36]. Although cognitive-behavioural interventions are recommended 
to treat fatigue in cancer survivors in guidelines issued by the American Society 
of Clinical Oncology [37], efficacy of these interventions has not been examined in 
patients continuing lifelong treatment, such as patients with CML. CBT for CRF has 
been developed for and tested in disease-free cancer survivors that completed cancer 
treatment and where only perpetuating factors play a role. In CML patients who are 
chronically treated with TKIs, although stable with good prognosis, both precipitating 
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and perpetuating factors will contribute to perceived fatigue. Management of fatigue 
in patients receiving chronic treatment with TKIs to control their disease might require 
a slightly different approach or at least some tailoring to their specific situation and 
needs. The possibility to adapt an existing evidence-based CBT for CRF in disease-
free cancer survivors [13] for application in patients with CML experiencing CRF as a 
lifesaving drug’s side effect was investigated in the first part of this thesis. 
PART II: FATIGUE IN PATIENTS WITH INCURABLE DISEASE
Patients with a diagnosis of advanced or metastatic cancer are often overlooked 
and underrepresented in the area of CRF and the broader psychosocial oncology 
discussion. Yet, their experiences are commonly different from those with early-stage 
disease as they are, despite advances in treatment, diagnosed with a disease that 
remains essentially incurable. Advances in cancer treatment mean that patients with 
incurable cancer are living longer with a disease that can be controlled for months 
or even years. These patients must live with the prospects of inevitable progressive 
loss of condition, development of symptomatic disease and in the very end entering 
the terminal stage before death. This changes the outlook on life, as patients often 
point out themselves, it is not only the quantity but also the quality that is important. 
Consequently, next to prolonging patients’ lives, treatment of incurable cancer 
is also aimed at maintaining as high a quality of life for as long as possible and 
managing physical and psychological symptoms [38]. The second part of this thesis 
is concerned with studying CRF in incurable cancer patients. It involves a study on 
dyadic agreement between patients and informal or family caregivers on patients’ 
fatigue severity, the examination of effects of psychosocial interventions for severe 
fatigue in incurable cancer patients, followed by the development of a study protocol 
for an ongoing three-armed RCT along with considering the barriers and challenges 
associated with running this trial, including professional gatekeeping.
Fatigue during cancer treatment with palliative intent
CRF is frequently reported as one of the symptoms that significantly compromises 
quality of life in patients with incurable cancer. CRF prevents participation in preferred 
activities, hinders activities of daily living, and is often associated with emotional 
disturbances. As such, CRF affects not only patients but also their informal or family 
caregivers [39, 40]. It is generally agreed that patients are the best raters of their 
fatigue severity. However, it is also important to understand caregivers’ perceptions 
of patients’ fatigue severity during cancer treatment with palliative intent. Caregivers’ 
perceptions drive responses to patients’ fatigue, which in turn can have an impact 
on patients. In addition, since caregivers are increasingly involved in the care for 
patients with incurable cancer and the monitoring and management of treatment-
15
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related symptoms, it is important to know whether they can give a meaningful 
additional rating of patients’ fatigue severity. The accuracy of caregiver ratings and 
the agreement over time along with predictors for agreement are examined in the 
second part of this thesis.
Approaches for the management of CRF
Given the profound impact of CRF on patients’ quality of life, it is surprising to note 
that, at present, there are no evidence-based interventions for CRF available for 
patients with incurable disease. Many factors are likely to contribute to CRF in patients 
with incurable cancer. CRF may result from the underlying disease or from secondary 
factors such as anemia, infection, malnutrition or dehydration, loss of muscle mass, 
pain, sleep disturbances, and treatment-related side effects. Furthermore, emotional 
distress including anxiety and depression, and cognitive or behavioural factors 
such as inappropriate coping or a low level of physical activity can also add to 
CRF [20, 21]. Management of CRF should first focus on identifying treatable 
somatic causes. However, clinical experience with fatigued patients indicates that a 
treatable somatic cause cannot always be found. Based on findings from previous 
studies in other cancer populations, two non-pharmacological approaches for CRF 
seem promising in the management of CRF in incurable cancer patients. The first 
approach is concerned with optimising levels of physical activity through exercise 
therapy, which can be helpful in reducing CRF by improving physical capacity [41]. 
The second approach comprises psychosocial interventions for CRF, aimed at 
changing fatigue-related thoughts, emotions and behaviours [18]. The second part of 
this thesis includes a systematic review and meta-analysis of completed psychosocial 
interventional studies for the management of CRF in the subgroup of participants 
receiving treatment for incurable cancer.
The TIRED study: a randomised controlled trial
The efficacy of exercise or psychosocial interventions in reducing fatigue has not 
yet been examined in a large and homogeneous sample of patients with incurable 
cancer receiving treatment with palliative intent. Moreover, the role of the assumed 
mechanisms of change for these interventions, that is, a change in physical condition 
versus a change in fatigue-related cognitions, remains to be determined. We will 
describe the development of a study protocol for a three-armed RCT aimed to address 
CRF in patients receiving treatment for incurable cancer by either exercise therapy 
or CBT compared to usual care (TIRED study). Following previous experiences with 
CRF intervention research, we aimed to select only those patients most in need 
for a fatigue intervention for the TIRED study [18]. Therefore, potential participants 
were screened on the presence of severe fatigue by means of administering a multi-
dimensional fatigue questionnaire with a validated cut-off for severe fatigue. Patient 
identification and recruitment for the TIRED study started in January 2013 and proved 
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to be extremely challenging from the beginning. One well-known and persistent 
problem in palliative care research is gatekeeping by healthcare professionals, 
which can be described as professionals preventing potentially eligible patients from 
entering a supportive care trial as a participant. Gatekeeping by professionals was 
also observed in the TIRED study and jeopardized successful patient identification 
and recruitment. We will investigate whether gatekeeping is justified from a patient’s 
point of view. After a recruitment period of more than four years, we reached only 80% 
of our required sample size and thus enrolment of participants for the TIRED study is 
still ongoing. Results on the efficacy of the interventions and potential mechanisms 
of change are not expected until 2018 and will, therefore, be reported elsewhere. 
Lessons learned from conducting the TIRED study will be shared. These valuable 
insights will hopefully serve other investigators interested in performing intervention 
research for this important but complex patient population.
AIMS OF THE THESIS
The overall purpose of this thesis is to further develop existing knowledge on CRF 
and its management in understudied cancer populations in psychosocial oncology. 
The studies reported in this thesis are aimed to gain insight into the prevalence, 
impact and associated factors of CRF in patients with a rare cancer diagnosis, to 
test whether existing evidence-based interventions for CRF can be adapted for new 
target populations, to determine whether informal caregivers are able to provide an 
accurate additional rating of patients’ fatigue severity during cancer treatment with 
palliative intent, and to examine the current evidence on the effects of psychosocial 
interventions for fatigue in patients with incurable cancer, as well as to describe the 
development and conduct of an ongoing large-scale interventional study examining 
the effects of an exercise and psychosocial intervention for severe fatigue in patients 
with incurable cancer. 
OUTLINE OF THE THESIS
This thesis consists of ten chapters divided into two parts. The first part of this thesis 
is focused on fatigue in patients primarily characterized by a diagnosis of a rare cancer 
or with a cancer diagnosis at an uncommon age. The cross-sectional study described 
in Chapter 2 investigated the prevalence of severe CRF in patients diagnosed with 
cancer during adolescence and young adulthood compared with matched population-
based controls. This chapter also reports on the impact of severe fatigue on the 
quality of life of AYA cancer patients. In addition, correlates of fatigue severity were 
studied. Chapter 3 reports on the prevalence and impact of severe fatigue in patients 
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with GIST, a rare type of sarcoma. The introduction of TKIs has revolutionized the 
treatment of GIST. However, the use of TKIs is limited by the occurrence of different 
side effects, such as fatigue. In this chapter, several psychosocial, disease- and 
treatment-related factors were studied as potential correlates of fatigue severity in 
GIST patients during and after TKI treatment. Based on previous studies performed 
at the ECCF, Chapter 4 describes the adaptation of an evidence-based intervention 
for severe fatigue in disease-free cancer patients to address fatigue in CML patients 
receiving long-term TKI therapy. In this study, it was investigated whether the existing 
intervention could be successfully adapted for application in a new target population. 
The second part of this thesis is focused on fatigue in patients all diagnosed with 
incurable cancer. The longitudinal study presented in Chapter 5 evaluates agreement 
between incurable cancer patients and their informal caregivers about patients’ 
fatigue severity during cancer treatment with palliative intent. In addition, agreement 
over time and predictors of agreement are examined. To get a better understanding of 
the effects of psychosocial interventions on fatigue in patients with incurable cancer, 
Chapter 6 includes a systematic review and meta-analysis of available data from 
completed trials with patients during cancer treatment with palliative intent. Building 
on an established patient need and the results of Chapter 6, the design and rationale of 
a still ongoing RCT focused on addressing fatigue in incurable cancer patients (TIRED 
study) is described in Chapter 7. Chapter 8 reports on whether gatekeeping by health 
care professionals, a major barrier in patient recruitment for palliative supportive care 
trials, is justified. To facilitate future RCTs testing a supportive care intervention in 
advanced cancer patients, Chapter 9 captures valuable lessons learned from patient 
identification and recruitment for the TIRED study and shares strategies to overcome 
barriers and challenges that were encountered. Finally, Chapter 10 entails a summary 
and discussion in which practical implications of the findings presented in this thesis 
are discussed and recommendations for future research are formulated.
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ABSTRACT
Background
The current study determined the prevalence of severe fatigue in Adolescent and 
Young Adult (AYA) cancer patients (aged 18-35 years at diagnosis) consulting a 
multidisciplinary AYA team in comparison with gender- and age-matched population-
based controls. In addition, impact of severe fatigue on quality of life and related 
factors of fatigue severity were examined. 
Methods
AYAs with cancer (n=83) completed questionnaires including the Checklist Individual 
Strength (CIS-fatigue), Quality of Life (QoL)-Cancer Survivor, Hospital Anxiety and 
Depression Scale (reflecting psychological distress), and the Cancer Worry Scale 
(reflecting fear of cancer recurrence or progression). 
Results
The vast majority of participants had been treated with chemotherapy (87%) and 
had no active treatment at the time of participation (73.5%). Prevalence of severe 
fatigue (CIS-fatigue score ≥ 35) in AYAs with cancer (48%, n=40/83) was significantly 
higher in comparison with matched population-based controls (20%, n=49/249; p 
< .001). Severely fatigued AYAs with cancer reported lower QoL compared to non-
severely fatigued AYAs with cancer (p’s < .05). Female gender, being unemployed, 
higher disease stage (III-IV) at diagnosis, receiving active treatment at the time of 
participation, being treated with palliative intent, having had radiotherapy, higher fear 
of recurrence or progression, and higher psychological distress were significantly 
correlated with fatigue severity (p’s < .05). 
Conclusion
Severe fatigue based on a validated cut-off score was highly prevalent in this group 
of AYAs with cancer. QoL is significantly affected by severe fatigue, stressing the 
importance of detection and management of this symptom in those patients affected 
by a life-changing diagnosis of cancer in late adolescence or young adulthood.
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INTRODUCTION
Compared to adults, a diagnosis of cancer in adolescents and young adults (AYAs) 
between the ages of 18 and 35 years is rare. Advances in early detection and 
improvements in cancer treatments have resulted in an overall 5-year survival rate 
exceeding 80% in AYAs [1]. While AYAs with cancer face challenges similar to adult 
cancer patients, those in the heart of their youth experience unique cancer-related 
challenges in addition to usual age-related developmental tasks. The combination 
of achieving normal developmental milestones and simultaneously coping with a 
life-changing diagnosis of cancer frequently leads to psychosocial issues among 
AYAs with cancer [2]. Several studies have documented higher levels of distress and 
lower quality of life (QoL) in AYAs with cancer in comparison with healthy matched 
peers or adult cancer patients [3-5]. Moreover, treatment-related symptoms (e.g. pain 
and fatigue) and late effects (e.g. second cancers and cardiovascular disease) can 
interfere with a healthy body image, establishing social relationships, or attaining 
levels of autonomy and independence. With the expected further gains in overall 
survival of AYA cancer, it is important to address persistent disease- and treatment-
related symptoms that compromise several domains of QoL.
Cancer-related fatigue (CRF) is one of the most common and distressing symptoms 
reported by adult and childhood cancer patients both during and after cancer 
treatment [6, 7]. The most commonly used definition for CRF is formulated by the 
National Comprehensive Cancer Network (NCCN) and defines CRF as “a distressing, 
persistent, subjective sense of physical, emotional, and/or cognitive tiredness or 
exhaustion related to cancer or cancer treatment that is not proportional to recent 
activity that interferes with usual functioning” [8]. The vast majority of studies on the 
prevalence and severity of CRF have been conducted in adult or childhood cancer 
patients and only a few studies evaluated fatigue severity in AYAs with cancer. 
Moreover, the limited AYA-specific studies did not attempt to report on clinically 
relevant levels of fatigue by using a validated cut-off for severe fatigue [4, 9]. 
Knowledge on the prevalence of severe fatigue in AYAs with cancer is important, 
as we know from studies in adult cancer patients that severe fatigue is associated 
with more functional impairments, lower QoL, and more distress [6, 10]. For AYAs 
with cancer, the impact of severe fatigue might be even more pronounced because 
it can interrupt developmental milestones such as completing education, finding 
first or pursuing employment, beginning a romantic relationship, or starting a family. 
Understanding factors related to severe fatigue among AYAs with cancer will help 
health care providers identify who is more likely to experience this symptom. In 
addition, it will help researchers to determine potential factors that could be addressed 
in interventions targeting fatigue. 
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The present study determined the prevalence of clinically relevant levels of fatigue 
in AYAs with cancer using a validated cut-off for severe fatigue and compared the 
proportion of severely fatigued cases with the proportion of severely fatigued cases 
in a sample of gender- and age-matched population-based controls. In addition, the 
impact of severe fatigue on QoL and potential sociodemographic, treatment-related, 
and psychological correlates of fatigue severity was explored. A cross-sectional 
approach was used for this study to gather descriptive information about the presence 
of clinically relevant levels of fatigue among AYAs with cancer. 
MATERIALS AND METHODS
Patients
Patients aged 18-35 years at cancer diagnosis and who had been seen by at least 
one of the members of the AYA team of the Radboud university medical center, 
Nijmegen, The Netherlands, were invited to participate in this study. The AYA team 
is a dedicated multidisciplinary team including a medical oncologist, clinical nurse 
specialist, medical psychologist, and social worker. Patients consulting the AYA team 
receive regular medical care from their own treating specialist (oncologist, surgeon, 
haematologist, dermatologist, urologist, gynaecologist, etc.) and visit the AYA team 
for age-specific questions and care needs. In general, patients visiting the AYA team 
represent a group of patients with higher disease severity, diagnosed with relatively 
advanced stage of disease and undergoing intensive treatments, and reporting more 
problems with coping. The AYA team does not often see patients with low stage 
disease treated solely by surgery, such as in the case of thin melanomas. 
To depict the real-life heterogeneous sample of AYAs with cancer visiting the AYA 
team, AYAs with cancer were included in this first study on the prevalence of severe 
fatigue regardless of treatment status (during or after treatment), type of treatment 
(surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, hormonal 
therapy or combination), or the number of AYA team visits (some patients only had 
one introduction talk with one of the members of the team and did not receive specific 
care thereafter). Inclusion commenced January 2012 and ended March 2016.
Population-based controls
Population-based controls were derived from a cohort of panel members surveyed by 
CentERdata, a research institute at Tilburg University collecting data from a sample of 
more than 2000 Dutch households (http://www.centerdata.nl/en/). This CentERpanel 
represents the adult Dutch-speaking population with respect to demographic 
characteristics. Population-based controls provided self-reported data on age and 
gender and completed a multi-dimensional fatigue questionnaire (Checklist Individual 
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Strength, see measures). They had no sickness absence in the workplace (0 days) in 
the month prior to filling in the questionnaires. Further information on the presence of 
physical or mental health conditions in population-based controls was not available.
Procedure
Potential study participants were recruited via letters describing the study and inviting 
patients to participate in the study. Patients willing to participate had to actively opt-
in to the study by providing written informed consent by email to a member of the AYA 
team. Participants were then sent a single set of questionnaires by email that could 
be completed online. The study was deemed exempt from full review and approval by 
a research ethics committee (CMO Regio Arnhem-Nijmegen, 2016-2872).
Measures
AYAs with cancer completed a self-report questionnaire on sociodemographic data 
(i.e., age, gender, partner status, having children, education level, and employment 
status). A member of the AYA team (SK) extracted clinical data (i.e., cancer diagnosis, 
disease stage at diagnosis, time since initial cancer diagnosis, type(s) of treatment(s) 
received, duration of cancer treatment, treatment status at participation, and time 
since completion of cancer treatment) from patients’ medical records. AYAs with 
cancer completed the following questionnaires, including a multi-dimensional fatigue 
questionnaire:
Checklist Individual Strength, subscale fatigue severity (CIS-fatigue). The subscale 
fatigue severity of the CIS consists of eight items scored on a 7-point Likert scale. 
Total CIS-fatigue scores can range from 8 to 56, with scores greater than 34 indicating 
clinically relevant levels of fatigue [11]. The CIS-fatigue has been used in previous 
studies examining severe fatigue in cancer patients during and after cancer treatment 
[12-14]. A cut-off was used to group AYAs with cancer into two groups to indicate 
severely fatigued (≥ 35) and non-severely fatigued patients (< 35). 
Quality of Life-Cancer Survivor (QoL-CS). The QoL-CS consists of 41 items scored 
on a 10-point Likert scale and was used as a cancer-specific measure of QoL [15]. 
The impact of cancer diagnosis and treatment is assessed with four subscales, 
i.e., physical, social, psychological, and spiritual wellbeing. In addition to the four 
subscale scores, the total QoL score reflecting the average across all items was used 
in this study. Higher scores indicated better QoL for all subscales. 
Hospital Anxiety and Depression Scale (HADS). The HADS consists of 14 items scored 
on a 4-point Likert scale [16]. The summed total HADS scores range from 0 to 42, and 
were used to reflect psychological distress in our sample of AYAs with cancer [17]. 
Higher total scores indicate more psychological distress.
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Cancer Worry Scale (CWS). The CWS consists of eight items regarding concerns 
about cancer recurrence or progression of cancer. Items are scored on a 4-point 
Likert scale ranging from ‘never’ to ‘almost always’ [18]. Total CWS scores range from 
8 to 32, and can be used to assess cancer worrying. Higher total scores indicate more 
fear of cancer recurrence or progression. Patients with a recent recurrence (n=5) or 
receiving treatment with palliative intent (n=7) did not complete the CWS because the 
item wording of this measure was irrelevant to them.
Statistical Analyses
To compare mean fatigue severity and the prevalence of severe fatigue in AYAs 
with cancer with population-based controls derived form the sample of CentERdata 
(n=1923), AYAs with cancer were matched on gender and age (within a range of 0 to 
5 years) with 249 population-based controls. Given the relatively low proportion of 
CentERpanel members within the age range of our study sample, the highest possible 
ratio for matching AYAs with cancer to controls was 1:3. Precision matching was 
performed with STATA/SE. All other analyses were performed using SPSS Statistics 
(version 22.0). Descriptive statistics and frequencies concerning socio-demographic 
and clinical data were calculated. An independent samples t-test was used to 
compare fatigue severity scores between AYAs with cancer and matched population-
based controls. We used a Chi-square test to compare the proportion of severely 
fatigued cases in AYAs with cancer and matched population-based controls. Pearson 
and Point-Biserial correlations were calculated to examine associations between 
continuous variables or continuous and dichotomous variables, respectively. The 
significance level was set at .05. We did not adjust for multiple testing.
RESULTS
In total, 309 letters requesting participation in the study were sent to AYAs with 
cancer visiting one of the members of the AYA team. The total sample of 89 
participants comprised 57% of those who opted-in to the study (n=55) and 29% of 
all those solicited by mail (n=309). Six participants were excluded, four since they 
were diagnosed with cancer under the age of 18 years and two because they were 
aged above 35 years at diagnosis. Table 1 displays sociodemographic, disease and 
treatment-related characteristics of the final sample of 83 AYAs with cancer stratified 
by the presence of severe fatigue. Mean age at cancer diagnosis for the total sample 
was 27.3 years (SD 4.4) and mean time since cancer diagnosis was 2.1 years 
(SD 2.6). The most common diagnosis was testicular cancer (34%) followed by 
sarcoma (19%). Disease stage at diagnosis was known and applicable in 67 
participants. Of those, 36 (54%) were diagnosed with early-stage disease (stages 
I-II) and 31 (46%) with late-stage disease (stages III-IV). The majority of participants 
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had undergone surgery (n=70, 84%) and chemotherapy (n=72, 87%), but were not 
on active cancer treatment at the time of study participation (n=61, 73.5%). Mean 
duration of cancer treatment was 15.8 months (SD 20.6). For the subset of 61 patients 
not on active cancer treatment at the time of study participation, mean duration since 
completion of treatment was 17.5 months (SD 30.6)
Table 1. Characteristics of the study sample stratified by fatigue severity
Characteristics Total sample
(n=83)
Non-severely fatigued 
patients 
(n=43)
Severely fatigued 
patients 
(n=40)
Age at cancer diagnosis, 
mean (SD)
18-25 years
26-35 years
27.3 (4.4)
30 (36%)
53 (64%)
26.5 (4.6)
18 (42%)
25 (58%)
28.0 (4.1)
12 (30%)
28 (70%)
Age at participation, 
mean (SD)
18-25 years
26-35 years
> 35 years
29.4 (4.7)
19 (23%)
58 (70%)
6 (7%)
28.7 (5.0)
13 (30%)
27 (63%)
3 (7%)
30.2 (4.4)
6 (15%)
31 (77.5%)
3 (7.5%)
Gender
Male
Female
43 (52%)
40 (48%)
30 (70%)
13 (30%)
13 (32.5%)
27 (67.5%)
Partner a
Yes
No
58 (70%)
24 (29%)
32 (74%)
11 (26%)
26 (67%)
13 (33%)
Children a
Yes
No
27 (33%)
55 (66%)
30 (70%)
13 (30%)
25 (64%)
14 (36%)
Highest completed education a
Low
Intermediate
High
2 (2%)
36 (43%)
44 (53%)
0 (0%)
18 (42%)
25 (58%)
2 (5%)
18 (46%)
19 (49%)
Employed or studying a
Yes
No
Other
53 (64%)
26 (31%)
3 (4%)
37 (86%)
4 (9%)
2 (5%)
16 (40%)
22 (55%)
1 (2.5%)
Cancer diagnosis
Testicular cancer
Sarcoma 
Breast cancer
Haematological malignancy
Gynaecological cancer
Melanoma
Other b
28 (34%)
16 (19%)
10 (12%)
10 (12%)
9 (11%)
3 (4%)
7 (8%)
22 (51%)
5 (12%)
4 (9%)
2 (5%)
5 (12%)
2 (5%)
3 (7%)
6 (15%)
11 (27.5%)
6 (15%)
8 (20%)
4 (10%)
1 (2.5%)
4 (10%)
a  Information was not available for one AYA with cancer. b Including: glioma (n=1) sigmoid carcinoma (n=1), oropharyngeal 
cancer (n=1), neuroendocrine tumor (n=1), lung cancer (n=1), salivary gland cancer (n=1), and adrenal cancer (n=1).
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Characteristics Total sample
(n=83)
Non-severely fatigued 
patients 
(n=43)
Severely fatigued 
patients 
(n=40)
Cancer stage at diagnosis
Not applicable
Stage I
Stage II
Stage III
Stage IV
Unknown
9 (11%)
11 (13%)
25 (30%)
13 (16%)
18 (22%)
7 (8%)
3 (7%)
6 (14%)
18 (42%)
3 (7%)
11 (26%)
2 (5%)
6 (15%)
5 (12.5%)
7 (17.5%)
10 (25%)
7 (17.5%)
5 (12.5%)
Time since cancer diagnosis, 
mean (SD) in years 2.1 (2.6) 2.0 (1.8) 2.2 (3.3)
Lifetime cancer treatment c 
Surgery
Chemotherapy
Radiotherapy
Immuno- or targeted therapy
Hormone therapy 
70 (84%)
72 (87%)
24 (29%)
13 (16%)
7 (8%)
38 (88%)
38 (88%)
10 (23%)
5 (12%)
4 (9%)
32 (80%)
34 (85%)
14 (35%)
8 (20%)
3 (7.5%)
Duration of cancer treatment,
mean (SD) in months 15.8 (20.6) 15.0 (22.1) 16.7 (19.2)
Intent of cancer treatment
Curative
Palliative
71 (85.5%)
12 (14.5%)
40 (93%)
3 (7%)
31 (77.5%)
9 (22.5%)
Treatment status at participation
No active treatment 
Active treatment
61 (73.5%)
22 (26.5%)
36 (83.7%)
7 (16.3%)
25 (62.5%)
15 (37.5%)
c Multiple answers possible. 
Prevalence of Severe Fatigue and Impact on Quality of Life
AYAs with cancer reported a significantly higher fatigue severity score than matched 
population-based controls (31.5, SD 11.8 versus 24.9, SD 10.5, respectively, 
p < .001). The prevalence of severe fatigue in AYAs with cancer was significantly 
higher in comparison with matched population-based controls (48%, n=40/83 
versus 20%, n=49/249, respectively, p < .001). Severely fatigued AYAs with cancer 
reported significantly lower scores on all four QoL subscales (i.e., physical, social, 
psychological, and spiritual well-being) and on total QoL, compared to their non-
severely fatigued counterparts (p’s < .05, see Table 2).
Table 1. Characteristics of the study samply stratified by fatigue severity (continued)
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Table 2. Impact of Severe Fatigue on Quality of Life of AYAs with cancer
QoL-CS Non-severely fatigued 
patients (n=43)
Severely fatigued 
patients (n=40)
Mean difference Sig.
Physical well-being 8.28 (± 1.21) 6.57 (±1.49) -1.71 .000**
Social well-being 5.41 (±1.33) 4.81 (±1.30) -0.60 .042*
Psychological well-being 6.27 (±1.29) 4.90 (±1.59) -1.37 .000**
Spiritual well-being 4.21 (±1.16) 3.29 (±1.36) -0.92 .001**
Total QoL 6.12 (±0.82) 4.95 (±1.13) -1.17 .000**
*Mean difference is significant at the 0.05 level. **Mean difference is significant at the 0.01 level.
Table 3. Correlates of Fatigue Severity in AYAs with cancer
Correlates Correlation coefficients N Sig.
Sociodemographic variables
Age at cancer diagnosis
Age at participation
Gender (male/female)
Partner status (yes/no)
Children (yes/no)
Employed or studying (yes/no)
.194
.185
.336
.118
-.122
.394
83
83
83
82
82
79
.079
.093
.002**
.291
.273
.000**
Disease and treatment-related variables
Time since cancer diagnosis
Cancer stage at diagnosis (early/late)a
Duration of cancer treatment
Cancer treatment at participation (yes/no)
Time since completion of cancer treatment
Intent of cancer treatment (curative/palliative) 
Surgery (yes/no)
Chemotherapy (yes/no)
Radiotherapy (yes/no)
Immuno- or targeted therapy (yes/no)
Hormone therapy (yes/no)
.073
.322
.087
-.227
.060
.270
.178
.115
-.242
-.107
.064
83
67 
81
83
61
83
83
83
83
83
83
.513
.008*
.439
.039*
.646
.013*
.108
.302
.028*
.336
.563
Psychological variables
Psychological distress (HADS total)
Fear of recurrence or progression (CWS total)b
.553
.340
83
71 
.000**
.004**
*Correlation is significant at the 0.05 level. **Correlation is significant at the 0.01 level. a Cancer stage was unknown for n=7 
AYAs with cancer and not applicable for n=9 AYAs with cancer. b CWS was not administered to n=12 AYAs with cancer, because 
they either had a recurrence (n=5) or received treatment with palliative intent (n=7).
34
Chapter 2
Sociodemographic, Treatment-Related, and Psychosocial Correlates of 
Fatigue Severity
Correlations are listed in Table 3. Higher psychological distress was strongly 
correlated to fatigue severity (R = .55; p < .001). Female gender, being unemployed 
(not having a job, sick leave or disablement insurance act), higher disease stage (III-IV) 
at diagnosis, and higher fear of recurrence or progression were moderate correlates 
(R‘s 0.30 to 0.50; p’s < .01). In addition, receiving active treatment at the time of study 
participation, palliative intent of treatment and having had radiotherapy were weakly 
associated with fatigue severity (R‘s 0.10 to 0.30; p’s < .05). No significant associations 
were observed between fatigue severity and the other sociodemographic, disease- 
and treatment related variables (see Table 3; p’s > .05). 
DISCUSSION
In this study, severe fatigue affected almost half of the AYAs with cancer. The 
prevalence of severe fatigue in AYAs with cancer was more than twice as high in 
AYAs with cancer than in gender- and age-matched population-based controls (48% 
versus 20%). Severe fatigue as assessed with the CIS-fatigue is more prevalent 
amongst AYAs with cancer than adult disease-free breast cancer patients 3 years 
after diagnosis (38%) [19]. The prevalence amongst AYAs with cancer corresponds 
more closely with findings from a study performed in adult cancer patients during 
cancer treatment with palliative intent (47%) [13], which is remarkable given the 
major difference in prognosis between these two patient groups. In our sample, 
only a minority of the participants (n=12, 14.5%) were classified as being treated 
with palliative intent at the time of participation. Reasons for the high prevalence 
of severe fatigue in AYAs with cancer have not been studied. One might postulate 
that, in contrast to adult cancer patients, the higher prevalence of severe fatigue 
originates from the unique combination of being diagnosed and treated for cancer 
and the developmental milestones AYAs are confronted with during adolescence and 
young adulthood.
Alternatively, the higher prevalence of severe fatigue reported by participants in 
our study could be the result of selection bias. We recruited AYAs with cancer that 
consulted a multidisciplinary AYA team. The fact that patients consulted a specialized 
AYA team most likely indicates that these patients had additional disease and/
or treatment-related questions or problems, although not all patients had a need 
for continued and specific care by the AYA team after the first consultation. The 
percentage of patients having had chemotherapy as part of AYA cancer treatment 
was high (87%). This further supports the likelihood of selection bias in our sample 
and might overestimate disease severity of the entire AYA cancer patient population. 
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Nonetheless, we can conclude that within the subset of AYAs with cancer consulting 
a multidisciplinary AYA team, the prevalence of severe fatigue is substantial. 
Significant differences were found in physical, social, psychological, spiritual, and 
total QoL for severely fatigued AYAs with cancer in comparison with non-severely 
fatigued patients, which echoes previous studies reporting on the detrimental effects 
of severe fatigue in adult cancer patients [6, 10]. More psychological distress was 
a strong correlate of fatigue severity in the present study. In addition, more cancer 
worrying, female gender, and being unemployed were moderately related to fatigue 
severity. Geue et al. (2014) studied gender-specific differences in quality of life after 
AYA cancer and found lower QoL for women than men, including higher levels of 
fatigue [20]. The finding that more psychological distress and cancer worrying were 
associated with fatigue severity is in agreement with the impact of fatigue severity on 
QoL of AYAs with cancer in this study. However, given the cross-sectional design of 
our study we cannot draw conclusions on causality. This also limits interpreting the 
finding that being unemployed was linked to higher fatigue severity, although it may 
suggest that severely fatigued AYAs with cancer might not be able to find appropriate 
work. This emphasises the relevance of further research into this topic.
We only found weak or non-significant links between treatment-related variables and 
fatigue severity; receiving active treatment at the time of study participation, receiving 
treatment with palliative intent, and having had radiotherapy were significant but 
weakly related to fatigue severity. A moderate association was found between late-
stage cancer at diagnosis and fatigue severity. In previous studies among adult cancer 
patients during and after treatment, fatigue appeared to be unrelated to disease-
related variables, but the receipt of chemotherapy was associated with fatigue long 
after treatment [21]. A recently published review among breast cancer survivors after 
treatment also reported that survivors treated with chemotherapy were at higher risk 
for developing severe fatigue, as were those survivors with a higher disease stage at 
diagnosis [22]. As mentioned before, a noteworthy proportion of participants (87%) in 
our sample had been treated with chemotherapy.
The present study has several limitations. The sample size of our study was relatively 
small and the low participation rate increases the probability of bias by non-response. 
Unfortunately, small sample sizes are also seen in other studies in which patients of 
AYA age are asked to participate [23, 24]. Recruitment for our study took place over 
a period of 4 years. Additional efforts to increase data collection, such as multiple 
mailings of questionnaires or follow-up phone calls, were only made in the latter 
part of the study. Our response rate might have been higher when these efforts were 
made throughout the entire duration of the study. However, in the AYA HOPE study 
fewer than half of the eligible AYAs with cancer responded to questionnaires despite 
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extensive efforts such as multiple mailings, phone calls, and financial incentives 
[25]. One way to overcome the low response rate in AYA cancer research might be 
the use of in-person contact and patient-preferred paper-pencil rather than online 
surveys as recently suggested by Rosenberg et al. [26]. Given the low incidence 
of cancer in AYAs between the ages of 18 to 35 years, recruitment from multiple 
institutions in an (inter)national AYA network could also aid the collection of larger 
samples. This would also increase the ability to generalize findings, which is limited 
in our study since we recruited patients at a single university medical center. While 
a broad range of potential correlates of fatigue severity was studied, we cannot rule 
out the involvement of other potentially relevant factors that have not been examined 
in this study. For example, sleep problems are strongly correlated with higher levels 
of fatigue in patients with cancer [27]. In addition, a low level of physical activity and 
pain are also correlated with cancer-related fatigue [28]. There is evidence that the 
effect of sleep problems on fatigue is mediated by pain [29]. Unfortunately, we did not 
include validated instruments to assess sleep problems, physical activity, and pain as 
potential correlates of fatigue severity in our sample, which is a significant limitation 
of the study. Notwithstanding these limitations, the present study is the first to apply 
a clinically relevant cut-off for severe fatigue in AYAs with cancer aged between 18 
and 35 years at diagnosis.
In conclusion, given the high prevalence and significant impact of severe fatigue on 
quality of life of AYAs with cancer, health care providers should pay careful attention 
to this symptom. In particular, female AYAs with cancer, those with more advanced 
disease at diagnosis, higher levels of psychological distress, and more cancer worrying 
seem to experience higher levels of fatigue. The longer-term survivorship rates of AYA 
cancer illustrate the potential longevity of AYAs with cancer. It is therefore important 
to investigate the course and persistence of severe fatigue in AYAs with cancer in 
longitudinal, population-based studies. Such studies would also aid the development 
of age-specific interventions addressing persistent cancer-related fatigue in AYAs 
with cancer to enable full participation in society throughout survivorship. Although 
evidence-based interventions for the management of cancer-related fatigue in 
adult cancer survivors are available and recommended within guidelines issued by 
the American Society for Clinical Oncology [30], these interventions have not been 
tested extensively in AYAs with cancer. Researchers should investigate whether these 
interventions can also be successfully applied to alleviate persistent cancer-related 
fatigue, improve QoL, and facilitate participation in society for the understudied 
population of AYAs with cancer.
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ABSTRACT
Background
The introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of 
Gastro Intestinal Stromal Tumor (GIST) in 2000 was the start of a new era of targeted 
treatment. Since then the median survival of patients with GIST has substantially 
increased. Prolonged survival and chronic TKI use are associated with treatment-
induced symptoms, such as fatigue, which can compromise quality of life (QoL). This 
study determined the prevalence of severe fatigue in GIST patients compared to 
matched healthy controls (MHCs), the impact of fatigue on daily life, and associations 
between fatigue and current TKI use.
Methods
119 patients treated with surgery and/or a TKI for GIST were asked to participate. 
Participants completed questionnaires including the Checklist Individual Strength 
(CIS-fatigue), SF36-item Health Survey, EORTC-QoL Questionnaire, Fatigue 
Catastrophizing Scale, Self-Efficacy Scale, and the Hospital Anxiety and Depression 
Scale. 
Results
89 GIST patients (75%) completed questionnaires, 61 patients (69%) were on a TKI. 
Prevalence of severe fatigue measured with the CIS-fatigue was significantly higher 
in GIST patients (30%) than in 234 MHCs (15%). The prevalence of severe fatigue 
did not differ significantly between patients receiving treatment with curative (29%) 
or palliative intent (36%). Severely fatigued patients reported lower QoL and more 
impairment on all functional domains. TKI use, more psychological distress, and 
lower physical functioning were associated with fatigue. 
Conclusion
Severe fatigue occurs in 30% of GIST patients and in 33% of GIST patients on a TKI. 
The fatigue is disabling and is not only associated with current TKI use, but also with 
psychological distress and physical functioning. GIST patients should be informed 
about these associated factors of fatigue that deserve appropriate management.
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INTRODUCTION
Gastro-intestinal stromal tumors (GISTs) are the most frequent sarcomas of the 
gastrointestinal tract. It is a rare type of cancer, as all sarcomas represent about 1% of 
adult cancers. The curative treatment for localized GIST is radical surgical resection. 
However, GISTs are known for their recurrent nature and are regarded resistant to 
conventional chemotherapeutic agents and radiation therapy [1]. The introduction of 
the tyrosine kinase inhibitor (TKI) imatinib in 2000 and new TKIs in more recent years 
has changed the treatment of GIST profoundly [2]. Patients with locally advanced or 
metastatic GIST currently face an extended median overall survival from less than 
1 year in the past [1] to over 5 years nowadays [3]. Due to this extended survival, 
aspects regarding the quality of life become more relevant. 
Fatigue is one of the most frequently reported symptoms by cancer patients, 
especially during cancer treatment [4]. Although treatment with imatinib is generally 
well tolerated, almost all patients have at least one adverse event of any grade [5, 6]. 
Clinical trials investigating the tolerability and safety of imatinib most frequently use 
the National Cancer Institute-Common Terminology Criteria (NCI-CTC) to determine 
presence and severity of treatment-induced toxicities [7]. This clinician-assessed 
measure results in a classification of symptoms in grade I-II (mild-moderate) to grade 
III-IV (severe-disabling). While mild fatigue is a frequent toxicity of imatinib, severe or 
disabling fatigue is less often reported. However, it is known that the use of clinician-
reported measures underestimates the occurrence and severity of symptoms [8]. 
Patient-reported outcomes are more sensitive and valid measures for assessing 
fatigue, but have not been used before in GIST patients.
Physicians and patients often ascribe fatigue during TKI therapy to the drug itself. 
Remarkably, a randomised clinical trial comparing imatinib with placebo as adjuvant 
treatment of GIST found comparable percentages of fatigue in both groups [5]. 
This indicates that factors other than imatinib use may contribute to fatigue. There 
is evidence for the contribution of psychosocial factors to fatigue in patients with 
other malignancies, both after adjuvant treatment and during palliative treatment. 
For example, more negative social interactions and fatigue catastrophizing thoughts 
predicted higher levels of fatigue after completion of adjuvant treatment [9]. 
Additionally, a lowered level of physical activity contributed to fatigue in patients with 
advanced cancer [10]. Studies in patients receiving chemotherapy have documented 
negative effects of psychological distress on fatigue [11]. To our knowledge, no study 
has investigated the contribution of these aforementioned factors to the fatigue 
experienced by GIST patients.
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This observational study had three aims. First, the prevalence of severe fatigue in 
GIST patients was determined using a self-report questionnaire with a validated cut-
off for severe fatigue and compared to matched healthy controls (MHCs). Most studies 
on cancer-related fatigue (CRF) have been limited in including GIST patients and 
studies focusing on GIST patients have not had fatigue as the focus of examination. 
Second, the impact of severe fatigue on quality of life (QoL), psychosocial variables, 
and physical functioning was examined. Finally, more knowledge about the correlates 
of fatigue can contribute to its management. Which may, in turn, also help patients 
to adhere to the chronic use of TKIs. Therefore, the third study aim was to explore 
associations between fatigue and use of TKIs, psychosocial variables, and physical 
functioning. 
METHODS
Study population
This observational, cross-sectional study was conducted in outpatient clinics of the 
Radboud university medical center in The Netherlands. To equal the real-life general 
GIST population, 119 adult outpatients with localized or metastatic GIST who had 
been or were currently being treated for GIST were invited to participate in the study. 
Patients were categorized into three groups based on their current treatment status: 
(1) treatment completed (i.e. status after radical surgical resection +/- (neo)adjuvant 
imatinib), (2) treatment with curative intent (i.e. on active (neo)adjuvant TKI), or (3) 
palliative treatment and best supportive care (i.e. TKI for unresectable primary or 
metastatic GIST or BSC).
Data were collected in two periods. The first period ran from June-October 2012, 
collecting data from 55 out of 83 patients. The second period ran from January-
March 2015, collecting data from 35 out of 36 patients. If patients were willing to 
participate, they filled in questionnaires once after they had given written informed 
consent. Patients who did not participate either indicated that they did not want to 
participate or did not respond to the request to participate in the study. The medical 
ethical committee of the hospital approved the study. 
Matched healthy controls (MHCs, n=234) were derived from a cohort of panel members 
of CentERdata. CentERdata is a Dutch research institute at Tilburg University [12]. 
The CentERpanel is composed of more than 2000 Dutch households, representing 
the adult Dutch-speaking population with respect to demographic characteristics. 
MHCs had no sickness absence in the workplace (0 days) in the month prior to filling 
in the fatigue questionnaire, and were matched on age, gender, and educational level. 
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Measurement
MHCs completed the fatigue questionnaire and a questionnaire for demographic 
information. Demographic variables of patients were collected via a self-report 
questionnaire. Medical information of patients was retrieved from medical records. 
Patients completed the following questionnaires: 
Checklist Individual Strength, subscale fatigue severity (CIS-fatigue). A large number 
of instruments have been developed to measure fatigue. We assessed fatigue with 
8 items of the subscale fatigue severity (7-point Likert scale) of the CIS [13]. Scores 
range from 8 to 56. A score of 35 points or higher indicates severe fatigue, i.e. two 
standard deviations (SDs) above the mean of a healthy control group [13]. The CIS-
fatigue has been used previously for assessing CRF [14, 15]. 
EORTC Quality of Life Questionnaire (EORTC QLQ-C30, version 3.0). QoL was 
assessed with five functional scales and a scale on global health-related QoL of the 
EORTC QLQ-C30 [16]. Total scores on each subscale are converted to a 0-100 scale. 
A high scale score represents a high level of functioning or a high QoL, respectively.
Self-Efficacy Scale (SES). Sense of control regarding fatigue was measured with the 
SES [17]. The SES consists of 7 items scored on a 4-point Likert scale. Higher total 
scores are indicative for more self-efficacy. 
Fatigue Catastrophizing Scale (FCS). Catastrophizing in response to fatigue was 
measured with the FCS [18]. The FCS consists of 10 items scored on a 5-point Likert 
scale. Computing the mean of 10 items derives a total score. A higher total score 
indicates more catastrophizing. 
Hospital Anxiety and Depression Scale (HADS). The summed total score of the HADS 
was used to reflect psychological distress [19]. The HADS includes 14 items scored 
on a 4-point Likert scale. Higher total scores are indicative for more psychological 
distress.
Short-Form 36-item Health Survey (SF-36). Physical functioning was measured with 
the 10-item subscale physical functioning of the SF-36 [20]. A total score is calculated 
ranging from 0 to 100. A high score defines more favourable physical functioning. 
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Statistical Analysis
Patients were matched with 234 MHCs (ratio 1:3) by precision matching with STATA/
SE 12.1. Median and interquartile range (IQR) and mean and SD were used to describe 
variables. Independent samples t-tests and analyses of variance were used to test 
differences between groups on demographic variables, medical variables, and the 
presence of severe fatigue according to the CIS-fatigue. The impact of fatigue on QoL, 
psychosocial variables, and physical functioning was determined by independent 
samples t-tests. An exploratory multivariate regression analysis (method: enter) was 
conducted to determine whether receiving TKIs and/or psychosocial variables and/
or physical functioning were associated with fatigue severity. All tests were two-sided 
with a significance level of 0.05. Data were analysed using SPSS 20.
RESULTS
Ninety patients (76% response rate) filled in the questionnaires. The final sample 
comprised 89 patients, as one patient was excluded since the CIS-fatigue was not 
completed. Data on demographic and medical characteristics of all participating 
patients are shown in Table 1. Participants did not differ significantly on demographic 
variables from non-participants (age t(116) = -.354, p = .724, gender X2(1,118) = 
.400, p = .527). Median age of patients was 64 years (IQR 15), 52 of them were male 
(58%). Median time since GIST diagnosis was 32 months (IQR 55). Surgical 
resection had been the primary treatment option in 62 patients (70%). At the time 
of participation, 61 patients (69%) received a TKI (imatinib (n=52), sunitinib (n=7), 
nilotinib (n=2)). Furthermore, 23 patients had completed treatment, 24 were receiving 
treatment with curative intent, and 42 were receiving palliative treatment (n=39) or 
BSC (n=3). 
Prevalence and impact of severe fatigue and its correlates
Significantly more patients were severely fatigued according to the CIS-fatigue 
compared to MHCs, 30% versus 15% (p = .002), respectively. Mean fatigue severity 
was also significantly higher in patients (26.3, SD 10.8) than in MHCs (21.6, SD 13.7) 
(p = .004). Mean fatigue severity and the prevalence of severely fatigue did not differ 
significantly between the three groups, neither between patients receiving current TKIs 
or no TKIs (see Table 2A and 2B). 
Severely fatigued patients reported significantly lower global QoL than non-fatigued 
patients and were more impaired on all EORTC-QLQ functional scales (see Table 3). 
In addition, severely fatigued patients had less favourable physical functioning, 
lower self-efficacy, and reported more fatigue catastrophizing and psychological 
distress. The correlates of fatigue are shown in Table 4. More psychological distress, 
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lower level of physical functioning and currently receiving TKIs were significantly 
associated with fatigue severity (Adjusted R2 0.58).
Table 1. Demographic and medical characteristics
Patients 
 (n=89)
MHCs
(n=234)a
Age (years) 64 (IQR 15) 
range = 21-86
64 (IQR 14)
range = 18-90b
Gender
Male
Female
52 (58.4%)
37 (41.6%)
149 (63.7%)
85 (36.3%)
Educational level
Primary
Secondary
Tertiary
4 (4.5%)
48 (53.9%)
37 (41.6%)
0 (0.0%)
124 (53.0%)
110 (47.1%)
Time since initial diagnosis (months) 32  (IQR 55) 
range = 2-204
Location of primary tumor
Stomach
Small intestine
Rectum
Intra abdominal
Duodenum
Other/unknown
43 (48.3%)
20 (22.5%)
7 (7.9%)
3 (3.4%)
5 (5.6%)
11 (12.3%)
Primary treatment option
Surgical resection
TKI therapy
62 (69.7%)
27 (30.3%)
TKI therapy at the time of participation
Yes
  with curative intent (n=22)
  with palliative intent (n=39)
No 
61 (68.5%)
28 (31.5%)
Treatment status at the time of participation
Treatment completed c
Treatment with curative intent d
Palliative treatment (n=39) or BSC (n=3)e
23 (25.8%)
24 (26.9%)
42 (47.2%)
MHCs = Matched Healthy Controls; IQR = Interquartile Range; TKI = Tyrosine Kinase Inhibitor; BSC = Best Supportive Care. a 
84 patients could be matched with MHCs, not all patients could be matched to 3 controls; b Patients were matched with MHCs 
within an age range of 0-5 years; c Status after radical surgical resection +/- (neo)adjuvant imatinib; d On active (neo)adjuvant 
TKI; e TKI for unresectable primary or metastatic GIST or BSC.
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Table 2A. Mean fatigue severity and prevalence of severe fatigue based on treatment status at time of participation
Treatment completed 
(n=23)
Curative intent
(n=24)
Palliative intent #
(n=42)
p-value
Mean fatigue severity (SD) 23.43 (14.73) 26.25 (13.70) 27.88 (13.10) .460a
No. of severely fatigued patients (%) 5 (21.7%) 7 (29.2%) 15 (35.7%) .498b
a Independent samples t-test; b Pearson’s chi-squared test. # Also including Best Supportive Care.
Table 2B. Mean fatigue severity and prevalence of severe fatigue based on receiving TKI therapy at time of participation
TKI 
(n=61)
No TKI
(n=28)
p-value
Mean fatigue severity (SD) 27.08 (13.10) 24.57 (14.91) .424a
No. of severely fatigued patients (%) 20 (32.8%) 7 (25.0%) .458b
a Independent samples t-test; b Pearson’s chi-squared test. TKI = Tyrosine Kinase Inhibitor.
Table 3. Impact of severe fatigue on psychological factors and physical functioning
Non-severely fatigued 
patients (n=62)
Severely fatigued patients 
(n=27)
p-value
EORTC-QLQ-C30 (mean, SD)
Global health status/QoL 
Physical functioning 
Role functioning 
Emotional functioning 
Cognitive functioning 
Social functioning
82.0 (15.8) 
89.7 (12.0)
82.0 (23.6)
84.0 (19.3)
89.2 (17.1)
89.0 (18.1)
58.3 (15.7)
68.1 (20.6)
61.7 (29.1) 
68.2 (24.8)
66.7 (25.3)
63.0 (28.6)
.000*
.000*
.001*
.002*
.000*
.000*
SES (mean, SD)
Self-efficacy 20.2 (3.1) 18.4 (3.8) .017*
FCS (mean, SD)
Fatigue catastrophizing 13.7 (4.4) 23.2 (8.3) .000*
HADS (mean, SD)
Psychological distress 6.4 (4.4) 15.2 (7.6) .000*
SF-36 (mean, SD)
Physical functioning 82.3 (18.4) 58.0 (23.3) .000*
* Statistically significant values (p < 0.05)
EORTC-QLQ-C30 = EORTC Quality of Life Questionnaire; SES = Self-Efficacy Scale; FCS = Fatigue Catastrophizing Scale; HADS = 
Hospital Anxiety and Depression Scale; SF-36 = Short-Form 36-item Health Survey. 
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Table 4. Multivariate regression analysis (method: enter) to explore associations with fatigue severity
Dependent variable: CIS-fatigue
Independent variables Standardized Beta p-value
Current TKI therapy: no vs. yes .168 .019*
Self-efficacy (SES) -.065 .392
Fatigue catastrophizing (FCS) .176 .108
Psychological distress (HADS) .376 .001*
Physical functioning (SF-36) -.332 .000*
* Statistically significant values (p < 0.05)
CIS-fatigue = subscale Fatigue Severity, Checklist Individual Strength; TKI = Tyrosine Kinase Inhibitor; SES = Self-Efficacy Scale; 
FCS = Fatigue Catastrophizing Scale; HADS = Hospital Anxiety and Depression Scale; SF-36 = Short-Form 36-item Health 
Survey. 
DISCUSSION
This study investigated the prevalence and severity of fatigue by patient-reported 
outcomes (PRO’s) in GIST patients. Compared to matched healthy controls, the 
prevalence of severe fatigue is 50% higher among GIST patients, with about one-
third exceeding the cut-off for severe fatigue. Overall, mean fatigue severity and 
the proportion of severely fatigued patients did not significantly differ between the 
patients who finished treatment, patients on treatment with curative intent, and 
patients receiving palliative treatment or BSC, nor between patients with and without 
current TKIs. QoL is negatively affected by fatigue and severely fatigued patients 
reported worse functional, psychological, and physical well being compared to non-
severely fatigued patients. 
The National Comprehensive Cancer Network Guidelines on cancer-related fatigue 
(CRF) recommend assessment of fatigue by PRO’s and not by physicians’ ratings 
[21]. Previous studies in GIST patients did not assess fatigue with PRO’s. Instead, 
physicians rated fatigue on a numerical rating scale. In these studies, severe 
fatigue was seldom reported. However, physicians tend to underestimate patients’ 
symptoms [8]. This accords with the higher prevalence of fatigue in our study. The 
detrimental effect of fatigue on QoL and functional, psychological, and physical well-
being echoes with findings of other studies reporting on fatigue in patients with more 
common cancer types [22-25].
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We found that receiving TKIs was significantly associated with fatigue severity. 
However, 26% of severely fatigued patients did not receive TKIs and 67% of 
patients who currently received TKIs were not severely fatigued. This supports our 
expectation that factors other than TKI use may contribute to fatigue. We found that 
more psychological distress and lower physical functioning were also related to 
fatigue severity. The role of physical activity in CRF is well documented. More active, 
physically fit patients experience less fatigue during cancer treatment than patients 
with a lower level of physical activity [26]. In the current study, reduced physical 
functioning was indeed observed in severely fatigued patients. A Cochrane review 
concluded that interventions focusing on exercise could be beneficial for individuals 
with fatigue both during and after cancer treatment [27]. GIST patients may also 
benefit from physical activity programs. The level of psychological distress was also 
related to fatigue severity. One-third of all GIST patients (34%) had a score above 
the recommended threshold for identifying the presence of significant depressive 
symptoms [19]. This psychological distress might be attributable to the recurrent 
nature of GIST, which may lead to high levels of fear of disease progression, as found 
by Custers et al. (2015) [28]. Influencing psychological distress by psychosocial 
interventions may also reduce fatigue in GIST patients. An example of such a 
psychosocial intervention is cognitive behaviour therapy focused on (fatigue-related) 
behaviour and beliefs which was found to be effective in reducing fatigue in patients 
during and after cancer treatment [14, 15]. 
Contrary to our expectation, we did not find an association between fatigue-related 
beliefs and fatigue. However, previous research has shown that these beliefs are only 
present in severely fatigued patients and taking into account that in absolute numbers 
only 27 patients in our sample were severely fatigued. Moreover, though mean 
fatigue severity and prevalence of severe fatigue was higher in patients receiving 
palliative treatment compared to patients receiving treatment with curative intent, this 
difference was not statistically significant. However, we had a relatively small sample, 
which might have increased our chance of type II error. Therefore, replication in a 
larger sample of GIST patients is recommended since it is not unlikely that fatigue is 
more severe in patients receiving treatment with palliative intent.
Further limitations should be considered. First, the cross-sectional nature of our study 
does not allow us to draw conclusions about causality. Second, the extent to which 
the findings of this study can be generalized to all patients with GIST is limited by the 
relatively small sample size. The small sample size also limited our ability to study 
other potential correlates of fatigue in our exploratory regression analysis, such as 
pain or sleep dysfunction. Studies on fatigue in GIST patients would be strengthened 
if future investigators unite their efforts and collect larger samples of PRO’s. As a 
result of change in study personnel, data were collected in two distinct time periods. 
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Nevertheless, no relevant differences in treatment or other aspects during this interval 
existed that could have affected the combined study sample. Although we collected 
data from a heterogeneous sample for this exploratory study, a more homogenous 
sample could be a useful augment to future studies investigating fatigue within each 
GIST patient category. For example, heterogeneity in treatment modalities, length 
of treatment, dosage level, and extent of disease may also affect the presence and 
severity of fatigue within each patient group. While there was diversity in current 
treatment status, the majority of participants were on TKIs. Finally, information on 
comorbidity was not available for both GIST patients and MHCs. In MHCs, we used 
the criterion of no sickness absence in the workplace as a proxy for being healthy. 
However, this does not rule out the possibility of having symptoms or comorbidities 
with which they would still attend work. 
Bearing in mind that GISTs are rare tumors and research focusing on the experience 
of severe fatigue is lacking, the present research is an important first exploratory 
study. This research showed that severe fatigue is a relevant and disabling symptom 
for almost one-third of GIST patients. Patient-reported fatigue severity is associated 
with TKI use. Yet, if physicians keep interpreting the presence of fatigue as solely 
TKI-related, as a result, both physician and patient may feel they cannot influence 
the fatigue. The present study adds valuable knowledge by showing that next to TKI 
use, lower physical functioning and more psychological distress are also associated 
with fatigue. Physicians could play a crucial role in informing patients about these 
associated factors of fatigue that deserve appropriate management. 
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ABSTRACT
Background
Fatigue is one of the most important quality of life issues experienced by patients 
being treated with oral targeted therapy for chronic myeloid leukemia (CML). Yet, no 
intervention exists that specifically addresses strategies to reduce targeted therapy-
related fatigue. This study adapted an evidence-based clinic-delivered intervention 
(EBI) ‘cognitive behavior therapy for post-cancer fatigue’ for use in CML patients. 
The existing EBI was based on six established perpetuating factors of fatigue (i.e., 
Sleep, Activity, Helpful Thinking, Coping with Cancer, Social Support, Fear of Disease 
Recurrence). Study aims were to gauge reactions to (1) existing content and (2) a new 
Internet-assisted intervention delivery format. 
Methods
Guided by the ADAPT-ITT framework, we used a series of systematic steps and 
adaptation methodologies, including semi-structured interviews with CML patients 
and providers, and feedback from topical experts. 
Results
Patients were receptive to existing content topics and an Internet-assisted delivery 
format was acceptable. A key theme reflected the need for a new customized psycho 
educational module about CML as a disease and its treatment. Both providers and 
patients held positive views about the potential of the adapted EBI to improve fatigue. 
Conclusion
Findings offered essential guidance for the adaptation and reinforced the utility of 
the adapted intervention. Adapting existing EBI’s for new audiences contributes to 
advancing findings of evidence-based research, ultimately providing nurses and other 
health care providers with important referral options to interventions that may provide 
useful strategies to improve quality of life and reduce targeted therapy-related fatigue. 
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INTRODUCTION
Survival in patients with chronic myeloid leukemia (CML) improved considerably 
following the introduction of the first tyrosine kinase inhibitor (TKI) imatinib [1]. 
Although TKIs revolutionized treatment of chronic phase CML, they may need to 
be taken indefinitely and on a daily basis [2]. Accordingly, with the growing use of 
maintenance therapy in certain forms of cancer, CML has become a chronic condition. 
The transition from short-term active treatment to potentially lifelong maintenance 
treatment brings attention to finding ways to manage common side effects such as 
fatigue and pain. Although evidence-based interventions for managing these side 
effects are available for cancer patients during or after short-term active treatment 
[3,4], they are not designed for and have not been tested for efficacy in the expanding 
number of patients who are receiving maintenance treatment with TKIs.
To address the need for an intervention that supports CML patients in managing their 
health during maintenance TKI treatment, we have built upon a previously empirically 
supported version of a therapist-delivered cognitive behavioral program for disease-
free cancer patients [5] that specifically addresses one of the most common and 
debilitating side effects, that is fatigue. In this paper, we describe processes used 
to adapt an existing evidence-based intervention for application in CML patients 
with targeted therapy-related fatigue. Beyond this immediate goal, the current report 
seeks to illustrate an approach that can be applied to other existing evidence-based 
interventions for improving the lives of cancer patients. 
As background, fatigue proves to be one of the five most severe side effects in CML 
patients who are prescribed TKIs, alongside drowsiness, disturbed sleep, muscle 
soreness and cramping, and trouble remembering things, with one-third of patients 
reporting persistent moderate-to-severe symptoms [6]. Additionally, compared to age-
matched controls with no history of cancer, patients with CML who take a TKI report 
significantly worse fatigue severity and fatigue interference [7]. Moreover, fatigue is 
the most important factor that limits quality of life of CML patients [8]. Treatment 
of fatigue is particularly relevant as chronic side effects may affect adherence to 
TKI treatment, and adherence is a critical factor to ensure appropriate molecular 
responses [9]. 
Despite the acknowledged importance of this symptom, there are no published 
intervention studies addressing targeted therapy-related fatigue. However, previous 
research has demonstrated the efficacy of cognitive behavior therapy (CBT) designed 
for treating post-cancer fatigue [5,10]. The conceptual framework for the intervention 
developed by the Expert Center for Chronic Fatigue (Nijmegen, The Netherlands) is a 
model that distinguishes factors that precipitate fatigue from factors that perpetuate 
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fatigue [11]. The underlying assumption is that cancer treatment and/or the disease 
itself may trigger fatigue (precipitating factors), but that other factors such as sleep 
disturbance, physical inactivity, and fear of disease recurrence are responsible for the 
persistence of fatigue (perpetuating factors). As such, CBT for post-cancer fatigue 
is a tailored, individual-based, clinic-delivered intervention that itself was adapted 
from the original CBT for chronic fatigue syndrome developed by the Expert Center 
for Chronic Fatigue [12]. CBT for post-cancer fatigue sessions cover six possible 
perpetuating factors (the ‘Modules’): Sleep, Activity, Helpful Thinking, Coping with 
Cancer, Social Support, and Fear of Disease Recurrence (see Table 1 for a description 
of existing intervention modules). Evidence supports the efficacy of CBT for post-
cancer fatigue in decreasing severe fatigue and functional impairment [5,10]. Based 
on this evidence, it is now among the recommended interventions for addressing 
fatigue in disease-free cancer survivors in guidelines issued by the American Society 
of Clinical Oncology [13]. 
Table 1. Description of existing intervention modules of the original evidence-based intervention CBT for post-cancer fatigue
Module Content
(1) Sleep Patients are encouraged to maintain a regular sleep-wake pattern seven days a week with fixed bed 
and wake-up times and no daytime napping. If needed, attention is paid to additional sleep hygiene 
practices.
(2) Activity A distinction can be made between patients with fluctuating patterns of activity (i.e. bursts of activities 
followed by inactivity) and patients with a pattern of persistent inactivity. First, patients with fluctuating 
patterns establish a base level by evenly distributing their level of activity over the day. Upon reaching 
this base level, a graded activity program (e.g. walking) is started. Patients with persistent inactivity will 
start the graded activity program immediately.
(3) Helpful Thinking Dysfunctional fatigue-related cognitions [5] (e.g. catastrophizing, low self-efficacy, or unhelpful 
attributions) are discussed and more helpful ways of thinking are taught.
(4) Coping with Cancer Insufficient coping with cancer and/or its treatment [5] is targeted by talking or writing about these 
experiences (exposure) in order to help patients to process the experiences and improve coping skills.
(5) Social Support Some patients perceive a discrepancy between actual and desired social support, experience negative 
social interactions or have unrealistic expectations of others. These patients are helped to instil more 
realistic expectations toward their social support group and to communicate more assertively with others 
with respect to their current abilities.
(6) Fear of Disease Recurrence Some patients experience excessive fear of disease recurrence. Their fears and thoughts are discussed 
with a focus on how to deal with the uncertainty about their future health. Dysfunctional beliefs5 are 
challenged and it is discussed how to reduce ruminating about the possibility of disease recurrence.  
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Table 2. Adaptation Plan for CBT for targeted therapy-related fatigue modelled after ADAPT-ITT
Phases Methodologies
1. Assessment: What is the need?  Conduct needs assessment of CML patient audience. The literature reviewed clearly 
demonstrates the need to develop an intervention to address targeted therapy-related 
fatigue.
2. Decision: What evidence-based 
intervention is selected? 
Decision to adapt the CBT for post-cancer fatigue. Initial English-language translation of 
original therapy manual created using services of a professional translator.
3. Administration: What needs to be 
adapted and what added?
Conduct in-depth interviews with CML patients reporting targeted therapy-related fatigue, 
including response to use of Internet-assisted delivery channel. Conduct in-depth interviews 
with CML health care providers. Analyse results to inform next steps.
4. Production: How to produce and draft 
the evidence-based intervention?
Develop adaptation plan and table of modified text and/or new activities. Draft adapted 
evidence-based intervention and therapy manual to balance fidelity of core elements, 
underlying conceptual framework, and internal logic pathways. Document adaptations 
according to content, context, and concepts, language, and persons.
5. Topical experts: Who are the experts? Engage topical experts who developed the original CBT for post-cancer fatigue to ensure 
input, feedback and review of CBT for targeted therapy-related fatigue drafts.
6. Integration: What is going to be 
included in the adapted evidence-based 
intervention?
Integrate feedback and data from topical experts. Draft new CBT for targeted therapy-
related fatigue therapy manual and program components with attention to fidelity, fit and 
congruence to original evidence-based intervention. Review findings with topical experts 
and make final decisions and revisions. Finalize measures to be used to assess perpetuating 
factors.
7. Training Training of staff to implement CBT for targeted therapy-related fatigue involves the 
therapists reviewing the CBT therapy manual and rehearsing intervention elements in 
modelling and role-playing sessions with simulated patients. This 3-day in-person training 
was created and delivered by the topical experts.
8. Testing: Was the adaptation successful? Test adapted CBT for targeted therapy-related fatigue and evaluate efficacy in ongoing pilot 
randomized controlled trial.
CBT = Cognitive Behavior Therapy; CML = Chronic Myeloid Leukemia.
The current report describes a series of systematic steps and processes to adapt and 
modify an existing evidence-based intervention in response to the needs of another 
patient population. The process of modifying an evidence-based intervention without 
changing the intervention’s core elements and internal logic is often referred to as 
‘adaptation’ [14]. Instead of starting over and expending scarce resources, adapting 
existing evidence-based interventions has the potential to accelerate the translation 
of research into practice, thus providing health care professionals and patients with 
treatment options for new patient target groups. The adaptation process allows for 
changing context in terms of structure, intensity, format, metaphors, goals etc., while 
maintaining essential theoretical fidelity and fit. To guide the adaptation process, we 
developed a plan drawn from the adaptation literature [14-19], our prior experience in 
creating, trans creating and adapting interventions [20-24], the NCI’s Stages in Health 
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Communication Model [25], and the ADAPT-ITT Model [26]. Table 2 summarizes our 
plan modelled after the ADAPT-ITT model that includes 8 phases: (1) Assessment; (2) 
Decisions on evidence-based intervention selection; (3) Administration – What needs 
to be adapted; (4) Production; (5) Topical experts; (6) Integration; (7) Training and (8) 
Testing. This paper focuses primarily on the initial steps and methodologies (1-6), 
which provided the necessary foundation for informing the adaptation. The details on 
the training and specific results of the pilot study (steps 7 and 8), once complete, will 
be reported in the future.
As described in the upcoming sections, the adaptation process described here 
represents a series of sequential phases and steps that advance an idea in response 
to a patient need, to a final testing and evaluation phase. In our case, this adaptation 
was predicated on the need for an intervention that offered strategies for patients 
with CML to ameliorate targeted therapy-related fatigue. The adaptation described 
here also involves moving from a clinic-based face-to-face delivery during a 6-month 
period (bi-weekly sessions) to Internet-assisted delivery format using video telephony 
and tablet computer technology (i.e. FaceTime using iPads) during an 18-week period 
(weekly sessions) to reduce travel burden. Therefore, as part of our adaptation plan, 
we also sought to gauge CML patients’ interest in, and acceptability of, delivery 
channel, duration, and frequency of CBT for targeted therapy-related fatigue. 
METHODS
Phase 1 and 2 - Assessment and Decision
Our approach builds upon a previously effective evidence-based intervention for 
post-cancer fatigue [5] and an established patient need [8]. We were not proposing to 
develop a de novo intervention. Rather, the program builds on an existing intervention 
comprised of six modules, based on the precipitating-perpetuating model for fatigued 
disease-free cancer patients [5,10]. 
Phase 3 - Administration (what needed to be adapted?)
As part of the adaptation process, we conducted in-depth interviews with CML patients 
and providers. Next, findings were summarized and implications for adaptation of 
the existing evidence-based intervention were formulated in close collaboration with 
topical experts (i.e. developers of the original evidence-based intervention). Then, the 
original therapy manual and training materials were revised through intensive iterative 
back/forth communications among research members to incorporate feedback from 
patients and providers.
61
4
Adapting a fatigue intervention for patients with CML
Participants and Procedures
Eligible patients were ≥18 years old, able to speak and read English, diagnosed with 
chronic phase CML, not previously treated for other cancer (except non-melanoma 
skin cancer) in the past 2 years, under the care of a Moffitt Cancer Center physician, 
and on a TKI for ≥ 3 months. In addition, patients had to report moderate-severe 
fatigue in the past week as reflected by a Fatigue Symptom Inventory score of ≥ 4 
[27]. Patients were excluded if they had a clinical condition or disease (e.g. anemia 
or multiple sclerosis) that could account for the presence of moderate-severe fatigue. 
Potential patient participants were identified via review of medical records and 
appointment schedules by study coordinators. Identified patients were telephoned 
1 week before their next appointment to explain study procedures and screened for 
fatigue. Eligible patients that gave written informed consent were asked to stay after 
their appointment to be interviewed. 
Eligible providers were staff members in the Department of Malignant Hematology at 
Moffitt Cancer Center who cared for CML patients as a Medical Doctor, Advanced 
Registered Nurse Practitioner, Physician Assistant, or Registered Nurse. CML patients 
at Moffitt Cancer Center are treated by a limited sample of providers. Provider 
participants were identified and then invited for participation via e-mail. Eligible 
providers that gave written informed consent were scheduled for an interview.
Instrumentation and Data Collection  
Preceding the interview, patients provided demographic information (e.g. age, gender, 
race, ethnicity, marital status, and education) by completing a self-report form. 
Clinical information (e.g. CML diagnosis date, current TKI start date, and previous 
TKI [if applicable]) was collected via medical chart review. 
Patient and provider semi-structured interview guides were developed by two 
of the study investigators (PJ and CM) based on relevant literature, their clinical 
experiences, and discussion with the topical experts (HK and MG). The guides 
consisted of questions about: (1) general thoughts about fatigue in relation to TKIs 
and CML; (2) general thoughts about TKIs and CML (the provider guide had some 
additional questions to evaluate the type of education provided to patients before the 
start of TKI therapy); (3) overall reaction to CBT for targeted therapy-related fatigue 
program; (4) usefulness and ranking of existing modules; (5) other useful topics; and 
(6) reaction to Internet-assisted delivery channel (i.e. FaceTime using iPads), duration, 
and frequency of CBT for targeted therapy-related fatigue. To help elicit feedback 
about the existing six modules, the interviewers had the modules listed on cards. 
This made it easier to respond to each module one at a time and gather feedback. It 
also helped to facilitate ranking of the modules in terms of relative importance. New 
topics were also solicited.
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Two behavioral scientists (PJ and CM) with extensive interviewing experience 
conducted the individual interviews with patients and providers using the interview 
guides. Regarding the sample size for the patient interviews (n=10), we were guided 
by the concept of data saturation, which was defined in this study as the point 
that no new insights or themes were observed [28]. Our research team continually 
assessed the adequacy of this sample in terms of quality, comprehensiveness, and 
richness of information [29]. For example, was there sufficient depth of information 
to adequately inform the adaptation of the evidence-based intervention and at which 
point were no new insights observed. In addition to the number of interviews, the 
team also considered the amount of time spent with each CML patient (up to 60 
minutes) when defining data saturation and stopping data collection [30]. In terms of 
health care providers, our sample was defined (and somewhat limited) by the existing 
number of providers (n=4) at our institution who cared primarily for patients with CML. 
Albeit small, it was felt that this sample well represented the required perspectives 
to address potential modifications for the adapted evidence-based intervention. 
Time spent with providers was approximately 40 minutes. All interviews were audio-
recorded and transcribed by a local professional transcriptionist with experience in 
qualitative health research. Each patient received $50 and each provider received 
$35 for participating. Liberty Institutional Review Board, a central independent review 
board, approved the study.
Data Analyses 
All interviews were transcribed verbatim. Data transcripts were manually coded using 
directed content analysis techniques to extend and refine existing theory on CBT for 
post-cancer fatigue to CBT for patients experiencing targeted therapy-related fatigue 
[31]. Codes were generated and refined before and during data analysis using a series 
of iterative processes by two study researchers (HP and CM). First, the researchers 
created an initial codebook based on a priori (deductive) codes drawn from existing 
theory, the interview guides and research questions. The researchers then reviewed 
all transcripts carefully, highlighting all passages that described relevant data. All 
highlighted passages were coded using the predetermined codes. Any text that could 
not be coded into one of these initial codes was given a new inductive code (e.g. 
‘impact of fatigue’ for descriptions of how fatigue impacted areas of daily living) [31]. 
The same researchers independently hand-coded the transcripts, compared codes, 
and resolved discrepancies through consensus, to reach an optimal inter-rater 
agreement (95%) [32]. The data were summarized through descriptive summaries and 
data display matrices, in which supportive and expanded views of the existing CBT 
for post-cancer fatigue were identified. A summary listing of module content rankings 
was also included. The authors reviewed, validated, and verified interpretations, and 
study conclusions via weekly calls with topical experts. Representative, participant 
responses were selected to illustrate key findings.
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RESULTS
Of the initial 12 eligible patients who were approached for participation, one was found 
ineligible after consent and one declined to be interviewed; consequently, 10 patient 
interviews were conducted in total. Four providers were approached and consented 
for participation. The mean age of patient participants was 53 years (range 37 to 
70 years), 60% was male, and 70% Caucasian/30% African American. The majority 
of patients was employed, married and had some college education. The sample 
included patients with varying disease and treatment duration. Median time since 
diagnosis was 6.5 years (range 4 months to 10 years) and median time on current TKI 
was 11 months (range 3 months to 6 years). Ninety per cent of patients had used at 
least one TKI previously. The most frequently used current TKIs were nilotinib (50%) 
and dasatinib (40%).
Findings from patient and provider interviews
Illustrative quotations from patients and providers are incorporated in the text in 
italics. 
Thoughts about patients’ fatigue
Patients commonly described fatigue as ‘crushing’, being ‘worn out’ or ‘whipped 
out’, and having ‘zero energy’ or feeling ‘dead’. Some patients related that they 
‘cannot get out of bed in the morning’ others just ‘crash at the end of the day’. 
Fatigue impacts patients in a number of ways, most significantly seen in the change 
or reduction of social, family, and physical activities. In general, patients felt that their 
family members are supportive and understanding. Patients indicated that they do 
not often bring up fatigue to their providers. Most patients felt their providers think 
fatigue is a normal side effect of TKIs. 
Providers acknowledged fatigue as a common complaint, reported by an estimated 
70% or more of their CML patients. As such, most providers usually follow up on 
this concern by discussing sleep patterns, encouraging physical activity, or changing 
TKIs when more side effects are present.
Thoughts about patients’ medication and CML
A number of general thoughts about CML emerged. Considering that most patients 
wished they did not have a form of cancer at all; some patients described feeling 
very fortunate for having this type of cancer, since they felt ‘It’s the best one to have’. 
Alternatively, some patients felt guilty for doing well and looking so healthy compared 
to other patients seen at the Cancer Center. They stated that they ‘don’t look sick’. 
Most patients experienced a range of side effects from the TKIs (e.g. fatigue, nausea, 
diarrhea, joint pain, and muscle cramp), but related no intentional dose skipping as 
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they felt the TKI is ‘keeping me alive’ and is their ‘life preserver’. Unintentional dose 
skipping was reported by patients, mostly forgetting the second evening dose of 
nilotinib due to falling asleep. An overwhelming majority of patients clearly attributed 
their fatigue to the use of TKIs. In fact, only one patient did not specifically attribute 
fatigue to TKI use per se but rationalized the presence of fatigue with other factors 
(i.e., unhealthy diet, low level of physical activity, being overweight, and under stress). 
In addition, this patient explained that it was difficult to indicate whether the fatigue 
was related to TKI use since ‘I have been on a TKI for so many years and then I am 
ten years older’.
Providers thought intentional dose skipping due to side effects does occur in a few 
patients. All providers had the impression that patients attribute their fatigue to TKI 
use, and they inform patients about fatigue as a known side effect of all TKIs when 
initiating treatment.
Overall reaction to CBT for targeted therapy-related fatigue
Patients and providers had a positive attitude toward the intervention; thinking it 
is ‘worthwhile’, ‘great’, ‘a very novel approach’, and would be ‘helpful’ for fatigued 
patients. Several patients stated that ‘It is a good idea’ and one patient further 
elucidated ‘If we can help people out that would be very good, fatigue affects 
everything’. Overall, patients were highly positive and expressed being interested 
in and open to actually using the intervention. One patient preferred simply an email 
with information, not an intensive interaction with a therapist using video-telephony.
Usefulness and ranking of the existing modules
The majority of patients considered all six modules highly useful. The module Sleep 
currently applied to almost all patients, with waking up too early, falling asleep during 
the day, or not being able to sleep at bedtime being commonly reported. The module 
Activity applied to all but one patient. Patients experienced reduced or fluctuating 
activity patterns and considered this module highly pertinent. Most patients reported 
that the module Helpful Thinking about fatigue was not as applicable to them. Some 
patients did have hopeless thoughts such as ‘There is nothing I can do’ and ‘I just need 
to accept it’, but these thoughts did not seem to impact their everyday functioning. 
There were a variety of reactions when patients were asked about the module Coping 
with Cancer. More than half of the patients had no major concerns, accepting their 
situation and saying ‘It is what it is’. Yet, many identified that some thoughts and 
emotions were triggered before 3-monthly monitoring visits or in case of bad lab 
results. Reactions from patients who did report concerns ranged from ‘Why do I have 
this disease?’ and ‘How would I cope with it if I ever get to the point where it gets really 
bad’, to struggling with knowing that not taking the TKI would make them feel better 
but worsen their disease status. A few struggled with integrating the strict medication 
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regimen into daily life. Although the majority of patients indicated already receiving 
good support, they did consider the module Social Support a useful topic to discuss. 
A few patients reported changes in social support (e.g. people distancing from them) 
or unpleasant social interactions (e.g. being called ‘lazy’ when they were just too tired 
to do things). The majority of patients did not experience current issues that would 
be addressed in the module Fear of Disease Recurrence, but felt the module could 
be useful for others. In fact, patients found the term ‘disease recurrence’ confusing 
and instead referred to ‘increased disease activity’. An explanation for this is that a 
response evaluation in CML is determined by the value of a molecular marker (i.e. 
BCR-ABL transcript), instead of determining ‘recurrence’ of a solid tumor in patients 
of the original evidence-based intervention’s population. CML is often considered 
a slowly progressing disease with long periods of stability. Hence, the terms and 
language used needed to be edited to better reflect the experience of patients with 
CML. Even though most patients felt their disease was well controlled and felt that 
they did not currently need this module, thoughts about increasing disease activity 
did occur once in a while, mostly triggered by medical appointments or upcoming 
blood tests. However, some patients worried more about their future health. One 
patient stated ‘Ever since I was diagnosed, I’m waiting for the other shoe to drop’ and 
later on ‘For the first couple years I really did feel that, I had maybe a short period of 
time, I didn’t think that I would live that long and so that was a concern and it certainly 
impacted the way I was living my life’. Another patient expressed having thoughts 
about increase in disease activity all the time, especially after the last switch of TKIs, 
and expressed ‘I still have people who depend on me’. One patient mentioned the 
scary aspect of ‘dying at a young age’. In summary, the majority of patients felt all the 
topics were important for inclusion in the intervention, but the highest priority ones 
were identified as: Activity, Sleep, and Coping with Cancer. If any module did not 
apply to them now, all were open to future discussions.
In all, providers considered the content of the six modules useful. One provider did 
not recognize disrupted sleep/wake patterns as a problematic issue within this patient 
group. Reactions to the usefulness of the module on fear of disease recurrence (or 
‘increased disease activity’) varied among the providers. Some providers thought the 
content of this module would be more helpful for patients that needed to switch TKIs 
as a result of increased disease activity compared to patients with stable disease. 
In addition, one provider wondered about patients’ understanding of treatment 
response and stated: ‘The tests that we use to measure whether they are having a 
good response are very confusing to patients. It’s a lot of technical lingo’. According 
to providers, the most relevant topics were Activity, Helpful Thinking, and Sleep/
Coping with Cancer, with the latter two topics being ranked equally.
66
Chapter 4
Other useful topics
Patients mentioned several suggestions for additional topics, including more 
information on CML and TKIs, nutrition, and impact of CML and fatigue on personal 
relationships. Providers considered general information about CML and TKIs 
potentially useful, suggested support groups for fatigued CML patients, and raised 
fertility issues in younger patients. Some of these topics may be useful in other patient 
education venues outside of the current intervention.
Reactions to internet-assisted delivery, duration, and frequency of CBT 
for targeted therapy-related fatigue
Overall, patients were very receptive to intervention delivery via video-telephony (i.e. 
FaceTime using iPads). Duration and frequency of CBT for targeted therapy-related 
fatigue (i.e. 18 weeks, weekly sessions) was acceptable to patients. All patients were 
familiar with the Internet; most were daily users. One patient expressed a preference 
to meet the therapist in-person prior to starting the Internet-assisted intervention. 
Providers had some mixed feelings from a technology perspective; it was thought 
that older patients might be less receptive to the Internet-assisted delivery channel. 
However, we found no differences in the views of younger and older patients regarding 
their acceptability and interest in the Internet-assisted delivery channel.
Phases 4, 5 and 6 – Production, Topical Experts and Integration
Data and information obtained from the interviews were used to draft a creative 
brief. A creative brief is a well-identified summary/blueprint of findings that helps to 
inform the adaptation of the intervention. Table 3 displays the summary of interview 
findings with adaptation implications and was used to guide the modifications. The 
goal was to create a therapy manual for therapists that described the process of 
CBT as applied to patients with targeted therapy-related fatigue and CML and to 
provide a description of what should be covered in each module. The research team 
and topical experts (i.e. study consultants who had developed the original evidence-
based intervention) then began integrating findings into the therapy manual. The 
original therapy manual consists of several components: the first section gives an 
introduction to CRF, followed by an explanation of the model of perpetuating factors, 
a section on diagnostic measures for each perpetuating factor, and separate sections 
describing the content of each module. The research team and topical experts had 
weekly conference calls over a 16-week period to examine each component of 
the original manual to identify areas to modify, delete, or adapt content based on 
feedback from the patients and providers. For example, replacing ‘fear of disease 
recurrence’ with ‘fear of increased disease activity’. In addition, not all existing case 
vignettes and quotes in the therapy manual (original vignettes were geared toward 
disease-free cancer patients) were pertinent for CML patients. Therefore, these 
were replaced with vignettes and quotations derived from the interviews that better 
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reflected everyday experiences of CML patients. Feedback about the proposed 
Internet-assisted delivery channel (i.e. FaceTime using iPads) from patients and 
providers was generally positive. Some providers felt that elderly patients might be 
less receptive to Internet-assisted delivery, but previous studies indicated that elderly 
(cancer) patients appear to participate readily in Internet-assisted self-management 
programs [33,34]. Furthermore, no differences were found between younger and 
older patients in our sample with regard to openness to Internet-assisted intervention 
delivery, if they were given instructions.  Based on discussion with the topical experts 
and due to a comment by one of the patients, the first intervention session would be 
delivered in-person to facilitate therapeutic alliance.
Phases 7 and 8 - Training and Testing
Once the therapy manual was finalized, the topical experts created and delivered 
a 3-day in-person training to prepare two therapists for delivering the intervention 
(HK and HP). This training included both theoretical background and rationale for 
each of the intervention modules, familiarizing therapists with intervention delivery, 
role playing with simulated patients, and discussing video recordings of provider-
simulated patients’ interactions with feedback from a topical expert. The testing of 
the Internet-delivered CBT for targeted therapy-related fatigue is currently being 
evaluated in a pilot RCT conducted to determine if the intervention can effectively 
reduce fatigue in patients receiving maintenance treatment for CML. 
DISCUSSION
The success of targeted therapy in cancer has improved the overall survival of CML 
significantly and transformed CML to a chronic disease. Yet many patients suffer 
from targeted therapy-related fatigue. Thus, an Internet-assisted intervention titled 
‘Cognitive Behavior Therapy for Targeted Therapy-Related Fatigue’ was developed 
through an adaptation process to address this need. In general, patients and health 
care providers felt that all existing modules were relevant (to varying degrees), and 
had the potential to improve patients’ fatigue while on maintenance TKI treatment. 
Our results underscore the importance of a patient-tailored approach of selecting 
intervention modules. In CBT for targeted therapy-related fatigue, therefore, diagnostic 
assessment instruments will be used to determine which modules should be included 
and enhanced in the CBT for a particular patient. The CBT will vary only in which 
modules will be addressed, but within each module the therapy is standardized. For 
example, the module on fear of increased disease activity only pertained to a minority 
subset of patients; as such not all patients will receive that module as part of the 
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intervention. Further, although the standard term in the literature ‘fear of disease 
recurrence’ typically applies to patients who have completed treatment for early-
stage solid malignancies, patients suggested changing this term to ‘fear of increased 
disease activity’, an issue more relevant to patients who are on maintenance treatment 
to control their disease. 
Our study suggested that patients had a need for more information about their disease 
and treatment. Therefore, the most significant change to the existing therapy manual 
was the development of a new psycho-education module ‘understanding CML and TKI 
treatment’ to address this need. This module gauges patients’ overall understanding 
of their disease and treatment, together with a better acceptance of the long-term 
nature of the treatment needed. An interactive approach was determined to be most 
suitable for this module. Patients are asked questions about their understanding of 
CML and its treatment, and the therapist checks or verifies whether this accords 
with general factual knowledge. Content accuracy was guided by Guidelines Insights 
for CML from the National Comprehensive Cancer Network [2], patient information 
material about CML from the American Cancer Society [35], and peer-reviewed 
literature [36]. If patients have further questions, they would be referred to their health 
care provider.
The current study confirmed the utility of using a systematic process for adapting an 
evidence-based intervention. In particular, the use of the ADAPT-ITT model provided 
a number of features that allowed for ongoing input from multiple key stakeholders 
(i.e. patients, providers, topical experts, and research team members). However, we 
note that due to the nature of the formative research among patients with CML, we 
only interviewed a relatively small sample of participants from a single comprehensive 
cancer center. The sample of 4 health care providers at one institution, albeit limited 
perspectives, offers an exceedingly important snapshot of the views of nurses and 
other health care providers who primarily care for and are highly familiar with the 
needs and concerns of patients with CML. In this study, the adaptation process was 
greatly enriched by the topical experts who had developed the ‘original’ evidence-
based intervention, and their involvement was a significant strength to the process. 
Not only was their input essential in the development of the adapted therapy modules 
and manual, but their engagement also enabled us to train therapists in-person on 
how to deliver the core elements of the adapted intervention. We have provided 
further tips in Box 1, which might be helpful for researchers interested in undertaking 
similar adaptations of existing evidence-based interventions.
Overall, the use of a systematic process for adaptation allowed us to systematically 
track and pinpoint content areas that should remain the same as well as direct areas 
to be further customized and modified. Most importantly, it offered the research team 
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a highly fluid and flexible blueprint for documenting the adaptation procedures [26]. 
Our results provide evidence that CML patients have a need for more information 
on their disease and treatment. As CML is transforming into a chronic illness, 
practitioners should be aware that it is important for patients to better understand their 
disease and the way their response is monitored. This might help patients in better 
understanding and adjusting to the long-term nature of their treatment. The Internet-
assisted delivery channel of the intervention appears to be a suitable and flexible 
vehicle to disseminate information for CML patients while reducing travel burden. 
The pilot RCT will be useful to supplement the preliminary findings on acceptability of 
Internet-assisted intervention delivery reported in this study.
Our results set the stage for the pilot RCT (currently underway) that is evaluating 
the usability, feasibility and efficacy of the adapted CBT for targeted therapy-related 
fatigue. Ultimately, if proven effective, this will provide nurses and other health care 
professionals with important referral options to interventions offering practical and 
patient-tailored strategies to address the most important factor limiting quality of life 
of CML patients treated with TKIs. In summary, this work provides a strong foundation 
for addressing a major treatment consequence in the growing population of patients 
for whom targeted therapies are transforming cancer from a life threatening to a 
chronic illness.
Box 1. Tips for researchers interested in undertaking similar adaptations of an existing evidence-based intervention
Researchers might find the following tips helpful: 
·  Upon initiating a project, form a collaborative professional relationship with the original intervention developers and 
clinicians who have experience with delivering the intervention. Ask them to be part of the team.
·  Adhere to systematic and iterative steps that guide the adaptation process driven by initial need for the intervention 
through the final testing of the adapted intervention. This provides an adaptation blueprint that endorses relevancy, 
rigor and meaning.
·  Establish a multidisciplinary team (local, national or international) to ensure inclusion of varied perspectives and 
who bring content-specific knowledge, methodological, and theoretical expertise. This might include well-versed 
researchers with backgrounds in psychology, nursing, and education as well as providers who care for the patient 
group. Include a team member with experience in developing and/or adapting interventions or education programs.
·  Engage key stakeholders such as patient and providers to make adaptations to ensure the ecological validity of the 
intervention, while still maintaining fidelity to the intervention’s core elements. 
·  Maintain a robust and consistent communication plan with study team members to ensure discussions and decisions 
about adaptation adjustments.
·  Finally, carefully document processes and justify modifications of the intervention protocol to monitor success, and 
revisions of the adapted components.
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ABSTRACT
Background
Informal caregivers (ICs) are increasingly involved in the monitoring of symptoms 
during advanced cancer patients’ treatment with palliative intent. A common, but 
subjective symptom during this extended treatment phase is fatigue. This exploratory 
longitudinal study aimed to determine agreement between patients and ICs about 
patients’ fatigue severity. In addition, predictors of agreement over time were studied.
Methods
A sample of 107 advanced cancer patients (life expectancy ≥ six months) and their 
ICs completed the subscale fatigue severity of the Checklist Individual Strength based 
on the patient’s status at baseline and six months later. This 8-item subscale has a 
validated cut-off to determine the presence of clinically relevant levels of fatigue. ICs’ 
own fatigue severity, strain, self-esteem, and relationship satisfaction were examined 
as predictors of agreement. 
Results
107 dyads completed measures at baseline, 69 dyads six months later. At baseline, 
ICs’ significantly overestimated patients’ fatigue severity (p < .001) with a moderate 
amount of bias (Cohen’s d = 0.48). In 81 of the 107 dyads (76%) there was congruence 
about the presence or absence of severe fatigue. On a group level, congruence did 
not significantly change over time. On a dyad level, there was a tendency to either 
remain congruent or reach congruence. Next to baseline congruence, ICs’ fatigue 
severity and strain predicted ICs’ in fatigue ratings (R2 = 0.23). 
Conclusion
The majority of ICs accurately predict presence or absence of clinically relevant levels 
of patients’ fatigue. ICs’ own fatigue severity and strain should be taken into account, 
as they influence agreement. 
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INTRODUCTION
A diagnosis of cancer, particularly when the disease is incurable, impacts not only the 
patient but also the informal caregiver (IC) [1]. ICs are faced with new responsibilities 
in medical, emotional, and practical domains [2]. The main aims of care for patients 
with incurable cancer are to prolong patients’ lives, while maintaining acceptable 
quality of life (QoL) by providing pain and symptom relief [3]. Due to advances in 
medical treatment, patients with certain types of incurable cancer receiving treatment 
with palliative intent may now live for an extended period [4, 5]. This extended phase 
of cancer treatment with palliative intent is associated with the occurrence of several 
physical and psychological symptoms. One of the most frequently reported symptoms 
is fatigue [6]. Fatigue is often cited as being among the most distressing symptoms 
[7-9] and has a negative impact on QoL, performance status, and daily activities 
[7, 10, 11]. Both patients and ICs have to deal with this distressing and disabling 
symptom [12].
Cancer-related fatigue (CRF) is defined by the NCCN as “a distressing, persistent, 
subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion 
related to cancer or cancer treatment that is not proportional to recent activity and 
interferes with usual functioning” [13], which cannot be objectively measured. Patients 
directly perceive their fatigue, whereas ICs can only know about the patients’ fatigue 
indirectly, that is, from what the patient communicates verbally or non-verbally. It is 
important to understand ICs’ perceptions for several reasons. First, perceptions drive 
IC responses to patients’ fatigue, which in turn can have an impact on patients. For 
example, failing to perceive that the patient feels severely fatigued would prevent ICs 
from giving attention to this symptom, thereby potentially resulting in a perceived lack 
of social support by the patient. In turn, it is known that a perceived lack of social 
support can be a perpetuating factor of fatigue [14]. Second, ICs are increasingly 
involved in the care for advanced cancer patients. For example, monitoring and 
management of symptoms during palliative treatment may rely on information from 
ICs. It is therefore important to know whether an IC can give a meaningful additional 
rating of the severity of patients’ fatigue.
Studies focusing on patient and proxy-ratings typically assess physical and 
psychosocial symptoms by asking both patients and proxies to complete 
questionnaires based on the patients’ status. Findings of a review by Tang & 
McCorkle (2002) confirmed that ICs’ ratings of terminal cancer patients’ QoL agreed 
moderately well and when discrepancies existed, ICs held a more negative view 
of patients’ QoL than did patients [15]. However, agreement in fatigue ratings has 
not been studied extensively in incurable cancer patients receiving treatment with 
palliative intent. A cross-sectional study focusing on agreement in symptom ratings 
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by 52 advanced lung cancer patients and their ICs found that fatigue ratings were 
moderately correlated [16]. Yet, ICs rated patients’ fatigue significantly higher than 
did patients themselves. ICs’ perceived lack of social support, self-reported health, 
and caregiver self-esteem influenced agreement in various dimensions of symptoms. 
However, none of these three factors appeared to have an impact for agreement on 
fatigue. Another cross-sectional study, assessing agreement between 66 advanced 
cancer patients and their ICs found that agreement for lack of energy was poor to 
fair [17]. In addition, levels of disparity were correlated with IC characteristics (e.g. 
emotional state, caregiver burden) on several individual symptoms and on all symptom 
subscales of the Memorial Symptom Assessment Scale. However, these studies 
had a cross-sectional design and thus it is not possible to determine the pattern of 
agreement in fatigue ratings over time, nor temporal relationships between patients’ 
and ICs’ ratings of fatigue and other variables. Furthermore, no attempt was made to 
determine agreement on clinically relevant levels of fatigue, even though decisions 
about symptom management will often be based on the evaluation of whether fatigue 
is severe enough to be clinically relevant. 
The present exploratory longitudinal study had three aims. First, we aimed to examine 
at the dyadic and group level whether ICs’ ratings of patients’ fatigue are congruent 
with patients’ ratings both when fatigue severity is measured continuously, and when 
the presence or absence of clinically relevant levels of fatigue is determined using a 
questionnaire with a validated cut-off for severe fatigue. Based on previous studies 
reporting poor agreement for more subjective symptoms [15, 18], we expected lack of 
agreement for ICs’ ratings of patients’ fatigue severity on a continuous level. However, 
we did not have hypotheses about the magnitude of this expected disagreement 
or about the agreement of ICs’ and patients’ ratings for clinically relevant levels 
of fatigue. Second, we studied the patterns of agreement over time to investigate 
whether agreement between ICs’ and patients’ perceptions changed over time. 
We had no specific hypothesis for this research question. Finally, predictors for the 
degree of agreement between ICs’ and patients’ fatigue severity ratings over time 
were explored. Based on the findings of previous studies [16, 17], we explored several 
characteristics associated with the IC (i.e. ICs’ fatigue severity, caregiver strain, and/
or caregiver self-esteem) that could explain a significant amount of variance in ICs’ 
perceptions. For ICs with a partner relation to the patient, relationship satisfaction 
was added as a potential predictor since it has been suggested that this relates to 
closeness [19], i.e. sharing thoughts or feelings [20], and thus might influence the 
congruence between ICs’ and patients’ perceptions.
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METHODS 
Study population
The current study was part of a larger study examining fatigue in advanced cancer 
[21, 22]. Patients were recruited between December 2008 and June 2010 from two 
Dutch hospitals, the Radboud university medical center (Nijmegen) and the Jeroen 
Bosch Hospital (Den Bosch). Patients with advanced (i.e. incurable or metastatic) 
cancer who visited the department of medical oncology for cancer treatment with 
palliative intent with a life expectancy of at least six months were invited to participate 
in the study together with their IC. Potential patient participants were identified by 
the treating physician and telephoned by a researcher to explain study procedures. 
In addition, patients received written information. Eligible patients that gave consent 
were asked to identify their principal IC. ICs could either be the patients’ partner or 
have another relation to the patient (e.g. parent, daughter/son, or friend). Identified 
ICs were telephoned by a researcher to verify willingness to participate and also 
received written information. All patients and ICs gave oral informed consent. Paper 
versions of the questionnaires were sent to patients and ICs by mail in separate 
packages, which could be returned in a self-addressed, stamped envelope. ICs were 
explicitly instructed to complete the questionnaires apart from their patient-partners. 
Medical ethical committees of both hospitals approved the study.
Fatigue measurement
Fatigue severity in patients and ICs was assessed with the subscale fatigue severity 
of the Checklist Individual Strength (CIS-fatigue) [23]. Besides reporting their own 
fatigue, ICs also responded to a version of the CIS-fatigue adapted to elicit their 
perspective on the patients’ fatigue. ICs were instructed to focus on how their partner 
(or parent, daughter/son, or friend) had felt during the last two weeks. In addition, 
first-person item statements were changed into the third-person perspective (e.g. 
‘My partner feels fatigued’). The CIS-fatigue consists of 8 items, scored on a 7-point 
Likert scale. Total scores range from 8 (no fatigue) to 56 (severe fatigue). The cut-off 
for severe fatigue is set at 35, i.e. two standard deviations (SD) above the mean of a 
healthy control group [23]. This cut-off has been used previously for assessing severe 
fatigue in cancer patients during or after curative cancer treatment [24-27] as well as 
in patients receiving cancer treatment with palliative intent [28]. The CIS-fatigue was 
administered at baseline (T0) and six months later (T1).
Patient and informal caregiver characteristics
At baseline, characteristics of the patients including demographic data (i.e. age and 
gender) and medical data (i.e. tumour type and treatment modality) were retrieved 
from medical records. In addition, ICs answered demographic questions (i.e. age, 
gender, and relation to the patient) at T0 and questionnaires about caregiver strain 
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and caregiver self-esteem at T0 and T1. The Caregiver Strain Index (CSI) contains 13 
yes/no statements about perceived caregiver strain [29]. Total scores range from 0 
to 13 and a score of 7 or more indicates high caregiver burden. Positive experience 
of caregiving was measured with the subscale self-esteem of the Caregiver Reaction 
Assessment-Dutch (CRA-D) [30]. The CRA-D self-esteem consists of 7 items scored 
on a 5-point Likert scale of 1-5. Total scores range from 7 to 35 and a higher score 
represents more caregiver self-esteem [31]. ICs with a partner relationship to the 
patient also completed a questionnaire about their relationship satisfaction. The 
subscale marital satisfaction of the Maudsley Marital Questionnaire (MMQ) [32] 
consists of 10 items scored on a 9-point Likert scale of 0-8. Total scores range from 
0 (very satisfied) to 80 (very dissatisfied).
Statistical analysis
Only data from dyads where both members had completed the CIS-fatigue were 
included in the analyses. Due to the natural course of the illness, significant attrition 
was expected. No missing data were replaced. Analyses for T1 data only included 
dyads that completed the CIS-fatigue at both T0 and T1. 
ICs’ ratings of patients’ fatigue at baseline
First, an intraclass correlation coefficient (ICC) [33] was calculated to examine 
congruence between patient and IC proxy ratings on the CIS-fatigue [34]. The 
strength of congruence as reflected by the ICC was labelled as follows: ≤ 0.40 poor to 
fair agreement; 0.41-0.60 moderate agreement; 0.61-0.80 good agreement; 0.81-1.00 
excellent agreement [35]. Second, for each dyad, a continuous congruence score 
(CCS) was calculated by subtracting the patients’ CIS-fatigue score from the ICs’ 
CIS-fatigue proxy score, so that a positive CCS denoted the ICs’ proxy assessment 
of patients’ fatigue severity as being higher than that of the patient [36]. Given the 
possible range of 8 to 56 for scores on the CIS-fatigue, possible CCSs ranged between 
-48 and 48. In accordance with previous studies examining dyadic congruence, a 
minimal threshold for a clinically relevant CCS was set at >10% of the possible range 
[37, 38]. Therefore, CCSs exceeding 4.8 or -4.8 were considered clinically relevant. At 
the group level, additional paired samples t-tests were used to determine the mean 
CCS at baseline, being indicative of bias in ICs’ proxy score relative to those of the 
patient. The statistical magnitude of any observed bias was examined by calculating 
the effect size (Cohen’s d) using mean CCS and SD [39]. An effect size of at least 0.2 
was considered small, 0.5 was considered moderate, and 0.8 was considered large 
[39, 40]. 
To examine absolute congruence, CIS-fatigue scores of patients and ICs’ CIS-fatigue 
proxy scores were dichotomized as denoting the presence (≥35) or absence (<35) 
of severe fatigue. Dyadic congruence about the presence or absence of severe 
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fatigue was determined and coded (0=congruence, 1=incongruence). At the group 
level, proportion agreement was calculated to evaluate the amount and direction of 
congruence between patients and ICs. Incongruent dyads were further classified as 
to whether the IC under- or over-estimated the presence of severe fatigue relative to 
the patient. 
ICs’ ratings of patients’ fatigue over time
First, a paired samples t-test was used to test whether the means for CCS at T0 
and T1 differed over time. Second, two separate Bland-Altman plots were drawn 
for agreement at T0 and T1 to visually inspect patterns of agreement over time 
[41, 42]. In this graphical method, the differences between patient and IC ratings 
(CCS) are plotted against the gold standard, i.e. patients’ fatigue ratings [43]. The 
95% limits of agreement were defined as the mean CCS ± 1.96 times the SD of the 
differences. Horizontal lines were drawn for the mean CCS and the upper and lower 
limits of agreement. We inspected width of the 95% limits of agreement, trends in 
agreement, and consistency of variability across the graph for T0 and T1. In addition, 
we calculated the proportion of dyads with a CCS exceeding the threshold for clinical 
relevance. 
To examine absolute congruence over time, we calculated the numbers and 
percentages of dyads that were classified as congruent or incongruent about the 
presence or absence of severe fatigue at T0 and T1.
Predictors of continuous congruence
Bivariate correlations between baseline predictors and CCS at T0 and T1 were 
determined. Following the methods described by Snow et al. (2005), a multivariate 
hierarchical regression analysis was conducted to determine which IC characteristics 
at T0 significantly predicted CCSs at T1 [36]. Predictors were entered into the 
regression model in three blocks: (1) CCS at T0, (2) T0 predictors that significantly 
correlate with CCS at T1, (3) the remaining predictors. All data analyses were performed 
using Statistical Package for Social Science (SPSS; version 20) for Windows. The 
significance level was set at 0.05.
RESULTS
Patients’ and ICs’ characteristics
Of the 142 eligible dyads for the larger study, 131 agreed to participate and 107 
completed the CIS-fatigue at T0, enabling inclusion in this study (75% response). Due 
to expected attrition, 69 of the 107 dyads filled out the CIS-fatigue at both time points 
(64% response). The most common reason for loss of dyads was because the patient 
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died during the study (n=21), followed by patients that did not want to participate any 
further mostly because of disease deterioration (n=14) or for unknown reasons (n=4). 
The demographic and medical characteristics of the total group of 107 patients and 
ICs are presented in Table 1.
Table 1. Baseline characteristics (n=107)
Patients 
N (%)
Informal Caregivers 
N (%)
Mean age in years (min-max) 59 (30-79) 60 (27-80)
Gender
Male
Female
43 (40.2)
64 (59.8)
55 (51.4)
52 (48.6)
Relation to patient
Partner
Other
96 (89.7)
11 (10.3)
Tumor type
Gastrointestinal
Breast
Urogenital
Bone and soft tissue
Gynaecologic
Other
31 (29.0)
28 (26.2)
13 (12.1)
11 (10.3)
10 (9.3)
14 (13.1)
Treatment modality
Chemotherapy
Targeted therapy
Hormonal therapy
Chemo + Targeted therapy
Other
55 (51.4)
19 (17.8)
13 (12.1)
15 (14.0)
5 (4.7)
ICs’ ratings of patients’ fatigue at baseline
At baseline, the intraclass correlation indicated excellent agreement between 
patient and IC proxy ratings (ICC = 0.81). Patients’ mean CIS-fatigue scores and 
ICs’ mean CIS-fatigue proxy scores were 31.9 and 36.6, respectively. ICs’ CIS-
fatigue proxy scores differed significantly from patients’ CIS-fatigue scores. ICs 
tended to overestimate the level of fatigue (mean difference 4.74, SD 9.97, t: 4.917, 
p < .001). The effect size suggested that the amount of systematic bias was moderate 
(Cohen’s d = 0.48). At the group level, the mean CCS for fatigue severity did not 
exceed the clinically relevant threshold (i.e. 4.8 or -4.8). The CCS for each dyad 
exceeded the clinically relevant threshold in 68 of the 107 dyads (64%). 
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When the cut-off for severe fatigue (i.e. ≥ 35) was applied, 81 of the 107 dyads (76%) 
were congruent about the presence (n=43) or absence (n=38) of severe fatigue in 
patients. Of the remaining 26 incongruent dyads, 22 ICs (85%) overestimated the 
presence of severe fatigue, while only 4 ICs (15%) underestimated the presence of 
severe fatigue.
ICs’ ratings of patients’ fatigue over time
The following results are related to the 69 dyads that completed the CIS-fatigue 
(patient and proxy-rating) at both T0 and T1. Dyads lost to follow-up (n=38) were 
not significantly different with respect to mean CCS at T0 compared to dyads that 
completed both assessments (n=69). In addition, ICs’ own fatigue severity, self-
esteem, relationship satisfaction, and strain did not differ significantly at baseline (all 
p’s > 0.05).
The mean CCS for fatigue severity was lower at T1 (2.97, SD 10.28) compared to T0 
(4.62, SD 10.54), though not significantly so (p > 0.05). Figures 1A and 1B depict 
Bland-Altman plots of the difference between patient and IC ratings of patients’ 
fatigue. For both time points, a wide range for the limits of agreement was found. No 
trends were observed and variability across the graph was consistent at both time 
points. The CCS for each dyad exceeded the clinically relevant threshold in 45 (65%) 
and in 48 (70%) of the 69 dyads at T0 and T1, respectively.
We calculated the numbers and percentages of dyads that were classified as 
congruent or incongruent about the presence or absence of severe fatigue at T0 and 
T1. Forty-two of the 51 dyads (82%) that were classified as congruent at T0 were also 
congruent at T1. However, 13 of the 18 dyads (72%) that were incongruent at T0 were 
in agreement about the presence or absence of severe fatigue at T1. 
Predictors of continuous congruence
Table 2 shows descriptives for patients’ fatigue and ICs’ own fatigue severity, strain, 
self-esteem, and relationship satisfaction at T0 and T1. All variables remained largely 
stable over time (p’s > 0.1). Table 3 displays predictor-outcome correlations for T0 
and T1. The CCS at T0, ICs’ own fatigue severity and strain correlated significantly 
with the CCS at T1 (p’s < 0.05). 
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Figure 1A. Bland-Altman plot for agreement at T0 (n=69)
Figure 1B. Bland-Altman plot for agreement at T1 (n=69)
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Table 2. Descriptives of patient and caregiver variables for dyads who completed both T0 and T1
Descriptives T0 Descriptives T1
Patient and caregiver variables Mean SD N Mean SD N
Patient fatigue 30.68 13.32 69 31.71 14.50 69
Caregiver fatigue proxy scores 35.30 14.08 69 34.68 16.16 69
Caregiver fatigue 22.70 13.39 69 22.59 13.27 68
Caregiver strain a 2.87 1.86 68 2.87 2.06 67
Caregiver self-esteem a 26.38 3.78 66 25.78 4.25 68
Caregiver relationship satisfaction b 9.42 9.36 60 10.37 10.41 60
a Due to missing data total N is < 69. b Only calculated for ICs with a partner relation to the patient.
Table 3. Predictor-CCS correlations for dyads who completed both T0 and T1
Predictor-CCS T0 
correlations
Predictor-CCS T1 
correlations
Baseline predictor variables R P-value R P-value
CCS T0 1 n.a. .373 .002*
Caregiver fatigue .335 .005* .418 <.001*
Caregiver strain a .272 .025* .342 .004*
Caregiver self-esteem a -.319 .009* -.234 .058
Caregiver relationship satisfaction b .075 .571 .239 .066
* Statistically significant values (p < .05).
CCS = Continuous Congruence Score. a Due to missing data total N is < 69. b Only calculated for ICs with a partner relation to 
the patient. 
Subsequently, three-block hierarchical regression was used. In block 1, the CCS at 
T0 was entered as a control variable. Block 2 predictors included those variables that 
significantly correlated with CCS at T1 (ICs’ own fatigue severity and strain). Remaining 
predictors in block 3 (self-esteem and relationship satisfaction) were entered based 
on previous research [16, 19]. The CCS at T0 predicted 13% of the variance in CCSs 
at T1. ICs’ own fatigue severity and strain accounted for an additional 10% of the 
variance in CCSs at T1. Block 3 variables did not account for significant additional 
variance. Thus, 22% of the variability in CCSs at six months was explained by the 
CCS at baseline, ICs’ own fatigue severity and strain (Table 4).
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Table 4. Regression model to predict CCS T1
Unstandardized 
Coefficients
Model Summary
Beta S.E. d.f. R2 R2 change F change
Block 1
CCS T0 .357 .125
1, 56 .127 .127 8.137*
Block 2
CCS T0
Caregiver fatigue
Caregiver strain
.247
.138
1.135
.128
.109
.766
1, 54 .224 .098 3.395*
Block 3
CCS T0
Caregiver fatigue
Caregiver strain
Caregiver self-esteem
Caregiver relationship satisfaction
.231
.108
.986
-.193
.161
.132
.112
.788
.440
.149
1, 52 .250 .026 .884
* Statistically significant values (p < .05). CCS = Continuous Congruence Score.
DISCUSSION
The present exploratory longitudinal study was performed to determine congruence 
between patients and ICs about patients’ fatigue severity both on a continuous 
and clinically relevant level during cancer treatment with palliative intent in patients 
with a life expectancy of at least six months. In addition, we examined a number 
of possible predictors of agreement between ICs’ and patients’ ratings of patients’ 
fatigue. The results show that ICs rate patients’ mean fatigue severity significantly 
higher than patients themselves. This echoes with findings in other studies where, 
across diseases and symptoms, ICs tend to over report on more subjective patient 
symptoms and underestimate quality of life [44]. However, the overestimation effect in 
our study was only of moderate size and patient and IC ratings of patients’ fatigue on 
a continuous scale were highly correlated. When fatigue ratings were dichotomised 
around a cut-off of clinically significant fatigue, there was a greater degree of 
agreement. In the small proportion of incongruent dyads, overestimation was more 
likely to occur. No trend for a change in ratings of fatigue on a continuous scale over 
time was observed. When fatigue ratings were dichotomised, an overall tendency to 
either remain congruent or reach congruence over time existed. 
We found that in addition to baseline congruence, several characteristics of the ICs 
also predicted congruence at six months. The fact that ICs’ own fatigue severity and 
strain were associated with less congruence could be due to a reporting bias, which in 
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itself could be related to negative affect on the part of the IC. That is, more strained ICs 
report higher levels of fatigue for themselves and for their patient partners, because 
both measures are confounded or inflated by negative affect. Mulligan et al. (2014) 
showed that negative affect is not only associated with reporting your own symptoms, 
which is already a well established finding, but also with reports of symptoms in others 
[45]. Contrary to our expectations, we did not find a relationship between caregiver 
self-esteem and relationship satisfaction and congruence. However, overall mean 
scores reflected a reasonable amount of caregiver self-esteem and high relationship 
satisfaction, which may have prevented us from finding significant results due to a 
restriction of range effect.
In the present study, it is hard to know what an IC is actually rating when they rate 
the patients’ fatigue. We do not know how ICs estimate how tired the patient feels. It 
would be interesting to explore whether they are for example relying on behavioural 
or verbal correlates of fatigue to make the judgement. McPherson and Addington-
Hall (2004) analysed family members’ narratives and found that family members draw 
on different sources when evaluating advanced cancer patients’ pain, anxiety, and 
depression, such as contextual cues, expectations, behavioural referents, knowledge 
in general and knowledge of the patient [46]. Whether this also applies to estimating 
fatigue remains to be determined. Davis et al. (2007) used a think-aloud approach 
to study discordance in parent-proxy and child self-reported quality of life [47]. 
Application of this qualitative approach while ICs complete the fatigue questionnaire 
might be helpful in further unravelling this.
Measurement issues do not only play a role in the IC-proxy rating. Fatigue is a 
subjective symptom and we worked on the assumption that the patient’s experience 
is primary and that the patient’s expressed ratings are the most valid measures. 
Therefore, patients’ fatigue ratings were taken as the gold standard to which the IC-
proxy rating was compared. Yet, patients’ ratings themselves might be affected by 
various factors. For example, a response shift may cause patients to continuously rate 
fatigue at the same level as previously, even though the IC can observe more fatigue-
related behaviour (e.g. resting more). Alternatively, a qualitative study reported that 
advanced cancer patients admitted intentionally minimizing symptoms to prevent ICs 
from becoming distressed [48]. Thus, for consultations where important treatment 
decisions are to be made, a second rating of patients’ fatigue by an IC may provide 
physicians with a more complete reflection of patients’ fatigue and facilitate discussing 
how well patients are holding up with treatment.
The study has several limitations including the high attrition rate, which resulted in a 
rather small sample size for the longitudinal analyses. The main reason for attrition 
was because the patient died during the study. Although this might have led to a 
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selected group of relatively fit patients at T1, we did not find significant differences 
between dyads that completed the study and dropouts with respect to baseline CCS 
or IC characteristics. Next, the patient-IC relationship was quite homogeneous, with 
almost 90% having a partner relationship. This limits the possibility of generalizing 
our findings to ICs with a different relation to the patient. A further limitation is that 
we adapted the CIS for proxy use without validation of the adapted version. In 
addition, although we tried to secure non-contamination of questionnaires between 
patients and ICs, it is possible that ICs discussed questions or answers with patients. 
Moreover, we focused on IC characteristics as potential predictors for agreement 
but other factors, such as cognitive functioning, patients’ performance status, or 
presence of other symptoms, were not measured in this study and may also impact 
agreement. Also, cancer staging information was not recorded, though based on 
eligibility criteria only patients with a stage 3 or 4 cancer diagnosis were eligible. 
Information about performance status or time since diagnosis was not collected and 
would have been particularly useful in the context of our findings on the course of 
agreement over time. Finally, we analysed our data without multiple test adjustment 
following recommendations for exploratory studies by Bender & Lange (2001), 
thus significant results should be viewed as exploratory results [49]. Despite these 
limitations, to our knowledge this was the first exploratory study investigating ICs’ 
perceptions of patients’ fatigue with a longitudinal design, allowing to study the 
pattern of agreement over time and to explore temporal relationships between IC 
characteristics and agreement. Moreover, the current study used a cut-off point to 
determine clinically meaningful agreement about the presence or absence of severe 
fatigue, adding to studies that merely examined agreement on a continuous level. 
In conclusion, ICs can accurately predict presence or absence of clinically relevant 
levels of severe fatigue in advanced cancer patients receiving treatment with palliative 
intent. However, on a continuous level ICs tend to overestimate patients’ fatigue. For 
ICs, this may trigger the feeling that they need to do more for the patient, which could 
lead to increased IC strain. We suggest that it would be useful to include measures of 
ICs’ ratings of patients’ fatigue when delivering extended care for advanced cancer 
patients. Agreement did not change significantly over time. It is however important 
to take into account ICs’ affective state when asking for judgments about patients’ 
fatigue in both research and clinical settings, as the response is likely to be affected 
if the IC is fatigued or feeling strained. The latter finding also seems to point to the 
need to attend to ICs’ own fatigue and burden in the context of caring for a patient 
with advanced, incurable cancer.
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ABSTRACT 
Background  
Fatigue is a prevalent and burdensome symptom for patients with incurable cancer 
receiving cancer treatment with palliative intent and is associated with poorer quality 
of life. Psychosocial interventions seem promising for the management of fatigue 
among cancer patients.
Objectives 
To assess the effects of psychosocial interventions for fatigue in adult patients with 
incurable cancer receiving cancer treatment with palliative intent.
Search methods  
We searched the following databases: CENTRAL, MEDLINE, Embase, CINAHL, 
PsycINFO, seven clinical trial registries, and the reference lists of articles. The date of 
the most recent search was 29 November 2016.
Selection criteria  
We included randomised controlled trials of psychosocial interventions in adults aged 
18 years or over undergoing cancer treatment with palliative intent for incurable cancer 
compared with usual care or other control groups. Psychosocial interventions were 
defined as various kinds of interventions aiming to influence or change cognitions, 
emotions, behaviour, social interactions, or a combination of these. Psychosocial 
interventions of interest to this review had to involve at least two interactions between 
the patient and the care provider, in which the care provider gave the patient personal 
feedback concerning the changes they were trying to achieve. We included trials if 
they had fatigue as an outcome of interest.
Data collection and analysis  
We used standard methodological procedures expected by Cochrane. Two authors 
independently considered trials for inclusion in the review, assessed risk of bias, 
and extracted data, including information on adverse events. We also assessed the 
evidence using GRADE (Grading of Recommendations Assessment, Development 
and Evaluation) and created a ‘Summary of findings’ table.
Main results 
We identified 14 studies (16 reports) that met inclusion criteria for this review involving 
3077 randomised participants in total. The majority of these studies had a mixed 
sample of participants and we obtained data for the subset of interest to this review 
(diagnosed with incurable cancer and receiving cancer treatment) from the study 
investigators of 12 studies. These 12 studies included in the subset meta-analysis for 
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fatigue post-intervention involved 535 participants. The studies investigated a broad 
range of psychosocial interventions with different intervention aims and durations. 
There were sources of potential bias, including a lack of description of the methods 
of blinding and allocation concealment and small size of the study populations.
Findings from our meta-analysis did not support the effectiveness of psychosocial 
interventions for reducing fatigue post-intervention (SMD -0.25, 95% CI -0.50 to 
0.00; not significant; 535 participants, 12 studies; very low-quality evidence). First 
follow-up findings on fatigue suggested a benefit for participants assigned to the 
psychosocial intervention compared to the control group (SMD -0.66, 95% CI -1.00 
to -0.32; 147 participants, 4 studies; very low-quality evidence), which was not 
sustained at second follow-up (SMD -0.41, 95% CI -1.12 to 0.30; not significant; very 
low-quality evidence).
Results for our secondary outcomes indicated very low-quality evidence for the 
efficacy of psychosocial interventions in improving physical functioning post-
intervention (SMD 0.32, 95% CI 0.01 to 0.63; 307 participants, 7 studies). These 
findings were not sustained at first follow-up (SMD 0.37, 95% CI -0.20 to 0.94; not 
significant; 122 participants, 2 studies; very low-quality evidence). Findings did 
not support the effectiveness of psychosocial interventions for improving social 
functioning (MD 4.16, 95% CI -11.20 to 19.53; not significant; 141 participants, 4 
studies), role functioning (MD 3.49, 95% CI -12.78 to 19.76; not significant; 143 
participants, 4 studies), emotional functioning (SMD -0.11, 95% CI -0.56 to 0.35; not 
significant; 115 participants, 3 studies), or cognitive functioning (MD -2.23, 95% CI 
-12.52 to 8.06; not significant; 86 participants, 2 studies) post-intervention. Only three 
studies evaluated adverse events. These studies did not find a difference between the 
number of adverse events in participants from the intervention versus control group.
Using GRADE, we considered the overall quality of evidence for our primary and 
secondary outcomes to be very low. As such, we have very little confidence in the 
effect estimate and the true effect is likely to be substantially different from the 
estimate of the effect. Limitations to study quality and imprecision due to sparse 
data resulted in downgrading of the quality of the data. Additionally, most studies 
were at high risk of bias due to their small sample size for the subset of patients with 
incurable cancer (fewer than 50 participants per arm) leading to uncertainty about 
effect estimates.
Authors’ conclusions  
There is a lack of evidence around the benefits of psychosocial interventions to 
reduce fatigue in adult patients with incurable cancer receiving cancer treatment with 
palliative intent. Additional studies with larger samples are required to see if there is 
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a benefit of psychosocial interventions to address fatigue in patients with incurable 
cancer.
BACKGROUND  
This review is partly based on suggested wording from the Cochrane Pain, Palliative 
and Supportive Care Review Group (PaPaS CRG).
Description of the condition  
According to the World Health Organization, palliative care is “an approach that 
improves the quality of life of patients and their families facing the problem associated 
with life-threatening illness, through the prevention and relief of suffering by means 
of early identification and impeccable assessment and treatment of pain and other 
problems, physical, psychosocial and spiritual” (WHO 2002). For a long time, cancer 
treatment with palliative intent for patients with incurable cancer was considered 
as the terminal phase, reflecting the last months or year before an expected death. 
However, due to advances in the medical treatment of cancer, more patients with 
incurable cancer receiving cancer treatment with palliative intent can now expect 
to be chronically ill for an extended period of years (Italiano 2008; Miller 2008). This 
leads to ambiguous medical prognoses: patients with incurable cancer may be 
sick enough to die, but could also live for many years (Lynn 2003). Nowadays, it is 
more common to distinguish three stages of cancer treatment with palliative intent 
(Wanrooij 2010). The first phase, disease palliation, has the aim of reducing disease 
activity to improve survival time and quality of life. The second phase, symptom 
palliation, primarily aims to prevent and treat symptoms to improve quality of life. 
The last phase, terminal palliation, focuses on quality of life and quality of dying. The 
current review will focus on patients with incurable cancer receiving cancer treatment 
aimed at disease palliation (phase 1) or receiving cancer treatment aimed at disease 
palliation combined with symptom palliation (phase 1 and 2). This implies that patients 
need to receive some form of cancer treatment.
Fatigue is one of the symptoms most commonly reported by patients receiving 
cancer treatment with palliative intent (Barnes 2002), with reported prevalence rates 
up to 99% (Butt 2008; Hauser 2008; Radbruch 2008; Stone 2008; Teunissen 2007). 
It is frequently cited as being among the most distressing symptoms (Butt 2008; 
Hofman 2007; Paiva 2013). Fatigue is associated with reduced quality of life, poor 
performance status, and difficulty in performing daily activities (Butt 2008; Hauser 
2008; Tanaka 2002). Many factors are likely to contribute to fatigue in patients with 
incurable cancer receiving cancer treatment with palliative intent. Fatigue could result 
from the underlying disease itself, as well as the cancer treatments patients receive. 
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Psychosocial factors can also contribute to fatigue, e.g. sleeping problems and mood 
disturbances such as depression and anxiety (Peters 2014).
There are various ways to define and measure fatigue and there is no consensus 
about the definition of fatigue in cancer patients (Minton 2009; Minton 2013). Cancer-
related fatigue (CRF) is a term that is most widely used to describe this symptom. 
The National Comprehensive Cancer Network (NCCN) defines CRF as “a distressing, 
persistent, subjective sense of physical, emotional and/or cognitive tiredness or 
exhaustion related to cancer or cancer treatment that is not proportional to recent 
activity and interferes with usual functioning” (Mock 2000). A more simple distinction 
between a subjective lack of energy (symptom) or a confirmable decrease in strength 
over time (physical or muscular weakness) has also been used (Stone 1999). The 
most simplified operationalization of fatigue is to ask patients whether or not they 
feel fatigued or tired. We will use the NCCN definition of fatigue for this review. 
However, we will also include studies with tiredness, weakness, lack of energy or 
exhaustion as an outcome of interest. Although according to the NCCN guidelines 
fatigue should be measured by using self-report instruments with established cut-off 
scores (Mock 2000), studies measuring fatigue via other self-report instruments will 
also be included.
Efforts to manage fatigue during cancer treatment with palliative intent for patients 
with incurable cancer should first focus on identifying and treating somatic causes. 
Often, no specific somatic cause of fatigue can be identified other than the underlying 
disease itself or the cancer treatments patients receive. In these situations, the 
management of fatigue usually involves multiple strategies. These strategies can be 
divided into pharmacological and non-pharmacological interventions. Pharmacological 
interventions include stimulant drugs, corticosteroids, erythropoietic agents and 
antidepressants. A Cochrane review focusing on pharmacological interventions 
for fatigue concluded that no recommendation could be given for a specific drug 
treatment for fatigue in palliative care patients (Mücke 2015). Non-pharmacological 
interventions include both psychosocial interventions as well as physical activity. 
Psychosocial interventions are the focus of this review, and will be explained further 
below. The role of physical activity/exercise in the management of fatigue during and 
after cancer treatment is supported by evidence from a Cochrane review (Cramp 
2012). However, it remains unclear whether exercise is also effective for patients 
receiving cancer treatment with palliative intent. Only a few included RCTs were 
focused on this particular patient group.
Description of the intervention  
Psychosocial interventions seem promising for the management of fatigue among 
patients with incurable cancer. For this review, psychosocial interventions are defined 
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as various kinds of interventions aiming to influence or change cognitions, emotions, 
behaviour, social interactions, or a combination of these, in order to achieve better 
mental health and/or fewer problems, for example less fatigue. Such interventions 
may include cognitive behavioural therapy, coping skills training, motivational 
therapy, mindfulness-based stress reduction, and psycho-educational or educational 
therapies, which may be combined with mind-body elements such as yoga, relaxation 
breathing or progressive muscle relaxation. Psychosocial interventions of interest in 
this review involve systematic treatment with at least two interactions between the 
patient and the care provider, in which the care provider gives the patient personal 
feedback concerning the changes they are trying to achieve. Exercise interventions, 
often primarily aimed at increasing physical fitness or level of physical activity, will 
be excluded.
How the intervention might work  
Although there are various interventions aimed at CRF that can be labelled as 
psychosocial, the majority draw techniques from cognitive therapies, behavioural 
therapies, and educational theories. Psychosocial interventions usually include a 
rationale or framework for therapy and collaborative goal setting (Peyrot 2007). Education 
about disease and the role of behaviour, beliefs, and emotions in disease and symptoms 
are common elements of therapy (Authier 1975). In addition, establishing a therapeutic 
alliance between a therapist and a patient is a key component of a psychosocial 
intervention (Frank 1990; Martin 2000; Orlinsky 2004), which consists of an emotional 
bond, agreement on goals, and active collaboration (Bordin 1979; Gaston 1990).
Generally, psychosocial interventions assume that thoughts, feelings, and actions 
are interconnected and can influence fatigue and its consequences. During the 
intervention, patients learn to change thoughts, actions or feelings in relation to 
symptoms. Psychosocial interventions differ in the assumptions made about the 
mechanisms responsible for the change in fatigue brought on by the intervention. 
The assumed mechanisms of change of each intervention are different, depending 
on the theoretical models underpinning them. Psychosocial interventions can use 
one or a combination of techniques or treatment methods to influence symptoms and 
their consequences (Peyrot 2007). An example of a mechanism for reducing fatigue is 
cognitive restructuring used in cognitive therapies (Beck 1970; Beck 1976) to change 
dysfunctional beliefs (e.g. catastrophising or feeling helpless with respect to fatigue) 
and encourage patients to develop more helpful beliefs (Beck 2011). This is thought to 
reduce symptoms or change negative emotional states which worsen symptoms like 
fatigue. Another possible mechanism for reducing fatigue is behaviour modification 
(Bandura 1969) to change behavioural responses to fatigue (e.g. resting when 
fatigued). Influencing these behavioural patterns by, for example, gradually increasing 
physical activity in patients, can be used to reduce symptoms and enhance patients’ 
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self-efficacy (Bandura 1997). These are only examples of assumed mechanisms, and 
more potentially-effective techniques and treatment methods with their own specific 
therapeutic mechanisms responsible for the reduction in CRF are available, such as 
yoga or (psycho) educational therapies (see also the American Society of Clinical 
Oncology [ASCO] clinical practice guidelines; Bower 2014).
While research has provided empirical support for the efficacy of psychosocial 
interventions for fatigue irrespective of the presence of a medical condition, knowledge 
about the therapeutic mechanisms of these interventions is scarce. The limited work 
that has been done is primarily performed in the field of cognitive behaviour therapy 
(CBT) for patients with medically-unexplained fatigue (i.e. chronic fatigue syndrome 
[CFS]). Mediation analysis of CBT for CFS demonstrated that changes in both beliefs 
and behaviour can mediate the effects of CBT (Chalder 2015; Wiborg 2011; Wiborg 
2012). Mediation analysis of CBT for patients with multiple sclerosis showed that 
the decrease in fatigue was explained by a change in beliefs about fatigue (Knoop 
2012). The lack of knowledge about therapeutic mechanisms is even more evident for 
interventions reducing fatigue in patients with cancer. Although CBT was found to be 
effective for reducing post-cancer fatigue (Gielissen 2006) and is now recommended 
in the ASCO clinical practice guidelines for cancer-related fatigue (Bower 2014), the 
mechanisms of change are not known, but the effects on fatigue were not mediated 
by an increase in objective physical activity or fitness (Gielissen 2012; Prinsen 2013). 
To permit unequivocal conclusions to be drawn about the therapeutic mechanisms of 
psychosocial interventions that may produce a reduction in fatigue, further research 
is needed.
Why it is important to do this review  
Advances in the medical treatment of patients with incurable cancer have led to 
prolonged survival. Maintaining quality of life is an important goal of cancer treatment 
with palliative intent. Fatigue is not only a prevalent symptom, but also a factor 
affecting patients’ quality of life. A previous Cochrane review (Goedendorp 2009) 
investigated the effectiveness of psychosocial interventions among adult cancer 
patients receiving cancer treatment. However, few RCTs in that review included only 
patients with incurable cancer receiving cancer treatment with palliative intent, and 
the review did not analyse the effectiveness of psychosocial interventions for fatigue 
in these patients separately. The current review will replace Goedendorp 2009. It will 
differ from the previous review by focusing exclusively on fatigue in patients with 
incurable cancer. Our current review will aid oncologists providing cancer treatment 
with palliative intent, to inform patients about evidence-based psychosocial interven-
tions for fatigue.
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OBJECTIVES  
To assess the effects of psychosocial interventions for fatigue in adult patients with 
incurable cancer receiving cancer treatment with palliative intent.
METHODS
Criteria for considering studies for this review  
Types of studies  
We only included randomised controlled trials (RCTs). We required full journal 
publication, with the exception of online clinical trial results, summaries of otherwise 
unpublished clinical trials, and abstracts with sufficient data for analysis.
Types of participants  
We included studies of adult patients (aged 18 years and above) with a diagnosis of 
incurable (advanced or metastatic) cancer. We included studies in which participants 
received some form of disease-focused treatment, such as chemotherapy, hormonal 
therapy, targeted therapy, immunotherapy, surgery, and/or radiation therapy. For 
studies with a mixed sample of participants with either curable and incurable cancer 
and/or either receiving cancer treatment or not receiving cancer treatment, we only 
included those participants with incurable cancer and receiving cancer treatment. We 
contacted the authors with a request for data or results where separate information on 
cancer diagnosis and/or treatment was not reported in the study. If separate data for 
the subset of participants of interest to this review could not be provided or authors 
did not respond after two reminders, we only included the study if it reported 80% or 
more having incurable cancer and receiving cancer treatment. We excluded studies in 
which patients received terminal care (i.e. hospice or end-of-life care).
Types of interventions  
We included studies with a broad range of psychosocial interventions compared to usual 
care or control conditions (not being a psychosocial intervention). These interventions 
included psychotherapy, psycho-education, or support groups, and interventions 
including elements such as cognitive restructuring, changing coping strategies, self-help 
or self-care, relaxation, energy conservation, or stress management. The psychosocial 
interventions could be given individually or in groups, and by care providers from different 
professions such as psychologists or nurses. We only included psychosocial interventions 
involving a systematic treatment with at least two contacts between the patient and the 
care provider, in which personal feedback concerning the changes the patient was trying 
to achieve was given. For example, in the first session a care provider might advise 
a patient to change their coping behaviour aiming to reduce fatigue, whilst discussing 
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the progress of the patient and giving feedback on the patient’s behaviour in following 
sessions. We excluded studies in which interventions were exclusively aimed at exercise.
Types of outcome measures  
Studies used a variety of outcome measures. Included studies had fatigue, tiredness, 
weakness, lack of energy, lack of vitality, or exhaustion as an outcome of interest. 
Fatigue could be assessed by specific validated fatigue questionnaires with multiple 
items or by other self-report methods. Examples of the latter are one or more items 
on fatigue as part of a quality of life instrument, a Numerical Rating Scale (NRS), a 
Visual Analogue Scale (VAS) assessing fatigue, or assessment of fatigue as part of 
a symptom list and scored as ‘present’ or ‘absent’. Secondary outcomes included 
physical, social, role, emotional, and cognitive functioning assessed by a suitable 
instrument such as the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30) or the Short Form Health Survey.
We measured adverse events of psychosocial interventions as absent or present. We 
provided a narrative description of these effects. In addition, we analysed measures 
of function when used as an outcome measure in studies.
Primary outcomes
1.  Fatigue post-intervention (alternative terms: tiredness, weakness, lack of energy, 
lack of vitality, or exhaustion).
Secondary outcomes
1. Fatigue (first and second follow-up);
2. Physical functioning (post-intervention and at first and second follow-up);
3. Social functioning (post-intervention);
4. Role functioning (post-intervention);
5. Emotional functioning (post-intervention);
6. Cognitive functioning (post-intervention);
7. Adverse events of psychosocial interventions (post-intervention).
Search methods for identification of studies  
Electronic searches  
We searched the following databases without language or date restrictions:
· 	The Cochrane Central Register of Controlled Trials (CENTRAL) (via CRSO) searched 
29/11/16;
· 	MEDLINE (via Ovid) 1946 to Nov week 3 2016;
· 	Embase (via Ovid) 1974 to 2016 Nov 29;
· 	CINAHL (via EBSCOhost) 1982 to November 2016;
· 	PsycINFO (via Ovid) 1806 to November week 3 2016.
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We used Medical Subject Headings (MeSH) or equivalent and text word terms. 
We exploded MeSH terms where appropriate. Where appropriate we applied the 
Cochrane filter for the identification of RCTs, as published in the Cochrane Handbook 
for Systematic Reviews of Interventions (Higgins 2011). The search strategies can be 
found in Appendix 2-6.
Searching other resources  
We searched the metaRegister of controlled trials (mRCT) (http://www.controlled-trials.
com/mrct), clinicaltrials.gov (http://www.clinicaltrials.gov), the WHO International 
Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/), the 
Australian New Zealand Trials Registry (http://www.anzctr.org.au/), the ISRCTN 
register (http://www.isrctn.com/), the UMIN Clinical Trials Registry (http://www.umin.
ac.jp/ctr/), and the Netherlands Trial Register (http://www.trialregister.nl/trialreg/
index.asp) with the keywords ‘cancer’ and ‘fatigue’ to identify additional completed 
or ongoing studies. In addition, we checked relevant reviews and reference lists of 
retrieved articles for additional studies, and we performed citation searches on key 
articles. Where necessary, we contacted authors for additional information.
Data collection and analysis  
Selection of studies  
Two review authors (HP, MP) independently determined eligibility by reading the 
abstract of each study identified by the search. These two authors independently 
eliminated studies that clearly did not satisfy inclusion criteria, and obtained full copies 
of the remaining studies. The same two authors read these studies independently to 
select relevant studies, and in the event of disagreement, a third author adjudicated 
(HK). We did not anonymise the studies before assessment. We included a Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart 
which shows the status of identified studies (Moher 2009), as recommended in Part 
2, Section 11.2.1 of the Cochrane Handbook (Higgins 2011).
Data extraction and management  
Two review authors (HP, MP) independently extracted data using a standard form 
and checked for agreement before entry into Review Manager (RevMan 2014). We 
included information about:
Participant characteristics
·	 Demographic characteristics such as age and gender;
·	 Disease characteristics such as cancer diagnosis and cancer treatment;
·	 Inclusion/exclusion criteria for participation in study.
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Psychosocial intervention characteristics
We extracted the following information for each study arm:
·	 Nature, type of delivery, and content of the intervention and control condition;
·	 	Time point of delivery of intervention in relation to cancer treatment (during or 
after);
·	 Duration of the intervention and total number of sessions;
·	 Description and number of intervention providers;
·	 Duration and nature of training and supervision given to the intervention providers;
·	 Participant adherence and contamination;
·	 Intervention provider treatment integrity and existence of treatment protocol.
Methods and outcomes
·	 Random sequence generation;
·	 Allocation concealment;
·	 Incomplete outcome data (amount, nature and handling of missing data);
·	 Size of the study and power calculation;
·	 Blinding of outcome assessors;
·	 Quality of the control condition;
·	 Equality of treatment expectations;
·	 Therapist and/or researcher allegiance;
·	 Key outcomes and measurement instruments used to assess fatigue;
·	 Adverse events of the psychosocial intervention;
·	 Timing, frequency and duration of follow-up for each outcome;
We collated multiple reports of the same study, so that each study rather than 
each report was the unit of interest in the review. We collected characteristics of 
the included studies in sufficient detail to populate the ‘Characteristics of included 
studies’ table. A study authored and co-authored by five of the review authors was 
included in the ‘Characteristics of ongoing studies’ table.
Assessment of risk of bias in included studies  
Two authors (HP, MP) independently assessed risk of bias for each study, using the 
criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins 2011) and adapted from those used by the Cochrane Pregnancy and 
Childbirth Group. We resolved any disagreements by discussion. We completed a 
‘Risk of bias’ table for each included study using the ‘Risk of bias’ tool in RevMan 
(RevMan 2014).
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We assessed the following for each study:
·	 	Random sequence generation (checking for possible selection bias). We assessed 
the method used to generate the allocation sequence as: low risk of bias (any truly 
random process, e.g. random number table; computer random number generator) 
or unclear risk of bias (method used to generate sequence not clearly stated). We 
excluded studies using a non-random process (e.g. odd or even date of birth; 
hospital or clinic record number).
·	 	Allocation concealment (checking for possible selection bias). The method used 
to conceal allocation to interventions prior to assignment determines whether 
intervention allocation could have been foreseen in advance of, or during 
recruitment, or changed after assignment. We assessed the methods as: low risk 
of bias (e.g. telephone or central randomisation; consecutively numbered sealed 
opaque envelopes) or unclear risk of bias (method not clearly stated). We excluded 
studies that did not conceal allocation (e.g. open list).
·	 	Blinding of outcome assessment (checking for detection bias). This is usually 
assessed based on the methods used to blind study participants and personnel 
from knowledge of which intervention a participant received. However, in RCTs 
investigating the effects of psychosocial interventions, it is impossible to blind 
the care providers to the intervention they are giving to patients. It is also nearly 
impossible to blind the patients to the intervention to which they were assigned. 
We judged risk of bias in blinding of outcome assessment on whether the 
measures were administered and collected by an assessor who was blind to the 
treatment allocation. We assessed the methods as: low risk of bias (study states 
that outcome assessment was blinded and describes the method used to achieve 
blinding); unclear risk of bias (study states that it was blinded but does not provide 
an adequate description of how it was achieved); or high risk of bias (studies in 
which outcome assessors were not blinded).
·	 	Incomplete outcome data (checking for possible attrition bias due to the amount, 
nature and handling of incomplete outcome data). We assessed the methods used 
to deal with incomplete data as: low risk (< 10% of participants did not complete 
the study or > 10% with sensitivity analysis or mixed model analysis); unclear risk 
of bias (used ‘last or baseline observation carried forward’ analysis, as progression 
in terms of fatigue is not unexpected in advanced cancer patients with missing 
outcome data); or high risk of bias (used ‘completer’ analysis or post-intervention 
t-test).
·	 	Selective reporting (checking for possible reporting bias). We assessed studies as 
being at low risk of bias (all the data fully reported in the study); unclear risk of bias 
(data not fully reported in the study, but authors responded to data requests); or 
high risk of bias (data not fully reported in the study and authors did not respond 
to data requests).
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·	 	Size of the study (checking for possible biases confounded by small size). We 
assessed studies as being at low risk of bias (≥ 200 participants per treatment 
arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of 
bias (< 50 participants per treatment arm).
·	 	Yates 2005 developed a quality rating scale designed to measure the quality 
of RCTs for psychological interventions. Based on their recommendations, we 
included two further items to assess (1) the quality of the control condition and 
the efforts made to ensure that as many features as possible have been controlled 
for (adequate, partial, inadequate); and (2) equality of treatment expectations 
(adequate, inadequate). Furthermore, when reported, we noted the allegiance 
of the therapist and/or researcher to a particular psychosocial intervention (see 
‘Characteristics of included studies’ table) to take an allegiance effect into account 
(Berman 1985; Wampold 2001; Dragioti 2015).
Measures of treatment effect  
We evaluated fatigue outcomes at both post-intervention and follow-up assessments 
using RevMan (RevMan 2014). We calculated the mean difference and 95% confidence 
interval (CI) for continuous data. If not reported, we planned to calculate standard 
deviations using the methods described in the Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins 2011). We standardized mean differences of 
assessment tools measuring fatigue in different ways in order to combine results 
across tools and used mean differences otherwise. We planned to calculate the 
relative risks (RRs) and 95% CI where dichotomous data were reported (i.e. studies 
measuring fatigue as present or absent). We planned to report the proportion of 
participants experiencing any adverse events of psychosocial interventions, and 
combine studies using RR (and 95% CI).
Unit of analysis issues  
One study had more than two intervention arms (Johansson 2008). It was decided that, 
the three arms which had relevant interventions for the aim of this review would be 
combined into one intervention group. We planned to report intra-cluster correlations 
and undertake adjustment where necessary for any identified randomised cluster 
trials.
Dealing with missing data  
We analysed data for all participants in the group to which they were randomised, 
regardless of whether or not they received the allocated treatment. We did not exclude 
trials on the basis of missing data. In the Discussion section we address the potential 
impact of missing data on the findings of the review.
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Assessment of heterogeneity  
We assessed clinical diversity by documenting the participant characteristics 
represented in each study, focusing on factors such as age, gender, study eligibility 
criteria, cancer diagnosis and cancer treatment. Furthermore, we documented 
heterogeneity in psychosocial interventions, such as duration, delivery, profession 
of the care providers, and nature of the control condition. In addition, we assessed 
diversity in ways of measuring fatigue and timing of fatigue assessment.
Assessment of reporting biases  
We assessed the possibility that publication bias affected this review as a whole using 
a funnel plot.
Data synthesis
Two authors (HP, MP) independently assessed heterogeneity by visual inspection of 
the forest plot, and based on the quantitative results of both the X2 and the I2 statistic. 
We performed meta-analysis for clinically homogeneous studies according to the 
inverse-variance method for continuous outcomes. We planned to use fixed-effect 
models, but since the patient populations were quite variable in cancer diagnosis 
and treatment (as were the interventions), we employed random-effects models. We 
expressed results as standardised mean differences (SMDs) or mean differences 
(MDs) for continuous outcomes. For any dichotomous outcomes, we would have 
expressed results as risk ratios (RR) using the Mantel-Haenszel method. We used 
Review Manager software for analysis (RevMan 2014). We presented a narrative 
synthesis for studies for which required data were unavailable for meta-analysis.
Quality of the evidence
Two review authors (HP, MP) independently rated the quality of each outcome. We 
used the GRADE (Grades of Recommendation, Assessment, Development and 
Evaluation) system to rank the quality of the evidence using the GRADEprofiler Guideline 
Development Tool software (GRADEpro 2015), and the guidelines provided in Chapter 
12.2 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
The GRADE approach uses five considerations (study limitations, consistency of 
effect, imprecision, indirectness and publication bias) to assess the quality of the 
body of evidence for each outcome. The GRADE system uses the following criteria 
for assigning grade of evidence:
·	 	High: we are very confident that the true effect lies close to that of the estimate of 
the effect;
·	 	Moderate: we are moderately confident in the effect estimate; the true effect is 
likely to be close to the estimate of the effect, but there is a possibility that it is 
substantially different;
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·	 	Low: our confidence in the effect estimate is limited; the true effect may be 
substantially different from the estimate of the effect;
·	 	Very low: we have very little confidence in the effect estimate; the true effect is 
likely to be substantially different from the estimate of effect.
We decreased the grade rating by one (- 1) or two (- 2) if we identified:
·	 Serious (-1) or very serious (-2) limitation to study quality;
·	 Important inconsistency (-1);
·	 Some (-1) or major (-2) uncertainty about directness;
·	 Imprecise or sparse data (-1);
·	 High probability of reporting bias (-1).
‘Summary of findings’ table
We included a ‘Summary of findings’ table to present the main findings in a transparent 
and simple tabular format. In particular, we included key information concerning the 
quality of evidence, the magnitude of effect of the interventions examined, and the sum 
of available data on the outcomes of fatigue, physical functioning, social functioning, 
role functioning, emotional functioning, cognitive functioning, and adverse events of 
psychosocial interventions.
Subgroup analysis and investigation of heterogeneity  
Where sufficient data were available, we planned to undertake subgroup analysis 
for the primary outcome based on aspects of the intervention that may influence its 
effectiveness: duration (short versus intermediate-long), intervention delivery (group 
versus individual, psychologist versus other profession), intervention type (mono 
versus multidisciplinary), and aim of the intervention (aimed at decreasing fatigue 
versus other). We did not perform subgroup analysis for the intervention deliverer 
(psychologist versus other profession), as insufficient data were available. In addition, 
we planned to perform subgroup analysis for type of assessment tool (continuous 
versus dichotomous) and for studies in which some level of fatigue was an eligibility 
criterion for patient participation versus those in which it was not. Due to insufficient 
data available, we were unable to perform these subgroup analyses. Given the low 
number of studies with a low overall risk of bias (i.e. an estimated low risk of bias 
in all domains of the ‘Risk of bias’ assessment) we did not use subgroup analysis 
based on overall risk of bias. We performed post-hoc subgroup analyses based on 
the provision of additional sessions between post-intervention and first and second 
follow-up assessments of fatigue (no additional sessions versus booster sessions).
Sensitivity analysis  
We performed post-hoc sensitivity analyses based on the number of participants 
per treatment arm at post-intervention and follow-up assessments, excluding those 
studies with fewer than 10 participants per treatment arm.
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2874 records
identied through 
database searching
1916 records after 
duplicates removed
1741 records excluded
4 records unable 
to retreive full-text
1916 records screened
132 full-text articles excluded
23 full-text articles excluded 
with reasons (21 studies)
171 full-text articles 
assessed for eligibility
14 studies included 
in qualitative synthesis
(across 16 reports)
12 studies included 
in quantitative synthesis
(meta-analysis)
7 additional records 
identied through 
other sources
Figure 1. Study flow diagram
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RESULTS  
Description of studies
Key characteristics of the included studies are summarized below and in the 
Characteristics of included studies table. The excluded studies with potential 
relevance to this review are listed with reasons for their exclusion in the Characteristics 
of excluded studies table.
Results of the search
Our search identified 1909 unique citations after duplicates were removed through 
database searching. An additional seven citations were identified through conference 
abstracts or other references. After initial screening of the 1916 titles and abstracts 
for relevance to the review we retained 171 citations. We were unable to retrieve full-
texts for four citations and excluded a further 132 citations that, based on the full text, 
and in some cases correspondence with original study investigators, did not meet the 
eligibility criteria. We excluded 21 studies (23 reports) with reasons. Therefore, there 
were 14 studies (16 reports) that met the inclusion criteria and were included in the 
review. For a further description of our screening process, see the study flow diagram 
Figure 1.
Included studies 
Design
All 14 included studies were RCTs. In 13 studies the unit of randomisation was the 
individual participant (Armes 2007; Barsevick 2004; Barsevick 2010; Bordeleau 2003; 
Bruera 2013; Chan 2011; Classen 2001; Johansson 2008; Savard 2006; Sharpe 2014; 
Spiegel 1981; Steel 2016; Walker 2014). In one study the unit of randomisation was a 
group of 20 participants, with 10 being randomised to each condition (Edelman 1999).
Setting
Six studies were conducted in the United States of America (Barsevick 2004; 
Barsevick 2010; Bruera 2013; Classen 2001; Spiegel 1981; Steel 2016), three in the 
UK (Armes 2007; Sharpe 2014; Walker 2014), two in Canada (Bordeleau 2003; Savard 
2006), one in Australia (Edelman 1999), one in Hong Kong (Chan 2011), and one in 
Sweden (Johansson 2008). The primary settings were university-affiliated hospitals in 
five studies (Bordeleau 2003; Classen 2001; Spiegel 1981; Johansson 2008; Savard 
2006), cancer centres in seven studies (Armes 2007; Bruera 2013; Barsevick 2004; 
Barsevick 2010; Sharpe 2014; Steel 2016; Walker 2014), and a public hospital in two 
studies (Chan 2011; Edelman 1999).
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Cancer diagnosis
In this review, we were interested in the effects of psychosocial interventions in 
participants diagnosed with incurable cancer. In six studies, all participants were 
diagnosed with incurable cancer (Bruera 2013; Bordeleau 2003; Classen 2001; 
Edelman 1999; Savard 2006; Spiegel 1981). Five of those studies included patients 
with metastatic breast cancer (Bordeleau 2003; Classen 2001; Edelman 1999; 
Savard 2006; Spiegel 1981), the other study included patients with any diagnosis of 
advanced cancer (Bruera 2013). The eight remaining studies had a mixed sample of 
participants diagnosed with incurable and potentially curable cancer (Armes 2007; 
Barsevick 2004; Barsevick 2010; Chan 2011; Johansson 2008; Sharpe 2014; Steel 
2016; Walker 2014). The original study investigators of those eight studies were able 
to provide data for their subset of participants with incurable cancer and were thus 
included in the review.
Cancer treatment
In this review, we were interested in the effects of psychosocial interventions in 
participants receiving cancer treatment. In five studies, all participants were receiving 
cancer treatment during the intervention (Armes 2007; Barsevick 2004; Barsevick 
2010; Chan 2011; Classen 2001). In seven studies, not all participants were receiving 
cancer treatment (Bordeleau 2003; Johansson 2008; Savard 2006; Sharpe 2014; 
Spiegel 1981; Steel 2016; Walker 2014). However, the original study investigators 
of those studies were able to extract data for their subset of participants receiving 
cancer treatment and thus these studies were included in the review. In the remaining 
two studies, it was unclear or unknown whether all participants were receiving cancer 
treatment (Bruera 2013; Edelman 1999). Clarification was sought from the original 
study investigators. Bruera 2013 confirmed that all participants were receiving cancer 
treatment. Edelman 1999 did not collect data on who was receiving treatment at the 
time of study participation. Yet, we believe it is likely that participants were receiving 
at least some form of cancer treatment during the intervention given the study 
population of patients with metastatic breast cancer. Therefore, both studies were 
included in the review.
Participants
The total sample sizes for the included studies ranged from 45 (Savard 2006) to 500 
randomised participants (Sharpe 2014). However, as noted before, not all participants 
were diagnosed with incurable cancer and/or receiving cancer treatment. As a result, 
the sample sizes for the subset of participants of interest to this review were much 
smaller ranging from 15 (Walker 2014) to 110 evaluable participants (Chan 2011) 
at post-intervention assessment. Information on age and gender distribution was 
available for the total samples of the included studies, but not for the subset of interest 
to our review. The participants’ mean age for the total sample ranged from 50 years 
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(Edelman 1999) to 64 years (Walker 2014). No information on the age distribution 
was reported in Chan 2011, but these data were provided upon request. Nine studies 
included both men and women (Armes 2007; Barsevick 2004; Barsevick 2010; Bruera 
2013; Chan 2011; Johansson 2008; Sharpe 2014; Steel 2016; Walker 2014), with 
the proportion of males in the total sample ranging from 10% (Sharpe 2014) to 83% 
(Chan 2011). Four studies targeted only women (Bordeleau 2003; Classen 2001; 
Savard 2006; Spiegel 1981). Edelman 1999 did not provide any information on the 
gender distribution of the participants. We believe it is likely that only women were 
included given the study population of patients with metastatic breast cancer. Finally, 
it is important to note that Sharpe 2014 and Walker 2014 recruited only patients with 
a diagnosis of major depression comorbid with cancer.
Content of the intervention
A detailed description of the interventions delivered is provided in the Characteristics 
of included studies table. The interventions from 10 studies fell into one of three 
categories: cognitive behavioural therapies (n=5; Armes 2007; Savard 2006; Edelman 
1999; Johansson 2008; Steel 2016), supportive-expressive group therapies (n=3; 
Bordeleau 2003; Classen 2001; Spiegel 1981), and energy conservation approaches 
combined with either activity management or sleep modification techniques (n=2; 
Barsevick 2004; Barsevick 2010). Four interventions did not fall within these 
categories. In Bruera 2013 the intervention included psychosocial support and 
education combined with either methylphenidate or placebo. The intervention in 
Sharpe 2014 and Walker 2014 included antidepressant medication in combination 
with problem-solving therapy and behavioural activation. Chan 2011 examined the 
effects of a psycho educational intervention consisting of education and relaxation. It 
was unclear whether the intervention protocol used in this study included some kind 
of personal feedback. Clarification was sought from the original study investigators, 
who confirmed that participants received personal feedback.
Nature of the intervention
The purpose of the interventions varied. Six studies investigated interventions 
specifically aimed to address fatigue (Armes 2007; Barsevick 2004; Barsevick 2010; 
Bruera 2013; Chan 2011; Steel 2016). In addition to fatigue, the intervention of Steel 
2016 also aimed to reduce depression and pain. The intervention of Chan 2011 also 
aimed to reduce anxiety and breathlessness in addition to fatigue. Two of the six 
studies required some level of fatigue as an eligibility criterion for patient participation 
(Armes 2007; Bruera 2013). In the remaining eight studies, the intervention was aimed 
at mood disturbances and/or psychological benefit (Classen 2001; Johansson 2008; 
Savard 2006; Sharpe 2014; Spiegel 1981; Walker 2014), quality of life (Bordeleau 
2003), or survival benefit (Edelman 1999).
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Duration of the intervention
The total intervention duration varied between studies and ranged from short (two to 
three weeks) in four studies (Bruera 2013; Barsevick 2004; Barsevick 2010; Chan 2011) 
to long (12 months) in three studies (Bordeleau 2003; Classen 2001; Spiegel 1981). In 
the remaining seven studies, the intervention was given over a period of two to eight 
months and these were classified as having an intermediate duration (Armes 2007; 
Edelman 1999; Johansson 2008; Savard 2006; Sharpe 2014; Steel 2016; Walker 2014). 
In the study by Steel 2016, the total intervention duration was not clearly stated but it is 
likely that the intervention was given over a period of six months after which the post-
intervention assessment took place. In four studies, interventions consisted of an initial 
more intense intervention delivery during the first two (Edelman 1999; Savard 2006) or 
four months (Sharpe 2014; Walker 2014), followed by additional sessions (if needed) for 
a further period ranging from nine weeks (Savard 2006) to eight months (Sharpe 2014).
Providers
The intervention was delivered by nurses in four studies (Barsevick 2004; Barsevick 
2010; Bruera 2013; Chan 2011) and by a combination of therapists (i.e. two or more 
psychologists, psychiatrists, counselors, and/or social workers) in five studies 
(Bordeleau 2003; Classen 2001; Edelman 1999; Spiegel 1981; Savard 2006). In 
one study, psychologists, physiotherapists, and nurses delivered the interventions 
(Johansson 2008). In two studies, interventions were delivered by non-clinicians, i.e. 
a research fellow (Armes 2007) or master’s level/PhD therapists (Steel 2016). Finally, a 
team consisting of a nurse, psychiatrist and the participant’s primary care physicians 
delivered the interventions in Sharpe 2014 and Walker 2014.
Delivery of the intervention
The psychosocial interventions were delivered using different approaches. In six studies 
interventions were delivered individually, either face-to-face (Armes 2007; Chan 2011; 
Savard 2006) or by telephone (Barsevick 2004; Barsevick 2010; Bruera 2013). Four 
studies used blended methods for intervention delivery consisting of individual face-to-
face and telephone contacts (Johansson 2008; Sharpe 2014; Steel 2016; Walker 2014). 
In addition to these delivery channels, Johansson 2008 also used face-to-face group-
based interventions and Steel 2016 also used a web-based platform. In four studies 
interventions were delivered in groups (Bordeleau 2003; Classen 2001; Edelman 1999; 
Spiegel 1981).
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Training and supervision
Ten studies (Armes 2007; Barsevick 2004; Barsevick 2010; Bordeleau 2003; Bruera 
2013; Chan 2011; Sharpe 2014; Spiegel 1981; Steel 2016; Walker 2014) reported that 
providers of the intervention were trained. The remaining four studies did not report 
whether providers were trained before delivering the intervention (Classen 2001; 
Edelman 1999; Johansson 2008; Savard 2006). Supervision of intervention delivery 
was reported in 11 studies (Armes 2007; Barsevick 2004; Barsevick 2010; Bordeleau 
2003; Bruera 2013; Johansson 2008; Savard 2006; Sharpe 2014; Spiegel 1981; Steel 
2016; Walker 2014). Three studies did not report whether intervention delivery was 
supervised (Chan 2011; Classen 2001; Edelman 1999).
Control condition
Nine studies compared the effects of a psychosocial intervention to usual care. In 
eight of those studies the usual care was no intervention (Armes 2007; Chan 2011; 
Edelman 1999; Johansson 2008; Sharpe 2014; Spiegel 1981; Steel 2016; Walker 
2014), the other study assigned participants to a wait list condition (Savard 2006). In 
three studies, the intervention effects were compared to an attentional control group 
(Barsevick 2004; Barsevick 2010; Bruera 2013). In Classen 2001, participants in the 
control conditions were provided with a self-directed educational intervention, but the 
education materials were also provided to participants randomised to the intervention 
condition. In Bordeleau 2003, all participants received educational materials about 
breast cancer and its treatment, relaxation, and nutrition.
Outcome measures
Fatigue
All 14 included studies reported fatigue either as a primary, secondary or tertiary 
outcome. Ten studies used one instrument to measure fatigue (Chan 2011; Classen 
2001; Edelman 1999; Johansson 2008; Savard 2006; Sharpe 2014; Spiegel 1981; Steel 
2016; Walker 2014). The remaining four studies used two or more instruments (Armes 
2007; Barsevick 2004; Barsevick 2010; Bruera 2013). Five of the 14 studies used the 
fatigue subscale of the Profiles of Mood States (POMS) (Barsevick 2004; Barsevick 
2010; Classen 2001; Edelman 1999; Spiegel 1981). Another five studies used the 
fatigue scale of the EORTC QLQ-C30 (Armes 2007; Bordeleau 2003; Johansson 
2008; Sharpe 2014; Walker 2014). The four remaining studies used other instruments 
to evaluate fatigue: Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue 
Scale (Bruera 2013); Revised Piper Fatigue Scale, subscale intensity (Chan 2011); 
Multidisciplinary Fatigue Inventory (Savard 2006); and Functional Assessment of 
Cancer Treatment (FACT) Fatigue (Steel 2016). The four studies evaluating fatigue 
with more than one instrument used the following additional instruments: Visual 
Analogue Scale (VAS) of global fatigue (Armes 2007); Schwartz Cancer Fatigue Scale 
(Barsevick 2004); General Fatigue Scale (Barsevick 2004; Barsevick 2010); and the 
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subscale fatigue of the Edmonton Symptom Assessment Scale (ESAS) (Bruera 2013). 
Except for the single-item VAS of global fatigue used in the study of Armes 2007, all 
instruments are comprised of multiple items to measure fatigue.
Physical, social, role, emotional and cognitive functioning
Several measures of function were used in a number of the studies. Eight studies 
assessed physical functioning (Armes 2007; Barsevick 2010; Bordeleau 2003; Chan 
2011; Johansson 2008; Savard 2006; Sharpe 2014; Walker 2014). Six of those eight 
studies used the physical functioning scale of the EORTC-QLQ-C30 and the other two 
studies used the physical component of the Short-Form Health Survey (SF-12 and 
SF-36). Social and role functioning was assessed in four studies (Bordeleau 2003; 
Johansson 2008; Sharpe 2014; Walker 2014) using the scales of the EORTC QLQ-C30. 
Emotional functioning was assessed in three studies using either the scale of the 
EORTC QLQ-C30 (Bordeleau 2003; Johansson 2008) or the mental component of 
the SF-12 (Barsevick 2010). Cognitive functioning was assessed in two studies using 
the scale of the EORTC QLQ-C30 (Bordeleau 2003; Johansson 2008). Two studies 
used other measures to evaluate functioning. Barsevick 2004 used a total score for 
the Functional Performance Inventory, a 65-item scale consisting of six subscales, 
including body care, household maintenance, physical exercise, recreation, spiritual 
activities, and social activities. In addition to the physical and mental component 
summary scores of the SF-12, Barsevick 2010 also used the interference items from 
the Brief Pain Inventory adapted to apply to symptoms rather than pain only (SXINT) 
and the Eastern Cooperative Oncology Group Performance Status.
Adverse events
Only three studies assessed adverse events of the intervention and reported the 
number of adverse events for the total sample (Bruera 2013; Sharpe 2014; Walker 
2014). Bruera 2013 recorded the number of Grade ≥ 3 adverse events. Sharpe 2014 
and Walker 2014 defined adverse events as deaths from any cause, admission to a 
psychiatric ward, or attempted suicide. In addition, Chan 2011 reported that the sole 
reason for drop out of participants was due to deaths.
Post-intervention outcome assessments
As a result of variance in intervention duration, the time between baseline and post-
intervention outcome evaluation ranged from two weeks in Bruera 2013, eight weeks 
in Savard 2006, 26 weeks in Steel 2016, to 12 months in Bordeleau 2003, Classen 
2001 and Spiegel 1981. Two studies reported on the post-intervention assessment, 
but the number of weeks or months between pre- and post-intervention assessment 
were not clearly described (Barsevick 2004; Edelman 1999). In Armes 2007, the 
intervention consisted of 3 sessions coinciding with administration of chemotherapy, 
but the total length of chemotherapy in number of days or weeks was not mentioned. 
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Outcomes were assessed at the end of chemotherapy (T1), 4 weeks after the end of 
chemotherapy (T2), and 9 months after recruitment to the study (T3). Although the 
original study investigators indicated that T2 was identified as the main outcome for 
the study, we used T1 as this was the first post-intervention assessment. In the study 
of Barsevick 2010, post-intervention assessment was performed at Days 43-46 or 57-
60 depending on the type of cancer treatment participants received. The intervention 
in Sharpe 2014 was given over a 4-month period and then continued for a further 
eight months. The primary endpoint for the study was the 24-weeks assessment. 
Walker 2014 examined the same type of intervention as Sharpe 2014 in a group of 
participants with a poor prognosis cancer. Given this poor prognosis, the intervention 
continued for a further four months instead of eight months. In this study, Walker 
2014 averaged fatigue data over the participant’s time in the study (up to a maximum 
of 32 weeks) into a single fatigue score, but these averaged fatigue scores were not 
available for meta-analysis. Therefore, we used the fatigue data collected at 24-week 
assessment in line with Sharpe 2014. Johansson 2008 randomised participants to 
one of four study arms and assessments took place three, six, 12 and 24 months 
after randomisation. Participants from the three intervention arms in this study were 
combined into one intervention group for the aim of this review. However, the three 
interventions had different durations and start-points after randomisation. We selected 
the six-month assessment as post-intervention assessment for our meta-analysis.
Follow-up outcome assessments
Eight studies included one (Barsevick 2004) or two follow-up assessments in the 
trial (Armes 2007; Chan 2011; Edelman 1999; Johansson 2008; Savard 2006; Sharpe 
2014; Walker 2014). However, four of these studies (Edelman 1999; Savard 2006; 
Sharpe 2014; Walker 2014) provided more than one additional session (if needed) in 
the follow-up period. Therefore, these studies were excluded from the primary meta-
analyses for follow-up effects and included in subgroup analyses. The four remaining 
studies (Armes 2007; Barsevick 2004; Chan 2011; Johansson 2008) had different 
follow-up durations. First follow-up durations ranged from 3 weeks (Chan 2011) to 
6 months (Johansson 2008) after post-intervention assessment. Second follow-up 
administration varied between studies and ranged from 9 weeks (Chan 2011) to 18 
months (Johansson 2008) after post-intervention assessment.
Excluded studies
Of the 155 excluded full-texts in our review, only 21 studies (23 reports) had potential 
relevance to our study aim. We have listed the details regarding these 21 studies that 
we excluded in the Characteristics of excluded studies table.
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Ongoing studies
We identified two studies that have not been completed (Poort; Serfaty). The 
characteristics of these studies are listed in the Characteristics of ongoing studies 
table.
Risk of bias in included studies
We assessed the risk of bias using the Cochrane ‘Risk of bias’ tool (Figure 2 and 
Figure 3) (Higgins 2011).
Allocation (selection bias) 
Random sequence generation
Eight studies adequately described the method used to generate the random 
sequence and so we judged them to be at low risk of bias for this domain (Armes 
2007; Classen 2001; Edelman 1999; Johansson 2008; Savard 2006; Sharpe 2014; 
Steel 2016; Walker 2014). Five studies did not specify the method of randomisation 
(Barsevick 2004; Barsevick 2010; Bordeleau 2003; Bruera 2013; Spiegel 1981) and 
we judged them to be at unclear risk of bias. In addition, Chan 2011 used a ‘lucky 
draw method’ but no description was reported, therefore this study was also judged 
as having an unclear risk of bias. We did not identify any studies at high risk of bias 
for this domain.
Allocation concealment
Six studies fully described how the allocation of the sequence was concealed and 
we judged them to be at low risk of bias for this domain (Armes 2007; Bordeleau 
2003; Johansson 2008; Sharpe 2014; Steel 2016; Walker 2014). Eight studies did 
not adequately describe how the allocation of the sequence was concealed and we 
judged them to be at unclear risk of bias (Barsevick 2004; Barsevick 2010; Bruera 
2013; Chan 2011; Classen 2001; Edelman 1999; Savard 2006; Spiegel 1981). We did 
not identify any studies at high risk of bias for this domain.
Blinding (performance bias and detection bias)  
Five studies explicitly stated that the outcome assessors were masked to allocation 
and we judged them to be at low risk of bias for this domain (Chan 2011; Savard 
2006; Sharpe 2014; Steel 2016; Walker 2014). No mention of blinding of outcome 
assessors or researchers was made in the nine other studies and we judged them to 
be at unclear risk of bias (Armes 2007; Barsevick 2004; Barsevick 2010; Bordeleau 
2003; Bruera 2013; Classen 2001; Edelman 1999; Johansson 2008; Spiegel 1981). 
We did not identify any studies at high risk of bias for this domain.
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Figure 2. Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included 
studies
Figure 3. Risk of bias summary: review authors’ judgments about each risk of bias item for each included study
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Incomplete outcome data (attrition bias) 
Eight studies either had less than 10% missing data in the original study sample or 
more than 10% missing data but used adequate statistical analysis and as such we 
judged them to be at low risk of bias for this domain (Armes 2007; Barsevick 2004; 
Barsevick 2010; Bordeleau 2003; Chan 2011; Sharpe 2014; Steel 2016; Walker 2014). 
Three studies had more than 10% missing data and only included patients with at 
least one observation post-randomisation in the mixed model or slopes analysis and 
we judged them to be at unclear risk of bias (Classen 2001; Savard 2006; Spiegel 
1981). The remaining three studies had more than 10% missing data and based on 
their adopted method of analysis we judged them to be at high risk of bias (Bruera 
2013; Edelman 1999; Johansson 2008). Of note, these judgements were all based on 
the original study samples, since information on attrition for the subset of interest to 
this review was not available.
Selective reporting (reporting bias) 
Thirteen studies adequately reported fatigue outcomes for the original study sample 
and we judged them to be at low risk of bias for this domain (Armes 2007; Barsevick 
2004; Barsevick 2010; Bordeleau 2003; Bruera 2013; Chan 2011; Classen 2001; 
Edelman 1999; Johansson 2008; Savard 2006; Sharpe 2014; Spiegel 1981; Walker 
2014). In Steel 2016, the authors performed two separate analyses but presented data 
of one analysis only (i.e. for the subgroup of patients reporting clinically significant 
symptoms at baseline). However, the original study investigators provided data for 
the total group on request and thus this study was judged to be at unclear instead of 
high risk of bias. We did not identify any studies at high risk of bias for this domain. 
Visual inspection of the funnel plot did not suggest publication bias.
Other potential sources of bias
Size of study
Information on the total sample size is provided because these were used in a few 
analyses. Based on the total sample sizes, four studies had fewer than 50 participants 
per treatment arm and we judged them to be at high risk of bias for this domain 
(Armes 2007; Bruera 2013; Savard 2006; Spiegel 1981). Nine studies had between 
50 and 199 participants per treatment arm and we judged them to be at unclear risk 
of bias (Barsevick 2004; Barsevick 2010; Bordeleau 2003; Chan 2011; Classen 2001; 
Edelman 1999; Johansson 2008; Steel 2016; Walker 2014). We identified one study 
with more than 200 participants per treatment arm and we judged this study to be at 
low risk of bias (Sharpe 2014). However, the sample sizes for the subset of patients 
with incurable cancer included in the meta-analysis were much smaller. In fact, eight 
studies included in the subset meta-analysis would be judged to be at high risk of 
bias for this domain based on having fewer than 50 participants per treatment arm 
at baseline (Armes 2007; Barsevick 2004; Barsevick 2010; Edelman 1999; Johansson 
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2008; Savard 2006; Sharpe 2014; Walker 2014). The four remaining studies had 
between 50 and 199 participants per treatment arm and would therefore be judged 
to be at unclear risk of bias (Bordeleau 2003; Chan 2011; Classen 2001; Steel 2016).
Quality of the control condition
We judged the quality of the control condition to be adequate in three studies 
(Barsevick 2004; Barsevick 2010; Bruera 2013). In Barsevick 2004 and Barsevick 
2010, the purpose of the control conditions was to control for the amount of time 
and attention received by the intervention groups. In Bruera 2013, participants in 
the control condition also received (non-therapeutic) phone calls. Four studies were 
judged to have partially controlled features of the control group (Bordeleau 2003; 
Chan 2011; Classen 2001; Steel 2016). We judged the efforts made to ensure that 
as many features as possible have been controlled for in the control group to be 
inadequate in seven studies (Armes 2007; Edelman 1999; Johansson 2008; Savard 
2006; Sharpe 2014; Spiegel 1981; Walker 2014).
Equality of treatment expectations
Three studies were judged to have adequate equality of treatment expectations 
between intervention and control groups (Bruera 2013; Barsevick 2004; Barsevick 
2010). These three studies compared the effects of the intervention to an attentional 
control group. The remaining 11 studies were judged to have inadequate treatment 
expectations (Armes 2007; Bordeleau 2003; Chan 2011; Classen 2001; Edelman 
1999; Johansson 2008; Savard 2006; Sharpe 2014; Spiegel 1981; Steel 2016; Walker 
2014).
Allegiance of the therapist
None of the studies reported the allegiance of the therapist and/or researcher. Two 
studies (Bordeleau 2003; Classen 2001) were conducted to replicate the findings of 
previous research about the effects of supportive-expressive group therapy (SEGT). 
Thus, we assumed that the investigators had at least some allegiance to SEGT.
Effects of interventions
See: Summary of findings table.
In this review, we were interested in the effects of psychosocial interventions 
compared to usual care or control conditions (not being a psychosocial intervention) in 
participants with incurable cancer receiving cancer treatment with palliative intent. As 
mentioned earlier, several studies had a mixed sample of participants with incurable 
and potentially curable cancer and/or receiving and not receiving cancer treatment 
during the psychosocial intervention. The analyses described in the following sections 
are subset meta-analyses, including only those participants of interest to our review.
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Twelve of the 14 included studies were able to provide fatigue data for meta-analysis 
on the subset of interest to this review involving 535 participants in total at post-
intervention assessment (Armes 2007; Barsevick 2004; Barsevick 2010; Chan 2011; 
Classen 2001; Edelman 1999; Johansson 2008; Savard 2006; Sharpe 2014; Spiegel 
1981; Steel 2016; Walker 2014). With respect to measures of physical, social, role, 
emotional, and cognitive functioning, we received data from two to seven studies 
depending on the specific domain of functioning. Although Bordeleau 2003 could not 
provide fatigue data, they were able to provide data for all five domains of functioning. 
Data for adverse events were not available for the subset of interest to our review, 
but a narrative description on adverse events in the total sample has been provided 
further along this section.
As we were pooling data from heterogeneous populations and interventions, we used 
random-effects instead of fixed-effects models. Overall, we judged the quality of 
evidence for psychosocial interventions to be low. We downgraded the quality of 
evidence by two levels for risk of bias and imprecision.
Fatigue
Subset meta-analysis did not suggest a post-intervention outcome benefit for 
the psychosocial intervention group compared to the control group on the fatigue 
outcome measured with different instruments (SMD -0.25, 95% CI -0.50 to 0.00, P 
= 0.05; participants = 535; studies = 12; I2 = 43%; Analysis 1.1; Figure 4). We found 
very low-quality evidence to suggest a benefit of psychosocial interventions for the 
secondary outcome fatigue at first follow-up (SMD -0.66, 95% CI -1.00 to -0.32, P = 
0.0001; participants = 147; studies = 4; I2 = 0%; Analysis 1.2; Figure 5). Psychosocial 
interventions did not influence secondary fatigue outcomes at second follow-up 
(SMD -0.41, 95% CI -1.12 to 0.30, P = 0.26; participants = 91; studies = 2; I2 = 29%; 
Analysis 1.3; Figure 6).
Non meta-analysed data
Investigators of two included studies responded to our data request, but were unable 
to provide separate fatigue outcome data for meta-analysis. Bruera 2013 had a 
homogeneous sample of participants with incurable cancer receiving cancer treatment 
and found no statistically significant differences in the median improvement of FACIT 
Fatigue scores (P = 0.27) or ESAS Fatigue scores (P = 0.14) between intervention 
and control group. Bordeleau 2003 had a homogeneous sample of participants with 
incurable cancer, but not all participants were receiving cancer treatment. This study 
found a significant across-time deterioration in EORTC QLQ-C30 Fatigue scores 
(P = 0.003) using a mixed model for repeated measures. However, this deterioration 
did not differ between study arms and therefore this study also could not demonstrate 
a significant intervention effect.
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Physical functioning
We found very low-quality evidence to suggest a post-intervention outcome benefit 
of psychosocial interventions for physical functioning measured with different 
instruments (SMD 0.32, 95% CI 0.01 to 0.63, P = 0.04; participants = 307; studies 
= 7; I2 = 35%; Analysis 2.1). Psychosocial interventions were not associated with a 
statistically significant improvement in physical functioning at first follow-up (SMD 
0.37, 95% CI -0.20 to 0.94, P = 0.21; participants = 122; studies = 2; I2 = 36%; 
Analysis 2.2).
Figure 4. (Analysis 1.1) Forest plot of comparison: 1 Fatigue, outcome: 1.1 Post-intervention
Figure 5. (Analysis 1.2) Forest plot of comparison: 1 Fatigue, outcome: 1.2 First follow-up
Figure 6. (Analysis 1.3) Forest plot of comparison: 1 Fatigue, outcome: 1.3 Second follow-up
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Non meta-analysed data
Armes 2007 provided raw values instead of transformed scores for physical 
functioning and these could not be used for meta-analysis. This study had a mixed-
stage sample of participants receiving cancer treatment for incurable and potentially 
curable cancer. The study investigators used a random-slope/random-intercept 
mixed model and reported a significant improvement in physical functioning for the 
original study population (coefficient 10, 95% CI 2.5 to 17.5, P = .009). However, 
we cannot conclude whether this improvement also applies to the small subset of 
participants with incurable cancer.
Social functioning
We saw no effect of psychosocial interventions on post-intervention social functioning 
measured with the scale of the EORTC-QLQ-C30 (MD 4.16, 95% CI -11.20 to 19.53, 
P = 0.60; participants = 141; studies = 4; I2 = 55%; Analysis 3.1).
Role functioning
Psychosocial interventions did not influence post-intervention role functioning 
measured with the scale of the EORTC QLQ-C30 (MD 3.49, 95% CI -12.78 to 19.76, 
P = 0.67; participants = 143; studies = 4; I2 = 52%; Analysis 4.1).
Emotional functioning
Psychosocial interventions did not influence post-intervention emotional functioning 
measured with different instruments (SMD -0.11, 95% CI -0.56 to 0.35, P = 0.65; 
participants = 115; studies = 3; I2 = 23%; Analysis 5.1).
Cognitive functioning
There was no overall effect of psychosocial interventions on post-intervention cognitive 
functioning measured with the scale of the EORTC QLQ-C30 (MD -2.23, 95% CI -12.52 
to 8.06, P = 0.67; participants = 86; studies = 2; I2 = 23%; Analysis 6.1).
Adverse events
Data on adverse events were only available for the total study samples of three studies 
(Bruera 2013; Sharpe 2014; Walker 2014). Bruera 2013 had a homogeneous sample 
of participants with incurable cancer receiving cancer treatment and reported that 
the number of Grade ≥ 3 adverse events was similar between the methylphenidate 
and placebo arms, which were combined with a nursing or control intervention. 
Sharpe 2014 had a mixed-stage sample of participants with incurable and potentially 
curable cancer either receiving or not receiving cancer treatment. This study reported 
34 cancer-related deaths (7%) during the trial (10 in the intervention group and 15 
in the usual care group), one admission to a psychiatric ward (intervention group), 
and one attempted suicide (intervention group) for the total sample. None of these 
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events were judged by the study investigators to be related to the trial treatments or 
procedures. Walker 2014 had a mixed-stage sample of participants with incurable 
and potentially curable cancer either receiving or not receiving cancer treatment. This 
study reported 43 cancer-related deaths (30%) during the trial for the total sample (21 
in the intervention group and 22 in the usual care group). No other serious adverse 
events occurred.
Subgroup analyses
Intervention duration: short versus intermediate-long
Three studies (participants = 163) were classified as having short intervention 
durations (two to three weeks; Barsevick 2004; Barsevick 2010; Chan 2011). The 
remaining nine studies (participants = 372) had intermediate (two to eight months) 
or long (12 months) intervention durations (Armes 2007; Classen 2001; Edelman 
1999; Johansson 2008; Savard 2006; Sharpe 2014; Spiegel 1981; Steel 2016; Walker 
2014). Meta-analysis to examine post-intervention results for these subgroups did 
not demonstrate a subgroup difference (Chi2 = 0.21, P = 0.65; participants = 535; 
studies = 12; I2 = 0%; Analysis 7.1).
Intervention delivery: individual versus group
Three studies (participants = 195) delivered interventions in groups (Classen 2001; 
Edelman 1999; Spiegel 1981). Eight studies (participants = 312) had interventions 
delivered individually (Armes 2007; Barsevick 2004; Barsevick 2010; Chan 2011; 
Savard 2006; Sharpe 2014; Steel 2016; Walker 2014). One study (Johansson 2008) 
had interventions that were either delivered individually or in groups, we did not 
include this study in the subgroup analysis. We did not find evidence supporting a 
subgroup difference (Chi2 = 0.14, P = 0.70; participants = 507; studies = 11; I2 = 0%; 
Analysis 7.2).
Intervention type: mono versus multidisciplinary
Nine studies (participants = 452) had interventions delivered by professionals from 
a single discipline (Armes 2007; Barsevick 2004; Barsevick 2010; Chan 2011; 
Classen 2001; Edelman 1999; Savard 2006; Spiegel 1981; Steel 2016). Three studies 
(participants = 83) had interventions delivered by professionals from two or more 
disciplines (Johansson 2008; Sharpe 2014; Walker 2014). We did not find evidence 
supporting a subgroup difference (Chi2 = 0.20, P = 0.66; participants = 535; studies 
= 12; I2 = 0%; Analysis 7.3).
Intervention aim: fatigue specific versus other aim
Five studies (participants = 232) providing fatigue outcome data for meta-analysis 
investigated the effects of a psychosocial intervention aimed at fatigue (Armes 2007; 
Barsevick 2004; Barsevick 2010; Chan 2011; Steel 2016). The remaining seven studies 
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(participants = 303) had different intervention aims (Classen 2001; Edelman 1999; 
Johansson 2008; Savard 2006; Sharpe 2014; Spiegel 1981; Walker 2014). We did not 
find evidence supporting a subgroup difference (Chi2 = 1.08, P = 0.30; participants 
= 535; studies = 12; I2 = 7.5%; Analysis 7.4).
Additional sessions: no additional sessions versus booster sessions
Four studies (participants = 147) had no additional sessions between post-intervention 
and first follow-up assessment and were thus included in the primary meta-analysis 
for fatigue at first follow-up (Armes 2007; Barsevick 2004; Chan 2011; Johansson 
2008; Analysis 1.2). An additional four studies provided booster sessions between 
post-intervention and first follow-up assessment (Edelman 1999; Sarvard 2006; 
Sharpe 2014; Walker 2014). Three of those studies provided data for first follow-up 
(Edelman 1999; Sharpe 2014; Walker 2014). We did not find evidence supporting a 
subgroup difference (Chi2  = 0.61, P = 0.44; participants = 270; studies = 7; I2 = 0%; 
Analysis 7.5). Two studies (participants = 91) had no additional sessions between 
post-intervention and second follow-up assessment and were included in the primary 
meta-analysis for fatigue at second follow-up (Armes 2007; Chan 2011; Analysis 1.3). 
Three studies provided data for second follow-up but included booster sessions 
(Edelman 1999; Sharpe 2014; Walker 2014). We did not find evidence supporting a 
subgroup difference (Chi2 = 0.18, P = 0.67; participants = 202; studies = 5; I2 = 0%; 
Analysis 7.6).
Sensitivity analysis
Three of the 12 studies with fatigue outcomes that featured in the post-intervention 
meta-analysis had fewer than 10 participants per treatment arm post-intervention 
(Armes 2007; Johansson 2008; Walker 2014). We performed a sensitivity analysis, 
removing data from these three studies. This analysis also did not suggest a post-
intervention outcome benefit for the psychosocial intervention group compared to 
the control group (SMD -0.30, 95% CI -0.59 to 0.00, P = 0.05; participants = 476; 
studies = 9; I2 = 56%; Analysis 8.1). At first and second follow-up only one included 
study had at least 10 participants per treatment arm (Chan 2011). Sensitivity analyses 
demonstrated that the findings of this study (participants = 153) were in accordance 
with the results of the primary meta-analysis at first follow-up (SMD -0.70, 95% CI 
-1.10 to -0.30, P = 0.0005; Analysis 8.2) and second follow-up (SMD -0.23, 95% CI 
-0.67 to 0.22; P = 0.32; Analysis 8.3).
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DISCUSSION 
Summary of main results  
This review identified 14 studies for inclusion, with a wide range of patient samples 
and psychosocial interventions. Twelve of the 14 studies were able to provide data on 
fatigue for our subset meta-analysis involving 535 participants post-intervention. There 
was a lack of clear evidence to either support or not support the use of psychosocial 
interventions for reducing fatigue in patients with incurable cancer during cancer 
treatment. Seven of the 14 studies provided data on physical functioning involving 
307 participants post-intervention. Psychosocial interventions may improve physical 
functioning post-intervention or reduce fatigue at first follow-up, or both. However, 
most subsets of data were too small to be reliable and only a limited number of studies 
with a limited number of participants contributed to the follow-up findings. Four of the 
14 studies provided data on social and role functioning, three studies on emotional 
functioning, and two studies on cognitive functioning. We did not find evidence to 
either support or not support the use of psychosocial interventions for improving these 
domains of functioning post-intervention. In addition, there was a broad range of 
interventions and follow-up durations across studies with considerable attrition between 
assessments. Data on adverse events were sparse. Only three studies that included 
pharmacological interventions in addition to psychosocial interventions (Bruera 2013; 
Sharpe 2014; Walker 2014) reported on adverse events and found no difference in the 
number of adverse events between the intervention and control groups.
Overall completeness and applicability of evidence  
We searched widely for evidence using five databases with no restriction of language 
and using search terms to help identify as wide a range of psychosocial interventions 
as possible. We found some important gaps in the evidence.
The main limitation of the review comes from the relative lack of data in this field. 
Six studies consisted of a homogenous sample of patients with incurable cancer. 
The remaining eight studies were comprised of a mixed sample of potentially curable 
and incurable patients. As a result, interventions from these eight studies were not 
specifically tailored to patients with incurable cancer. Yet, tailoring of psychosocial 
interventions could be important in achieving intervention effects, especially given 
the major difference in prognosis of patients with incurable cancer compared to 
patients with potentially curable cancer. Although investigators from these mixed-
sample studies were able to provide data for the subset of incurable cancer patients, 
the sample sizes of these subsets were quite small. This is likely to result in a lack of 
power to detect treatment effects that may arise from the psychosocial interventions. 
In addition, our meta-analysis including means instead of individual patient data for 
the subsets of the total randomised study population is limited in that we were unable 
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to adjust for potential confounding factors. For these reasons, the results of the meta-
analyses must be interpreted with caution.
We identified a limited number of studies (six) investigating interventions specifically 
aimed to address fatigue. However, only two of these six studies reported that the 
presence of some level of fatigue was an entry criterion for trial participation. This 
may lead to floor effects, restricting the potential range of fatigue scores and resulting 
in less room for improvement. Furthermore, a specific feature of the data available 
from the identified studies was the heterogeneity of intervention and follow-up 
durations. In addition, only four of the twelve studies contributed to the findings on 
follow-up effects. Three additional studies provided data for follow-up assessments, 
but interventions in these studies continued between post-intervention and follow-
up assessments. Therefore, these three studies were excluded from the primary 
follow-up analysis and included in subgroup analyses that did not find a significant 
effect. Among the four studies that were included in the primary analysis for follow-up 
effects, there was considerable attrition between post-intervention and first follow-
up assessment (attrition rate 18.5%). Although specific information on the reasons 
for attrition for the subset of interest to this review was not available, the attrition 
is unlikely to be random. In fact, it may be possible that attrition was associated 
with deterioration of health or death of the participant. This has implications for 
interpretation of the follow-up findings and thus these results should be interpreted 
with caution.
Overall, studies were predominantly comprised of female participants. This limits the 
ability to generalize research findings to male patients. Also, among the six studies 
that consisted of a homogeneous sample of patients with incurable cancer, only 
one study investigated intervention effects for a population other than metastatic 
breast cancer (Bruera 2013). Finally, in two studies (Sharpe 2014; Walker 2014), the 
investigated population was diagnosed with a major depressive disorder comorbid 
with cancer. Fatigue outcomes in these participants may have been associated with 
this depression, making it difficult to distinguish fatigue as a symptom of depression 
from cancer-related fatigue.
Quality of the evidence
We evaluated overall quality of the evidence using GRADE (see: Summary of findings 
table). We downgraded the GRADE quality of the evidence for all outcomes to very 
low because of unclear risk of selection bias and imprecision due to sparse data. 
We have very little confidence in the effect estimate and the true effect is likely to be 
substantially different from the estimate of the effect.
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Potential biases in the review process
The review was conducted in keeping with the principles of the Cochrane Handbook 
for Systematic Reviews of Interventions (Higgins 2011). It comprised electronic 
database searches and manual follow-ups for further references to maximise recall. 
None of the authors of this review were involved in any of the excluded or included 
studies. All studies were independently assessed for inclusion by two review authors, 
so we are confident that we have attempted to reduce bias in the review process. 
However, as with all systematic reviews and meta-analyses, subjective judgement 
is involved at various stages in the review process, from identifying studies to data 
extraction and analysis. As a result, although the search strategies, data extraction 
and analyses were thorough, there is a possibility of missing relevant studies and 
data.
Agreements and disagreements with other studies or reviews
In the Cochrane review by Goedendorp 2009 (co-authored by review authors GB, 
MFG, and SV), which did not include a meta-analysis, it was noted that there is 
limited evidence for the effectiveness of psychosocial interventions during cancer 
treatment in reducing fatigue. No distinction was made between the effectiveness of 
psychosocial interventions for patients receiving cancer treatment with curative or 
palliative intent. In our meta-analysis, we did not find clear evidence supporting the 
effectiveness of a range of psychosocial interventions on fatigue outcomes among 
the subset of incurable cancer patients. In addition, Goedendorp 2009 concluded that 
psychosocial interventions designed specifically to alleviate fatigue are promising 
intervention types for patients during cancer treatment. In our meta-analysis, there 
was no indication that interventions specifically aimed at reducing fatigue had more 
potential than interventions with a different aim for patients with incurable cancer 
receiving cancer treatment with palliative intent. This review highlights the current 
lack of evidence for psychosocial interventions reducing fatigue in patients with 
incurable cancer receiving treatment with palliative intent. The optimal approach to 
psychosocial interventions for fatigued patients with incurable cancer and the true 
extent of potential benefits and harms remain uncertain.
AUTHORS’ CONCLUSIONS
Implications for practice
This review found insufficient evidence for the effectiveness of psychosocial 
interventions to treat fatigue in patients with incurable cancer receiving treatment with 
palliative intent. Therefore, specific implications for patients with incurable cancer, for 
clinicians, for policy makers, or for funders of the interventions cannot be given.
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Implications for research
Evidence
Further evidence is needed from high quality trials with large samples that fully 
report methodological characteristics and potential harms. Two ongoing studies were 
identified and aim to enrol 240 participants (Serfaty) and 219 participants (Poort) with 
a diagnosis of incurable cancer. Both studies with large samples have the potential to 
substantially aid answering of the research question of this review.
Population
More studies with a homogeneous study sample of patients with incurable cancer 
are needed. Targeting those patients most in need (i.e. those reporting clinically 
significant levels of fatigue) to eliminate potential floor effects has been recommended 
before (Bower 2014) and would be a helpful approach in future studies. Also, future 
studies should expand the focus beyond patients with metastatic breast cancer, as it 
is unknown whether findings from this patient group generalize to patients with other 
cancer diagnoses. Therefore, enriching the evidence with studies focusing on patients 
diagnosed with other types of incurable cancer would be helpful. Moreover, future 
studies should also include a substantial proportion of male participants and determine 
whether gender moderates treatment outcomes, as the majority of participants in the 
studies conducted thus far were females. Finally, given the difficulty of recruiting large 
enough samples in palliative care trials, multicentre studies are recommended, as 
studies with larger patient samples may be able to detect small but clinically relevant 
differences. Alternatively, application of novel research designs (e.g. replicated n-of-1 
trials) might also be a worthwhile approach given the difficulties in conducting RCTs 
in patients receiving cancer treatment with palliative intent.
Intervention
Psychosocial interventions are part of a broader portfolio of available interventions for 
cancer-related fatigue, also including interventions focused on physical activity and 
pharmacological approaches. For future research aimed at psychosocial interventions, 
we recommend that protocols for a trial, including a detailed description of the 
intervention and its components, should be published or otherwise made publicly 
available. Also, tailoring the content of interventions to patients with incurable cancer 
would be helpful, given the substantial difference in prognosis between patients with 
potentially curable and incurable cancer. This difference has implications for the 
psychosocial factors thought to maintain fatigue and addressed by the interventions. 
Moreover, we would recommend short interventions delivered over a period of several 
weeks or months, with follow-up assessments following shortly (within 3-8 months) 
after intervention delivery. This is not only recommended with the aim to prevent 
participant attrition as much as possible, which complicates the interpretation of 
findings, but also to minimize the burden of participation.
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Comparison
Given the current state of the evidence, we recommend that researchers conducting 
future trials compare psychosocial interventions to usual care or attentional control 
groups.
Outcome
There is no consensus on which instrument should be used to measure fatigue and 
reducing the variance in the outcome instruments used to measure the reduction 
in fatigue would be helpful. Also, future studies should clearly assess benefits and 
potential adverse events (e.g. increased psychological distress) of the intervention.
DIFFERENCES BETWEEN PROTOCOL AND REVIEW 
The final review differs from the protocol in four ways. First, we originally intended 
to select only those participants diagnosed with incurable cancer and receiving 
some form of active cancer treatment. However, several original study investigators 
of mixed sample studies did not respond to our request for subset data or were 
unable to select the subset of those participants. In those instances, we included 
studies when the sample involved > 80% of participants with incurable cancer and 
receiving some form of active cancer treatment. Second, we planned using fixed-
effect models in all meta-analyses in this review. However, the patient populations 
were quite variable in cancer diagnosis and treatment (as were the interventions) and 
thus we employed random-effects models. Third, we originally used the overall term 
‘measures of function’ in our protocol to reflect physical, social, role, emotional, and 
cognitive functioning as secondary outcomes of this review. In the final review, we 
have defined this outcome more clearly and changed our wording to all five individual 
domains instead of using an overall term. Last, we did not include different time 
points for outcomes in the protocol. Yet, some studies not only reported outcomes 
for post-intervention assessment but also for one or two follow-up assessments. We 
aimed to be as complete as possible in reporting our findings and thus also included 
fatigue and physical functioning data for first and second follow-up as secondary 
outcomes.
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CHARACTERISTICS OF INCLUDED STUDIES
Armes 2007
Methods Design: RCT. 
Duration of study participation: 36 weeks.
Participants UK, Guys and St. Thomas’ Hospital NHS Trust and Bromley Hospitals NHS Trust. 
60 patients (aged 59.1 years, 60% female) receiving chemotherapy and reporting significant fatigue.
Interventions Intervention group: brief, cancer-related fatigue-specific, behaviourally oriented intervention consisting of 
cognitive, behavioural, and general components.
Control group: standard care. Cancer-related fatigue was not assessed routinely and the provision of advice 
regarding its management was delivered in an ad hoc manner.
Outcomes VAS Fatigue, EORTC QLQ-C30 Fatigue, and EORTC QLQ-C30 Physical functioning. Adverse events were not 
described.
Notes Funding: Cancer Research UK Nursing Research Training Fellowship (CP1052/0101 and C1428/A180).
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Low risk Originally, minimization as the method of treatment allocation. After 
the first 10 patients, simple random, permuted, block randomisation 
implemented.
Allocation concealment 
(selection bias)
Low risk Statistician (unconnected to the study) generated randomisation, provided 
a central telephone service for patient allocation, and kept a copy of the 
randomisation codes.
Blinding of outcome assessment 
(detection bias)
Unclear risk Questionnaires either posted or given to patients in the chemotherapy 
clinic by first study author. Insufficient information to permit judgment of 
low or high risk.
Incomplete outcome data 
(attrition bias)
Low risk More than 10% missing data, but data analysed using t tests and random-
slope/random-intercept mixed models using a generalized linear latent 
and mixed model.
Selective reporting 
(reporting bias)
Low risk All the data are fully reported in the study.
Size of the study High risk Fewer than 50 participants randomised per treatment arm at baseline.
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Barsevick 2004
Methods Design: RCT. 
Duration of study participation: duration of participation depended on type of cancer treatment.
Participants USA, University of Utah health science center and Fox Chase Cancer Center. 
396 individuals (aged 56.3 years, 85% female) beginning chemotherapy, radiotherapy, or concurrent therapy for 
breast, lung, colorectal, advanced prostate, gynaecologic, or testicular cancer or lymphoma.
Interventions Energy Conservation and Activity Management (ECAM): information provided to aid in the formation of an 
accurate representation of the symptom of fatigue, guide the formulation and implementation of a plan for energy 
conservation, and appraise the effectiveness of symptom-management efforts.
Control group: information on nutrition and a healthy diet. No therapeutic nutritional information or information 
on symptom management.
Outcomes POMS Fatigue, Schwartz Cancer Fatigue Scale, General Fatigue Scale, and Functional Performance Inventory. 
Adverse events were not described.
Notes Funding: National Institute of Nursing Research (R01NR04573).
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Unclear risk No information on the method of randomisation was provided.
Allocation concealment 
(selection bias)
Unclear risk No information on allocation concealment was provided.
Blinding of outcome assessment 
(detection bias)
Unclear risk No information on blinding of outcome assessors was provided.
Incomplete outcome data 
(attrition bias)
Low risk More than 10% missing data for at least one data point on at least one 
fatigue measure, but used SAS mixed procedure restricted maximum 
likelihood method.
Selective reporting 
(reporting bias)
Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants randomised per treatment arm at 
baseline.
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Barsevick 2010 
Methods Design: RCT. 
Duration of study participation: between 43-46 and 57-60 days depending on the length of the chemotherapy cycle.
Participants USA, Fox Chase Cancer Center. 
292 patients (aged 53.9 years, 82% female) beginning a new chemotherapy regimen for breast, lung, colorectal, 
prostate, gynaecologic, bladder or testicular cancer, or lymphoma.
Interventions Energy and Sleep Enhancement (EASE): information about the symptom’s identity, cause, and pattern to form a mental 
image of the symptom, identification and implementation of self-care strategies to manage the symptom. Evaluation 
of the effectiveness of the strategies and adjustment of either coping methods or symptom representation.
Control intervention: information about nutrition and a healthy diet. Therapeutic nutritional information or 
information on symptom management not included.
Outcomes Funding: National Institute of Nursing Research (R01NR04573). 
Follow-up study of Barsevick 2004.
Notes Funding: supported by the National Institute of Nursing Research (R01NR04573). 
Follow-up study of Barsevick 2004, building upon that intervention by introducing an additional intervention 
component (sleep modification strategies).
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Unclear risk No information on the method of randomisation provided.
Allocation concealment 
(selection bias)
Unclear risk Random assignments generated by statistician and placed in sealed 
envelopes, numbered and selected sequentially for each stratification 
group. Unclear whether envelopes were opaque.
Blinding of outcome assessment 
(detection bias)
Unclear risk No information on blinding of outcome assessors provided.
Incomplete outcome data 
(attrition bias)
Low risk Less than 10% missing data and data were analysed using SAS mixed 
procedure (i.e., restricted maximum likelihood method).
Selective reporting 
(reporting bias)
Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants randomised per treatment arm at 
baseline.
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Bordeleau 2003 
Methods Study design: RCT. 
Duration of study participation: 12 months.
Participants Canada, coordinated at Samual Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, and six 
other (regional) cancer centers. 
237 women with metastatic breast cancer.
Interventions Supportive-Expressive Group Therapy (SEGT): weekly 90-minute therapist-led support group adhering to principles 
of supportive-expressive therapy. Intended to foster support among group members and encourage the expression of 
emotions about cancer and its effects on their lives. Relaxation exercise at the end of each seminar.
Control group: no participation in a support group. Every six months, all women received educational materials 
about breast cancer and its treatment, relaxation, and nutrition. All study participants could receive any medical or 
psychosocial treatment deemed necessary.
Outcomes EORTC QLQ-C30 Fatigue, POMS Fatigue, EORTC-QLQ C30 Physical, Social, Role, Emotional, and Cognitive functioning. 
Adverse events were not described.
Notes Funding: Medical Research Council of Canada and the Canadian Breast Cancer Research Initiative.
Summary data for the functional scales of the EORTC-QLQ-C30 were provided, but fatigue data of either the EORTC-
QLQ-C30 or the POMS could not be provided (reason: “It would take too much time to retrieve the data”). 
Allegiance effect: This trial was designed to replicate the findings of a previous study on the effects of SEGT, thus 
therapists and/or researchers probably had some allegiance to SEGT.
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Unclear risk No information on the method of randomisation provided.
Allocation concealment 
(selection bias)
Low risk Randomisation performed centrally, stratified for study center and for the 
presence of visceral metastases.
Blinding of outcome assessment 
(detection bias)
Unclear risk Questionnaires given to patients by the research assistant during 
baseline assessment, and mailed out four, eight, and 12 months after 
randomisation. No information on blinding of the research assistant 
provided.
Incomplete outcome data 
(attrition bias)
Low risk More than 10% missing data, but data analysed using SAS mixed model 
for repeated measures.
Selective reporting 
(reporting bias)
Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants randomised per treatment arm at 
baseline.
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Bruera 2013
Methods Study design: RCT. 
Duration of study participation: two weeks.
Participants USA, MD Anderson Cancer Center and Lundon B. Johnson General Hospital. 
190 patients with a diagnosis of advanced cancer and reporting fatigue.
Interventions Nursing Telephone Intervention (NTI): three components: (1) symptom assessment, (2) review of the types 
and dosages of medications and adverse events, (3) psychosocial support and patient education. Research 
nurse asked open-ended questions regarding general well being of the patient and family, listened 
empathetically, answered the patient’s questions, and provided supportive statements.
Control group: nontherapeutic phone calls by a nonprofessional who assessed symptoms and asked about 
medications. No psychosocial support or education provided. If patients raised concerns, they were directed 
to discuss them with their physician.
Outcomes FACIT Fatigue and ESAS Fatigue. Adverse events were documented.
Notes Funding: National Institute of Health-National Institute of Nursing Research Grant (R01) and ACS Research 
Scholar Grant for Independent Investigators.
Not eligible for meta-analysis. Summary data requested, but not could not be provided (reason: “No staff 
support to deal with the request”).
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Unclear risk Only reported that patients were randomly assigned to receive 
one of the four treatments but not how randomisation was 
performed.
Allocation concealment 
(selection bias)
Unclear risk Not stated.
Blinding of outcome assessment 
(detection bias)
Unclear risk Reported that all of the members of the research team were 
blinded to treatment assignment (methylphenidate or placebo), 
but no information reported on blinding of outcome assessors for 
the nursing or control telephone intervention.
Incomplete outcome data 
(attrition bias)
High risk More than 10% missing data, not described what was done 
with missing data, probably used complete-case analysis (only 
data from evaluable patients). Median differences between 
intervention and control group analysed using Wilcoxon two-
sample tests.
Selective reporting 
(reporting bias)
Low risk All data fully reported in the study.
Size of the study High risk Fewer than 50 participants randomised per treatment arm at 
baseline.
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Chan 2011
Methods Study design: RCT. 
Duration of study participation: three months.
Participants Tuen Mun Hospital, Hong Kong. 
140 patients with advanced lung cancer.
Interventions Psycho-educational intervention (PEI): PEI alters patients’ perceptions and sensations of symptoms through 
stress reduction; clarification of misconceptions; and the adoption of adaptive behaviours. A 40-minute 
educational package plus coaching of PMR delivered to patients within one week prior to the beginning of 
the course of radiotherapy, and reinforced three weeks after commencing radiotherapy.
Usual care: mandatory individual briefing of the radiotherapy procedure and brief discussion of side effects 
by therapy radiographer.
Outcomes Revised Piper Fatigue Scale Intensity subscale and SF-36 Physical functioning. Adverse events not described.
Notes Funding: Hong Kong Health Service Research Fund.
Personal feedback intended in the intervention protocol, as confirmed by the original study investigator.
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Unclear risk No explanation on the method of randomisation (lucky draw 
method) provided.
Allocation concealment
(selection bias)
Unclear risk Not reported how randomisation was performed.
Blinding of outcome assessment 
(detection bias)
Low risk Data collected by a research assistant blinded to group allocation.
Incomplete outcome data 
(attrition bias)
Low risk Less than 10% missing data post-intervention. However, missing 
data imputed by a carry-forward method while missing data were 
not at random but related to outcomes that can lead to attrition 
bias.
Selective reporting
(reporting bias)
Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants randomised per treatment arm 
at baseline.
140
Chapter 6
Classen 2001
Methods Study design: RCT. 
Duration of study participation: 12 months.
Participants USA, Stanford University Medical Center. 
125 women with metastatic breast cancer.
Interventions Supportive-Expressive Group Therapy (SEGT): participants were encouraged to confront their problems, 
strengthen their relationships, and find enhanced meaning in their lives in a supportive environment. 
Neither coping strategies nor psycho-education was taught in a didactic manner. Self-hypnosis exercise at 
the end of each session.
Control group: self-directed education intervention. Educational materials also offered to women in the 
treatment condition.
Outcomes POMS Fatigue. Adverse events not described.
Notes Funding: National Institute of Mental Health, National Cancer Institute, John D. and Catherine T MacArthur 
Foundation, and Fetzer Institute.
Allegiance effect: This trial was designed to replicate the findings of a previous study on the effects of SEGT, 
thus therapists and/or researchers probably had some allegiance to SEGT.
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Low risk Adaptive randomisation biased coin-design method.
Allocation concealment 
(selection bias)
Unclear risk Method of allocation concealment not stated.
Blinding of outcome assessment 
(detection bias)
Unclear risk For the first two years of the study, baseline and post-baseline 
assessments completed on a computer. No information on 
blinding of the outcome assessors provided.
Incomplete outcome data 
(attrition bias)
Unclear risk More than 10% missing data. Slopes analysis used but only 
participants who provided at least one follow-up point included 
in the analysis.
Selective reporting 
(reporting bias)
Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants randomised per treatment arm 
at baseline.
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Edelman 1999
Methods Design: RCT. 
Duration of study participation: 12 months.
Participants Australia, Royal North Shore Hospital. 
124 women with metastatic breast cancer aged between 30 and 65 years.
Interventions Cognitive Behavioural Therapy (CBT): cognitive and behavioural techniques, expression of feelings, and 
building of group support. Manual, handouts, and homework provided. Emphasis on gaining a greater 
sense of control through problem solving and goal setting. Participants were instructed on effective 
communication strategies and encouraged to communicate assertively with friends, family members, and 
medical staff.
Control group: No-therapy control group condition. Patients were informed about other community support 
groups that they could attend.
Outcomes POMS Fatigue. Adverse events not described.
Notes Funding: not specified.
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Low risk For every 20 patients a block randomisation procedure 
took place, with 10 being randomised to each 
treatment condition.
Allocation concealment
(selection bias)
Unclear risk No information on allocation concealment provided.
Blinding of outcome assessment 
(detection bias)
Unclear risk No information on blinding of outcome assessors 
provided.
Incomplete outcome data 
(attrition bias)
High risk More than 10% missing data and data analysed using 
independent samples t¬-tests.
Selective reporting 
(reporting bias)
Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants randomised per 
treatment arm at baseline.
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Johansson 2008
Methods Design: RCT. 
Duration of study participation: 24 months.
Participants Sweden, Uppsala University Hospital. 
481 consecutive patients with newly diagnosed prostate, gastrointestinal or breast cancer. Women with a 
mammography finding requiring surgery could also be included.
Interventions Intervention group: Individual support included individual psychological support, intensified primary health 
care, and nutritional support for some patients, and implied extra contact with at least two or three different 
professionals, irrespective of the patients’ need for support. All patients were contacted by a project psychologist. 
Current problems identified jointly by the patients and the psychologist were the focus of the intervention. 
Techniques used were derived from cognitive behaviour therapy, including relaxation techniques, identification and 
challenging of negative automatic thoughts and activity scheduling and daily planning. 
Group rehabilitation conducted by a psychologist, physiotherapist and an oncology nurse. Sessions included 
cognitive behavioural techniques, light physical training and relaxation. In two of the sessions, a physician presented 
information about cancer and cancer treatment, and a dietician provided dietary advice. All sessions offered 
opportunities to disclose and discuss concerns with group leaders and members.
Control group: standard care did not include regular follow-ups by a dietician or medical social worker. Patients could 
be referred to such services.
Outcomes EORTC QLQ-C30 Fatigue and EORTC QLQ-C30 Physical, Social, Role, Emotional and Cognitive functioning. Adverse 
events not described.
Notes Funding: Swedish Cancer Society.
There were three different intervention groups: individual support, group rehabilitation, and combined individual 
support and group rehabilitation. We combined these three groups into one to have sufficient sample size for the 
subset of patients with incurable cancer receiving systemic treatment with palliative intent (combined intervention 
groups n=26 versus n=17 standard care group).
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Low risk Patients randomised by an independent oncologic center (computer 
generated allocation schedule). Randomisation stratified for diagnosis and 
stage.
Allocation concealment 
(selection bias)
Low risk Patients randomised by an independent oncologic center (computer 
generated allocation schedule).
Blinding of outcome 
assessment
(detection bias)
Unclear risk Research nurse gave patients the baseline questionnaire with a prepaid 
envelope. At subsequent assessments, patients were contacted by one of 
the investigators by phone. Investigator gave instructions and mailed the 
questionnaires, written instructions and a prepaid envelope to the patients. 
No information on whether the investigators were blinded.
Incomplete outcome data 
(attrition bias)
High risk More than 10% missing data and data analysed using one-way ANOVA with 
repeated measures.
Selective reporting 
(reporting bias)
Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants randomised per treatment arm at baseline.
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Savard 2006
Methods Design: randomised clinical trial (May 1999 to June 2003). 
Duration of study participation: 36 weeks.
Participants Canada, three cancer clinics: Hôpital St-Sacrement, L’Hôtel-Dieu de Québec and L’Hôtel-Dieu de Lévis.
 45 patients with metastatic breast cancer reporting depressive symptoms.
Interventions Cognitive therapy: presentation of cognitive theory of emotions. Participants were encouraged to increase their level 
of daily activities and trained to identify their negative thoughts, to use cognitive restructuring, and to redefine their 
life goals. Future high-risk situations were identified, as well as strategies to cope with them.
Control group: participants waited for a period corresponding to the duration of the intervention (8 weeks) and were 
reassessed on the study variables before receiving cognitive therapy.
Outcomes Multidisciplinary Fatigue Inventory and EORTC QLQ-C30 Physical functioning. Adverse events not described.
Notes Funding: Canadian Breast Cancer Research Initiative (010436) and Canadian Institutes of Health Research.
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Low risk Prepared by principal investigator prior to study initiation using a 
computer-generated random numbers table.
Allocation concealment 
(selection bias)
Unclear risk Group allocation was contained in individually sealed envelopes. Unclear 
whether envelopes were sequentially sealed and opaque.
Blinding of outcome assessment 
(detection bias)
Low risk At the post-treatment evaluation, the participants met the independent 
evaluator to complete self-report scales. Evaluator was blind to study 
objectives and procedures and the patients’ group allocation.
Incomplete outcome data 
(attrition bias)
Unclear risk More than 10% missing data. Linear mixed models used to analyse data, 
but only patients with at least one observation post-randomisation 
included in the analysis.
Selective reporting
(reporting bias)
Low risk All data fully reported in the study.
Size of the study High risk Fewer than 50 participants randomised per treatment arm at baseline.
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Sharpe 2014
Methods Design: RCT.
Duration of study participation: 48 weeks.
Participants Scotland, UK, three cancer centres. 
500 adults with a diagnosis of cancer, a good cancer prognosis (predicted survival of at least 12 months) and major 
depression of at least four weeks duration.
Interventions Depression care: intensive, manualised, collaborative care-based multicomponent treatment programme specifically 
designed to be integrated with the patient’s cancer treatment. Nurses establish a therapeutic relationship with 
the patients, provide information about depression and its treatment, deliver brief evidence-based psychological 
interventions (problem-solving therapy and behavioural activation), and monitor patients’ progress. Psychiatrists 
supervise treatment, advise primary care physicians about prescribing antidepressants, and provide direct 
consultations to patients who are not improving.
Usual care: participant’s primary care physician and oncologist were informed about the major depression diagnosis 
and asked to treat their patients as they normally would. Patient was encouraged to consult their primary care 
physician to obtain treatment.
Outcomes EORTC QLQ-C30 Fatigue and EORTC QLQ-C30 Physical, Social, and Role functioning. Adverse events defined as deaths 
from any cause, admission to a psychiatric ward, or attempted suicide.
Notes Funding: University of Edinburgh and NHS Lothian, Cancer Research UK (grant numbers C5547/A7375), Chief Scientist 
Office of the Scottish Government, and Scottish Mental Health Research Network funded by NHS Research Scotland.
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Low risk Database software algorithm allocated participants in a 1:1 
ratio using a combination of stratification (by trial centre) and 
minimization (by age, primary cancer, and sex).
Allocation concealment 
(selection bias)
Low risk Secure web-based randomisation database implemented by a trials 
unit.
Blinding of outcome assessment 
(detection bias)
Low risk Trial statistician and staff who collected outcome data masked to 
allocated interventions; however, participants could not be masked 
because of the nature of depression care for people with cancer.
Incomplete outcome data 
(attrition bias)
Low risk Less than 10% missing data. Analysis of covariance used for data 
analysis. In addition, sensitivity analysis using multiple imputation 
performed.
Selective reporting 
(reporting bias)
Low risk All data fully reported in the study.
Size of the study Low risk More than 200 participants randomised per treatment arm at 
baseline.
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Spiegel 1981
Methods Design: RCT.
Duration of study participation: 12 months.
Participants USA, Stanford University School of Medicine. 
86 women with metastatic breast cancer.
Interventions Psychosocial Support Group (PSG): designed to be supportive, with a high degree of cohesion and relatively little 
confrontation and here-and-now interpersonal exploration. Interaction in the group often contained a considerable 
amount of self-disclosure and sharing of mutual fears and concerns.
Control group: Not described.
Outcomes POMS Fatigue. Adverse events not described.
Notes Funding: National Cancer Institute (N01-CN-55313 [DHEW]) and Veterans Administration.
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Unclear risk No information on the method of randomisation provided.
Allocation concealment
(selection bias)
Unclear risk No information on allocation concealment provided.
Blinding of outcome assessment 
(detection bias)
Unclear risk No information on blinding of outcome assessors provided.
Incomplete outcome data 
(attrition bias)
Unclear risk More than 10% missing data. Slopes analysis used to analyse data, 
but only participants who completed at least two assessments 
included in the analysis.
Selective reporting
(reporting bias)
Low risk All data fully reported in the study.
Size of the study High risk Fewer than 50 participants randomised per treatment arm at 
baseline.
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Steel 2016
Methods Design: RCT.
Duration of study participation: six months.
Participants USA, University of Pittsburgh Medical Center’s Liver Cancer Center. 
261 patients (aged 61 years, 73% male) with hepatocellular carcinoma, cholangiocarcinoma, gallbladder 
carcinoma, neuroendocrine carcinoma, pancreatic carcinoma, or other primary cancers that had metastasized to the 
liver (e.g. ovarian, breast, and colorectal cancer).
Interventions Web-based stepped collaborative care intervention: access to a psycho-educational web site and to a collaborative 
care coordinator with training and experiences with cognitive behavioural therapy and psycho-oncology.
Control group: usual care provided by the medical team. For ethical reasons, patients scoring high on a depression 
or pain measure were contacted by a care coordinator who provided education about the symptoms and referral 
options.
Outcomes FACT Fatigue. Adverse events not described.
Notes Funding: National Cancer Institute (K07CA118576, R21CA127046, and P30CA047904).
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Low risk The patients randomly assigned via a block randomisation design according to 
sex and vascular invasion.
Allocation concealment 
(selection bias)
Low risk Allocation concealment achieved through the use of a random number table 
that assigned consecutive patients across the group. A research assistant who 
was not part of the study placed the trial assignments in opaque envelopes 
consecutively per group.
Blinding of outcome 
assessment
(detection bias)
Low risk All data collected by trained interviewers using a structured computerized 
interview. The interviewers were blinded to study arm assignment.
Incomplete outcome data 
(attrition bias)
Low risk More than 10% missing data. Two separate general linear mixed models 
analyses performed: first with all participants and then with patients with 
clinically significant symptoms at baseline.
Selective reporting 
(reporting bias)
Unclear risk Effects of the intervention only reported for the subgroup of patients with 
clinically relevant symptoms at baseline (n=132), results for the entire sample 
not presented but were provided upon request.
Size of the study Unclear risk Between 50 and 199 participants randomised per treatment arm at baseline.
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Walker 2014
Methods Design: RCT.
Duration of study participation: 32 weeks.
Participants Scotland, UK, three cancer centres. 
142 adults with primary lung cancer, a predicted survival of at least three months and major depression for four weeks 
or longer.
Interventions Depression care: multicomponent, systematic, team-delivered treatment programme based on the collaborative care 
model and integrated with lung cancer care. Nurses establish a therapeutic relationship with the participants, provide 
information about depression and its treatment, deliver brief evidence-based psychological interventions (problem-
solving therapy and behavioural activation), and monitor patients’ progress. Psychiatrists supervise treatment, advise 
primary care physicians about prescribing to ensure rapid initiation and proactive adjustment of antidepressants, and 
provide direct consultations to patients who are not progressing.
Usual care: participant’s primary care physician and oncologist were informed of the diagnosis of major depression 
and asked to treat them as they normally would. Patient was encouraged to see their primary care physician to obtain 
treatment.
Outcomes EORTC QLQ-C30 Fatigue and EORTC QLQ-C30 Physical, Social, and Role functioning. Adverse events defined as death 
from any cause, admission to a psychiatric ward, or attempted suicide.
Notes Funding: University of Edinburgh, NHS Lothian, Cancer Research UK (grant numbers C5547/A7375 and C25786/ 
A10093), Chief Scientist Office of the Scottish Government, and Scottish Mental Health Research Network funded by 
NHS Research Scotland.
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Low risk Database software algorithm allocated participants in a 1:1 ratio using a 
combination of stratification (by trial centre) and minimization (by age, sex, and 
lung cancer type).
Allocation concealment 
(selection bias)
Low risk Secure web-based randomisation database implemented by a trials unit.
Blinding of outcome 
assessment 
(detection bias)
Low risk Trial statistician and staff who collected outcome data masked to allocated 
interventions; however, participants could not be masked because of the nature 
of depression care for people with cancer.
Incomplete outcome data 
(attrition bias)
Low risk More than 10% missing data. A summary measure approach used in the analysis 
of covariance, which copes with missing data and sensitivity analyses using 
multiple imputation were performed.
Selective reporting 
(reporting bias)
Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants randomised per treatment arm at baseline.
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CHARACTERISTICS OF EXCLUDED STUDIES
Study Reason for exclusion
Adamsen 2009 Mixed-sample study. None of the incurable cancer patients were receiving active cancer treatment.
Anderson 2015 Unable to determine whether intervention fulfilled our formulated criteria, no response received from study 
investigators.
Berglund 2007 Mixed-sample study. Study investigators were unable to retrieve the data.
Bigatao 2016 Unable to determine whether intervention fulfilled our formulated criteria and whether the study sample also 
included patients with incurable cancer.
Brown 2006 Does not meet our formulated criteria for psychosocial intervention. Study investigators confirmed that personal 
feedback was not intended.
Cunningham 1989 Unknown whether study sample also includes patients with incurable cancer. Unable to retrieve professional 
contact address of the original study investigators.
De Moor 2001 Did not meet our formulated criteria for psychosocial intervention.
De Raaf 2013 Did not meet our formulated criteria for psychosocial intervention. Study investigators confirmed that personal 
feedback was not intended.
Decker 1992 Mixed-sample study. Unable to retrieve professional contact address of the study investigators.
Fernandez 2011 No RCT, study investigators confirmed that all baseline measures were taken after randomization.
Focan 2015 Unable to determine whether intervention fulfilled our eligibility criteria, no detailed intervention content 
information was received from study investigators.
Forester 1985 Unknown whether study sample also included patients with incurable cancer. Unable to retrieve professional 
contact address of the study investigators.
Gaston-Johansson 2000 Mixed-sample study, no response received from study investigators.
Given 2002 Mixed-sample study, study investigators not willing to provide data. Entire study sample included < 80% of 
patients with incurable cancer, thus excluded from the review.
Godino 2006 Unknown whether study sample also included patients with incurable cancer, no response received from study 
investigators.
Oh 2010 Unknown whether study sample also included patients with incurable cancer, no response received from study 
investigators.
Ream 2006 Mixed-sample study, request for separate summary data sent to the study investigators but no response received.
Ream 2015 Unknown whether study sample also included patients with incurable cancer, no response received from study 
investigators.
Serfaty 2012 Unknown whether study sample also included patients with incurable cancer. Study investigators confirmed not 
knowing whether incurable cancer patients were part of the sample.
Strong 2008 Mixed-sample study, study investigators unable to provide data.
Yorke 2015 Did not meet formulated criteria for receiving cancer treatment. Study investigators confirmed that none of the 
participants were receiving cancer treatment with palliative intent during the intervention.
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CHARACTERISTICS OF ONGOING STUDIES
Poort
Study name TIRED study
Methods RCT
Participants Netherlands, Radboud university medical center with sites set up across the Netherlands. 
219 patients with a diagnosis of incurable cancer and reporting severe fatigue.
Interventions Cognitive behavioural therapy (CBT): 12-week CBT intervention designed to treat severe fatigue during systemic 
cancer treatment with palliative intent for incurable cancer. CBT consists of 10 individual, clinic-delivered 
sessions and will be delivered by trained psychologists. 
Control condition: usual care. Participants may be referred to psychological or exercise interventions by their 
general practitioner or oncologist.
Outcomes Checklist Individual Strength, EORTC QLQ-C30 Fatigue, Sickness Impact Profile, and EORTC QLQ-C30 Physical, 
Social, Role, Emotional, and Cognitive functioning.
Starting date January 2013, recruitment ongoing.
Contact information Hanneke Poort, MSc, Department of Medical Psychology, Radboud university medical center, Nijmegen,  
The Netherlands.
Notes Funding: Dutch Cancer Society (KUN2011-5259).
This study is performed by five of the review authors (HP, MP, GB, SV, HK).
Serfaty
Study name CanTalk study
Methods RCT
Participants UK, University College London with sites set up across England. 
230 patients with advanced, non-curative cancer and a clinical diagnosis of depression.
Interventions Cognitive behavioural therapy (CBT) in addition to treatment as usual (TAU): up to 12 sessions of individual 
CBT delivered face to face or on the telephone over three months. 
TAU: all patients receive TAU from oncology teams and from their general practitioners (GPs). Specific 
psychological support may be available for those who present with psychological needs at any time.
Outcomes Beck Depression Inventory-II single-item for fatigue.
Starting date July 2012, recruitment completed.
Contact information Dr Marc Serfaty, Division of Psychiatry, University College London, London, UK.
Notes Funding: National Institute for Health Research (NIHR) Health Technology Assessment Programme.
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SUMMARY OF FINDINGS TABLE
Psychosocial interventions compared with control intervention for fatigue during cancer treatment with palliative intent
Patient or population: patients with incurable cancer receiving cancer treatment with palliative intent
Settings: university-affiliated hospitals, cancer centres, public hospitals
Intervention: psychosocial interventions
Comparison: usual care or control conditions (not being a psychosocial intervention)
Outcomes Illustrative comparative 
risks* (95% CI)
Relative effect 
(95% CI)
No of 
Participants 
(studies)
Quality 
of the 
evidence 
(GRADE)
Comments
Assumed 
risk 
Corresponding 
risk
Fatigue Not known Not known Fatigue in the psychosocial 
interventions group was 
lower than in the control 
group (SMD -0.25, 95% CI 
-0.50 to 0.00)
535
(12)
⊕⊝⊝⊝ 
very low1,2
Physical 
functioning
Not known Not known Physical functioning in the 
psychosocial interventions 
group was higher 
(SMD 0.32, 95% CI 0.01 
to 0.63)
307
(7)
⊕⊝⊝⊝ 
very low1,2
An SMD of 0.32 
represents a small effect 
size with the upper end 
of the CI suggesting 
this may be clinically 
significant for some 
people.
Social 
functioning
Not known Not known Social functioning in the 
psychosocial interventions 
group was higher 
(MD 4.16, 95% CI -11.20 
to 19.53)
141
(4)
⊕⊝⊝⊝ 
very low1,2
Role 
functioning
Not known Not known Role functioning in the 
psychosocial interventions 
group was higher 
(MD 3.49, 95% CI -12.78 
to 19.76)
143
(4)
⊕⊝⊝⊝ 
very low1,2
Emotional 
functioning
Not known Not known Emotional functioning in the 
psychosocial interventions 
group was lower (SMD 
-0.11, 95%  CI -0.56 to 0.35)
115
(3)
⊕⊝⊝⊝ 
very low1,2
Cognitive 
functioning
Not known Not known Cognitive functioning in the 
psychosocial interventions 
group was lower (MD -2.23, 
95% CI -12.52 to 8.06)
86
(2)
⊕⊝⊝⊝ 
very low1,2
Adverse 
events
See 
comment
See 
comment
Not estimable No data available for 
meta-analysis.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding 
risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI). CI: confidence interval; SMD: standardized mean difference; MD: mean difference. 
1 Downgraded once: Unclear risk of selection bias. 2 Downgraded twice: Imprecision due to very sparse data.
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DATA AND ANALYSES
1 Fatigue
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
1.1 Post-intervention 12 535 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-0.50, 0.00]
1.2 First follow-up 4 147 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-1.00, -0.32]
1.3 Second follow-up 2 91 Std. Mean Difference (IV, Random, 95% CI) -0.41 [-1.12, 0.30]
2 Physical functioning
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
2.1 Post-intervention 7 307 Std. Mean Difference (IV, Random, 95% CI) 0.32 [0.01, 0.63]
2.2 First follow-up 2 122 Std. Mean Difference (IV, Random, 95% CI) 0.37 [-0.20, 0.94]
 
3 Social functioning
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
3.1 Post-intervention 4 141 Mean Difference (IV, Random, 95% CI) 4.16 [-11.20, 19.53]
4 Role functioning
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
4.1 Post-intervention 4 143 Mean Difference (IV, Random, 95% CI) 3.49 [-12.78, 19.76]
5 Emotional functioning
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
5.1 Post-intervention 3 115 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.56, 0.35]
6 Cognitive functioning
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
6.1 Post-intervention 2 86 Mean Difference (IV, Random, 95% CI) -2.23 [-12.52, 8.06]
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7 Subgroup analyses
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
7.1 Fatigue post-intervention 12 535 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-0.50, 0.00]
   7.1.1 short intervention duration 3 163 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.72, 0.48]
   7.1.2 intermediate-long intervention duration 9 372 Std. Mean Difference (IV, Random, 95% CI) -0.28 [-0.57, 0.02]
7.2 Fatigue post-intervention 11 507 Std. Mean Difference (IV, Random, 95% CI) -0.27 [-0.53, -0.00]
   7.2.1 group intervention delivery 3 195 Std. Mean Difference (IV, Random, 95% CI) -0.33 [-0.78, 0.11]
   7.2.2 individual intervention delivery 8 312 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.58, 0.14]
7.3 Fatigue post-intervention 12 535 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-0.50, 0.00]
   7.3.1 monodisciplinary intervention type 9 452 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.44, 0.04]
   7.3.2 multidisciplinary intervention type 3 83 Std. Mean Difference (IV, Random, 95% CI) -0.41 [-1.30, 0.47]
7.4 Fatigue post-intervention 12 535 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-0.50, 0.00]
   7.4.1 fatigue specific intervention aim 5 232 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.48, 0.31]
   7.4.2 other intervention aim 7 303 Std. Mean Difference (IV, Random, 95% CI) -0.37 [-0.72, -0.02]
7.5 Fatigue first follow-up 7 270 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.28]
   7.5.1 no additional sessions 4 147 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-1.00, -0.32]
   7.5.2 additional sessions 3 123 Std. Mean Difference (IV, Random, 95% CI) -0.43 [-0.90, 0.04]
7.6 Fatigue second follow-up 5 202 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.58, 0.07]
   7.6.1 no additional sessions 2 91 Std. Mean Difference (IV, Random, 95% CI) -0.41 [-1.12, 0.30]
   7.6.2 additional sessions 3 111 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.74, 0.30]
8 Sensitivity analyses
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
8.1 Fatigue post-intervention 9 476 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.59, 0.00]
8.2 Fatigue first follow-up 1 103 Std. Mean Difference (IV, Random, 95% CI) -0.70 [-1.10, -0.30]
8.3 Fatigue second follow-up 1 81 Std. Mean Difference (IV, Random, 95% CI) -0.23 [-0.67, 0.22]
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APPENDICES
1 GRADE system
The GRADE system uses the following criteria for assigning grades of evidence:
· High: we are very confident that the true effect lies close to that of the estimate of the effect;
· Moderate: we are moderately confident in the effect estimate; the true effect is likely to be 
close to the estimate of effect, but there is a possibility that it is substantially different;
· Low: our confidence in the effect estimate is limited; the true effect may be substantially 
different from the estimate of the effect;
· Very low: we have very little confidence in the effect estimate; the true effect is likely to be 
substantially different from the estimate of effect.
The grade of evidence is decreased further if the following are present:
· Serious (-1) or very serious (-2) limitation to study quality;
· Important inconsistency (-1);
· Some (-1) or major (-2) uncertainty about directness;
· Imprecise or sparse data (-1);
· High probability of reporting bias (-1).
The grade of evidence may be increased if:
·  Strong evidence of association: significant relative risk of >2 (< 0.5) based on consistent 
evidence from two or more observational studies, with no plausible confounders (+1);
·  Very strong evidence of association: significant relative risk of >5 (< 0.2) based on direct 
evidence with no major threats to validity (+2);
· Evidence of a dose response gradient (+1);
· All plausible confounders would have reduced the effect (+1).
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2 CENTRAL search strategy
#1 ((neoplas* or cancer*)):TI,AB,KY
#2 (carcinoma* or tumour* or adenocarcinoma*):TI,AB,KY
#3 (leukemi* or leukaemia* or lymphoma*):TI,AB,KY
#4 (tumor* or malignan* or melanoma* or sarcoma*):TI,AB,KY
#5 (“bone marrow transplant*” or “stem cell transplant*”):TI,AB,KY
#6 MESH DESCRIPTOR Neoplasms EXPLODE ALL TREES
#7 MESH DESCRIPTOR Bone Marrow Transplantation
#8 MESH DESCRIPTOR Stem Cell Transplantation EXPLODE ALL TREES
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10 MESH DESCRIPTOR Fatigue EXPLODE ALL TREES
#11 ((fatigue* or asthenia or asthenic or astheni*)):TI,AB,KY
#12 ((exhaustion or exhausted)):TI,AB,KY
#13 (((loss adj4 energy) or (loss adj4 vitality))):TI,AB,KY
#14 ((weary or weariness or weakness)):TI,AB,KY
#15 ((apathy or apathetic or lassitude or lethargic or lethargy)):TI,AB,KY
#16 ((sleepy or sleepiness or drowsy or drowsiness)):TI,AB,KY
#17 ((tired or tiredness)):TI,AB,KY
#18 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
#19 MESH DESCRIPTOR Psychotherapy EXPLODE ALL TREES
#20 ((psychosocial* or psycho-social*)):TI,AB,KY
#21 management” or psychotherapy* or “self
#22 educati* or psychoeducat* or relaxation
#23 counsel$ or (behaviour$ adj4 therap$) or “autogenic training”
#24  (behavior* adj4 therap*) or (relax* adj4 therap*) or (relax* adj4 treatment*) or (support* adj4 
group*)
#25 management” or psychotherapy* or “self
#26  imagery or “energy conservation” or “stress management” or psychotherapy* or “self care” or 
“self help”
#27 “nursing support”
#28 biofeedback or educati* or psychoeducat* or relaxation therap*
#29 “nursing intervention” or “nursing support”
#30  #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29
#31 #9 AND #18 AND #30
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3 MEDLINE search strategy 
1 exp Neoplasms/
2 Bone Marrow Transplantation/
3 exp Stem Cell Transplantation/
4  (neoplas$ or cancer$ or carcinoma$ or tumour$ or adenocarcinoma$ or leukemi$ or leukaemia$ 
or lymphoma$ or tumor$ or malignan$ or melanoma$ or sarcoma$ or “bone marrow transplant$” 
or “stem cell transplant$”).mp.
5 or/1-4
6 exp Fatigue/
7 (fatigue$ or asthenia or asthenic or astheni$).mp.
8 (exhaustion or exhausted).mp.
9 ((loss adj4 energy) or (loss adj4 vitality)).mp.
10 (weary or weariness or weakness).mp.
11 (apathy or apathetic or lassitude or lethargic or lethargy).mp.
12 (sleepy or sleepiness or drowsy or drowsiness).mp.
13 (tired or tiredness).mp.
14 or/6-13
15 exp Psychotherapy/
16 (psychosocial$ or psycho-social$).mp.
17  (counsel$ or (behaviour$ adj4 therap$) or “autogenic training” or (behavior$ adj4 therap$) 
or (relax$ adj4 therap$) or (relax$ adj4 treatment$) or (support$ adj4 group$) or imagery or 
“energy conservation” or “stress management” or psychotherapy$ or “self care” or “self help” 
or biofeedback or educati$ or psychoeducat$ or relaxation therap$ or “nursing intervention” or 
“nursing support”).mp.
18 or/15-17
19 5 and 14 and 18
20 randomized controlled trial.pt.
21 controlled clinical trial.pt.
22 randomized.ab.
23 placebo.ab.
24 drug therapy.fs.
25 randomly.ab.
26 trial.ab.
27 groups.ab.
28 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29 exp animals/ not humans.sh.
30 28 not 29
31 19 and 30
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4 EMBASE search strategy 
1 exp Neoplasms/
2 Bone Marrow Transplantation/
3 exp Stem Cell Transplantation/
4  (neoplas$ or cancer$ or carcinoma$ or tumour$ or adenocarcinoma$ or leukemi$ or leukaemia$ 
or lymphoma$ or tumor$ or malignan$ or melanoma$ or sarcoma$ or “bone marrow transplant$” 
or “stem cell transplant$”).mp.
5 or/1-4
6 exp Fatigue/
7 (fatigue$ or asthenia or asthenic or astheni$).mp.
8 (exhaustion or exhausted).mp.
9 ((loss adj4 energy) or (loss adj4 vitality)).mp.
10 (weary or weariness or weakness).mp.
11 (apathy or apathetic or lassitude or lethargic or lethargy).mp.
12 (sleepy or sleepiness or drowsy or drowsiness).mp.
13 (tired or tiredness).mp.
14 or/6-13
15 exp Psychotherapy/
16 (psychosocial$ or psycho-social$).mp.
17  (counsel$ or (behaviour$ adj4 therap$) or “autogenic training” or (behavior$ adj4 therap$) 
or (relax$ adj4 therap$) or (relax$ adj4 treatment$) or (support$ adj4 group$) or imagery or 
“energy conservation” or “stress management” or psychotherapy$ or “self care” or “self help” 
or biofeedback or educati$ or psychoeducat$ or relaxation therap$ or “nursing intervention” or 
“nursing support”).mp.
18 or/15-17
19 5 and 14 and 18
20 random$.tw.
21 factorial$.tw.
22 crossover$.tw.
23 cross over$.tw.
24 cross-over$.tw.
25 placebo$.tw.
26 (doubl$ adj blind$).tw.
27 (singl$ adj blind$).tw.
28 assign$.tw.
29 allocat$.tw.
30 volunteer$.tw. (201718)
31 Crossover Procedure/ (45499)
32 double-blind procedure.tw. (229)
33 Randomized Controlled Trial/ (391636)
34 Single Blind Procedure/ (21265)
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35 or/20-34 (1643586)
36 (animal/ or nonhuman/) not human/ (4924135)
37 35 not 36 (1458151)
38 19 and 37 (956)
5 CINAHL search strategy
S28 S18 AND S27
S27 S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26
S26 (allocat* random*)
S25 (MH “Quantitative Studies”)
S24 (MH “Placebos”)
S23 placebo*
S22 (random* allocat*)
S21 (MH “Random Assignment”)
S20 (Randomi?ed control* trial*)
S19  (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* 
mask* ) or (doubl* mask* ) or (singl* mask* )
S18 S5 AND S13 AND S17
S17 S14 OR S15 OR S16
S16  (counsel$ or (behaviour$ adj4 therap$) or “autogenic training” or (behavior* N4 therap*) or 
(relax* N4 therap*) or (relax* N4 treatment*) or (support* N4 group*) or imagery or “energy 
conservation” or “stress management” or psychotherapy* or “self care” or “self help” or 
biofeedback or educati* or psychoeducat* or relaxation therap* or “nursing intervention” or 
“nursing support”)
S15 psychosocial* or psycho-social*
S14 (MH “Psychotherapy+”)
S13 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12
S12 tired or tiredness
S11 sleepy or sleepiness or drowsy or drowsiness
S10 apathy or apathetic or lassitude or lethargic or lethargy
S9 weary or weariness or weakness
S8 (loss N4 energy) or (loss N4 vitality)
S7 exhaustion or exhausted
S6 (fatigue* or asthenia or asthenic or astheni*)
S5 S1 OR S2 OR S3 OR S4
S4  (neoplas* or cancer* or carcinoma* or tumour* or adenocarcinoma* or leukemi* or leukaemia* or 
lymphoma* or tumor* or malignan* or melanoma* or sarcoma* or “bone marrow transplant*” or 
“stem cell transplant*”)
S3 (MH “Hematopoietic Stem Cell Transplantation”)
S2 (MH “Bone Marrow Transplantation”)
S1 (MH “Neoplasms”)
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6 PsycINFO search strategy
1 exp Neoplasms/
2  (neoplas$ or cancer$ or carcinoma$ or tumour$ or adenocarcinoma$ or leukemi$ or leukaemia$ 
or lymphoma$ or tumor$ or malignan$ or melanoma$ or sarcoma$ or “bone marrow transplant$” 
or “stem cell transplant$”).mp.
3 exp Fatigue/
4 (fatigue$ or asthenia or asthenic or astheni$).mp.
5 (exhaustion or exhausted).mp.
6 ((loss adj4 energy) or (loss adj4 vitality)).mp.
7 (weary or weariness or weakness).mp.
8 (apathy or apathetic or lassitude or lethargic or lethargy).mp.
9 (sleepy or sleepiness or drowsy or drowsiness).mp.
10 (tired or tiredness).mp.
11 or/3-10
12 exp Psychotherapy/
13 (psychosocial$ or psycho-social$).mp.
14  (counsel$ or (behaviour$ adj4 therap$) or “autogenic training” or (behavior$ adj4 therap$) 
or (relax$ adj4 therap$) or (relax$ adj4 treatment$) or (support$ adj4 group$) or imagery or 
“energy conservation” or “stress management” or psychotherapy$ or “self care” or “self help” 
or biofeedback or educati$ or psychoeducat$ or relaxation therap$ or “nursing intervention” or 
“nursing support”).mp.
15 or/12-14
16 1 or 2
17 11 and 15 and 16
18 clinical trials/
19 (randomis* or randomiz*).tw.
20 (random$ adj3 (allocat$ or assign$)).tw.
21 ((clinic$ or control$) adj trial$).tw.
22 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
23 (crossover$ or “cross over$”).tw.
24 random sampling/
25 Experiment Controls/
26 Placebo/
27 placebo$.tw.
28 exp program evaluation/
29 treatment effectiveness evaluation/
30 ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw.
31 or/18-30
32 17 and 31
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ABSTRACT
Background
Fatigue is a common and debilitating symptom for patients with incurable cancer 
receiving systemic treatment with palliative intent. There is evidence that non-
pharmacological interventions such as graded exercise therapy (GET) or cognitive 
behaviour therapy (CBT) reduce cancer-related fatigue in disease-free cancer patients 
and in patients receiving treatment with curative intent. These interventions may also 
result in a reduction of fatigue in patients receiving treatment with palliative intent, by 
improving physical fitness (GET) or changing fatigue-related cognitions and behaviour 
(CBT). The primary aim of our study is to assess the efficacy of GET or CBT compared 
to usual care (UC) in reducing fatigue in patients with incurable cancer. 
Methods
The TIRED study is a multicentre three-armed randomised controlled trial (RCT) 
for incurable cancer patients receiving systemic treatment with palliative intent. 
Participants will be randomised to GET, CBT, or UC. In addition to UC, the GET 
group will participate in a 12-week supervised exercise programme. The CBT group 
will receive a 12-week CBT intervention in addition to UC. Primary and secondary 
outcome measures will be assessed at baseline, post-intervention (14 weeks), and at 
follow-up assessments (18 and 26 weeks post-randomisation). The primary outcome 
measure is fatigue severity (Checklist Individual Strength subscale fatigue severity). 
Secondary outcome measures are fatigue (EORTC-QLQ-C30 subscale fatigue), 
functional impairments (Sickness Impact Profile total score, EORTC-QLQ-C30 
subscale emotional functioning, subscale physical functioning) and quality of life 
(EORTC-QLQ-C30 subscale QoL). Outcomes at 14 weeks (primary endpoint) of either 
treatment arm will be compared to those of UC participants. In addition, outcomes at 
18 and 26 weeks (follow-up assessments) of either treatment arm will be compared 
to those of UC participants.
Discussion
To our knowledge, the TIRED study is the first RCT investigating the efficacy of GET 
and CBT on reducing fatigue during treatment with palliative intent in incurable cancer 
patients. The results of this study will provide information about the possibility and 
efficacy of GET and CBT for severely fatigued incurable cancer patients.
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BACKGROUND
Cancer is a leading cause of mortality worldwide, with 8.2 million deaths in 2013 [1]. As 
a result of improvements in treatment options for certain cancers, substantial progress 
has been made in curative treatment of cancer. Despite these positive developments, 
a substantial subgroup of cancer patients will (eventually) be diagnosed with incurable 
cancer. The medical treatment of incurable cancer has a palliative intention, with 
prolonging life as one of its main aims [2]. For some cancer types, advances in cancer 
treatment with palliative intent have resulted in an extended period of life, resulting 
in more long-term or chronic cancer treatment. Next to prolonging life, treatment of 
incurable cancer should also be aimed at maintaining quality of life for as long as 
possible and relieving physical and psychological symptoms [2]. As a result of the 
longer-term treatment of incurable cancer patients, aspects regarding quality of life 
and symptom management become even more important.
Fatigue in patients with incurable cancer
Fatigue is one of the most commonly reported symptoms during systemic treatment 
for incurable cancer, being reported by up to 99% of patients [3-7]. There are various 
ways to define fatigue, but cancer-related fatigue (CRF) is a term that is most widely 
used to address this symptom. The National Comprehensive Cancer Network (NCCN) 
defines CRF as “a distressing, persistent, subjective sense of physical, emotional 
and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is 
not proportional to recent activity and interferes with usual functioning” [8]. Studies 
show that CRF is among the most distressing symptoms [3, 9, 10] and is associated 
with reduced quality of life, poor performance status, and difficulty performing daily 
activities [3, 4, 11]. Many factors are likely to contribute to CRF in patients with 
incurable cancer. The multiple causes of CRF can result from the underlying disease, 
from secondary factors such as anaemia, infection, dehydration, and treatment side 
effects, or from loss of muscle mass. Apart from these physical factors, depression 
and anxiety can also contribute to CRF. There is also evidence suggesting that 
cognitive and behavioural factors, such as sleeping problems, fatigue catastrophising, 
and inappropriate coping are related to fatigue in patients with incurable cancer [12]. 
Management of CRF in incurable cancer patients should first focus on identifying and 
treating somatic causes, for example anaemia or hypothyroidism [8]. Yet, often no 
somatic cause for CRF can be found. When no somatic cause can be identified, the 
management of CRF can involve pharmacological treatment or non-pharmacological 
interventions. Thus far, no recommendation for a specific drug treatment for 
fatigue in palliative care patients could be given [13]. There is also no evidence-
based non-pharmacological intervention for CRF in incurable cancer patients. Two 
non-pharmacological approaches, Graded Exercise Therapy (GET) and Cognitive 
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Behaviour Therapy (CBT), seem promising interventions based on findings from 
studies addressing CRF in other cancer patients that will be discussed below. 
Exercise interventions for CRF in cancer patients
In contrast to the old advice to ‘get plenty of rest’ during cancer treatment, patients 
are now encouraged to optimise levels of physical activity [8]. A low level of physical 
activity during cancer treatment can lead to decreased physical functioning by a 
substantial loss of cardiopulmonary fitness and muscle mass [14]. On the other 
hand, increasing physical activity has been suggested as helpful in reducing CRF 
by improving physical capacity, resulting in a reduced effort to perform everyday 
activities [8]. Cramp & Byron-Daniel (2012) suggested that exercise interventions 
can help to reduce CRF both during and after adjuvant treatment for cancer [15]. 
Efficacy of exercise interventions for the subgroup of patients receiving cancer 
treatment with palliative intent was not examined in this Cochrane systematic review. 
Nonetheless, a systematic review by Lowe et al. (2009) did provide evidence that 
exercise interventions are feasible in patients with incurable cancer as the majority 
of participants were able to tolerate various physical activity interventions [16]. Three 
of the six reviewed studies had fatigue as one of the outcome measures and all three 
reported a reduction in fatigue [17-19]. However, the methodological quality of these 
pilot studies was evaluated as poor and only one study had a control condition [16].
Following the NCCN recommendations for exercise programs, our research group 
developed a 6-week GET intervention that was tailored to the physical fitness level 
of each participant and began at a low level of intensity and duration, progressed 
slowly, and was modified when the participant’s condition changed. This intervention 
was tested for feasibility and efficacy was explored in an uncontrolled pilot study 
of 26 incurable cancer patients. GET was not only feasible in terms of participants’ 
adherence and evaluation, but also efficacious with significant improvements in self-
reported fatigue and quality of life [20]. A large-scale randomised controlled trial 
(RCT) is needed to confirm these promising results. 
Cognitive Behaviour Therapy for CRF in cancer patients
Most research on the efficacy of CBT for CRF has been done in cancer survivors or 
cancer patients receiving cancer treatment with curative intent. Systematic reviews 
and meta-analyses have indicated that CBT can reduce fatigue in cancer survivors 
[21, 22]. Two RCTs performed by our research group have demonstrated that fatigue 
and functional impairments in severely fatigued cancer survivors can be significantly 
reduced by CBT for CRF [23, 24]. This fatigue-specific intervention targets several 
cognitive-behavioural perpetuating factors of CRF. The intervention is based on the 
underlying assumption that cancer treatment and/or the cancer itself may trigger 
fatigue (precipitating factors), but that other factors such as sleep disturbance, 
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physical inactivity, and dysfunctional thoughts about fatigue might be responsible for 
the persistence of fatigue (perpetuating factors) [25]. Positive intervention effects of 
CBT for CRF were sustained at 2-years follow-up [26]. The efficacy of CBT for CRF 
compared to usual care was also assessed in an RCT aimed at cancer patients during 
cancer treatment with curative intent [27]. Despite a significant reduction in fatigue 
immediately after the intervention for patients in the CBT arm, no differences were 
observed between these two conditions at follow-up with effects diminishing after 
seven months [28].  It should be noted though, that being severely fatigued was not 
an entry criterion for this RCT, and thus a floor effect may be present in this trial.
While there are no RCTs to date that investigated the efficacy of CBT specifically 
aimed at reducing fatigue in incurable cancer patients receiving cancer treatment with 
palliative intent, two previous RCTs provide indirect support for the positive effects 
of CBT on fatigue outcomes in a sample of cancer patients of whom a subgroup had 
incurable cancer [29, 30]. Although these RCTs did show an overall effect on fatigue, it 
is not clear whether this can be generalised to the group of cancer patients receiving 
treatment with palliative intent since subgroup analyses were not performed. Based 
on our previous experience with CBT for CRF in both cancer survivors and patients 
receiving cancer treatment with curative intent, and results of a recent study which 
suggested that the same perpetuating psychosocial factors are associated with 
fatigue in patients receiving cancer treatment with palliative intent [12], we think it 
is important to examine the efficacy of CBT for CRF in an RCT for this new target 
population.
The role of physical activity and fitness versus fatigue-related cognitions 
as mediators of the reduction in CRF
Exercise interventions aiming to reduce CRF in cancer patients are based on the 
assumption that a lack of physical activity and deconditioning during cancer treatment 
can worsen fatigue [31]. It is assumed that with exercise interventions physical activity 
and fitness can be increased, resulting in a reduction in CRF. CBT aimed at reducing 
CRF in cancer patients is based on the assumption that several fatigue-related 
cognitions (i.e. low self-efficacy and catastrophising thoughts) and behaviours are 
related to the persistence of fatigue [25]. Targeting cognitions with CBT is assumed to 
result in less dysfunctional thoughts about fatigue, which contributes to the reduction 
in CRF. Although these assumptions are widespread, the role of an increase in 
physical activity and fitness versus a change in fatigue-related cognitions in reducing 
CRF has not yet been investigated in interventions for patients with incurable cancer. 
To investigate which factors contribute to a reduction in CRF, mediation analysis can 
be helpful. This technique provides insight into which factors mediate the expected 
reduction in CRF brought on by GET and CBT. Mediation analysis can thereby help us 
to better understand how interventions work [32].
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Aims of the TIRED study
We designed a multicentre RCT to test the efficacy of either GET or CBT compared 
to Usual Care (UC) in reducing fatigue (primary outcome) in incurable cancer 
patients receiving systemic treatment with palliative intent. In addition, the efficacy 
on improving quality of life and functional impairment will be studied. All outcomes 
will be assessed at baseline, and at 14, 18 and 26-weeks post-randomisation. We 
will assess the efficacy of GET or CBT compared to UC directly post-intervention at 
14-weeks post-randomisation, which is the primary endpoint of this study. In addition, 
we will determine whether the expected intervention effects are sustained at follow-
up assessments (18-weeks and 26-weeks post-randomisation). Furthermore, if GET 
and/or CBT are efficacious in reducing CRF, we will perform a mediation analysis 
to test if the changes in four variables (i.e. physical activity, physical fitness, self-
efficacy with respect to fatigue, and/or fatigue catastrophising) mediate the reduction 
in fatigue.
METHODS
Design
A non-blinded multicentre RCT (the TIRED study) will be conducted to evaluate the 
efficacy of GET and CBT compared to UC for severely fatigued incurable cancer 
patients receiving cancer treatment with palliative intent. 
Participants
Inclusion and exclusion criteria are listed in Table 1. Patients diagnosed with 
incurable cancer, receiving systemic treatment with palliative intent, and with a cancer 
treatment plan based on an expected survival of at least 6 months as judged by their 
oncologist, will be further assessed for eligibility by nurses and oncologists. We will 
include patients diagnosed with one of the following cancer types: breast, colorectal, 
prostate, renal cell, bladder, endometrial, ovarian, cervical, bone and soft tissue, or 
melanoma. Systemic cancer treatment may include chemotherapy, hormone therapy, 
targeted therapy, and/or immunotherapy, possibly combined with surgery and/or 
radiotherapy. The presence of severe fatigue reflected by a score of 35 or higher on 
the subscale fatigue severity of the Checklist Individual Strength (CIS-fatigue) will be 
used as a criterion for study entry [33].
Recruitment
Nurses and oncologists working at oncology outpatient clinics of two University-
affiliated hospitals and seven Regional hospitals in the Netherlands will recruit 
patients. Patients will be screened for the presence of severe fatigue as part of 
clinical care by administering the CIS-fatigue prior to the start or during systemic 
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treatment with palliative intent when patients visit the outpatient clinic. When eligible 
patients are severely fatigued, the nurse or oncologist will present the TIRED study by 
giving patients written information and solicit permission to have a researcher contact 
them. Those patients who agree to be contacted will be called by the coordinating 
researcher (HP), who will further inform them about the details and purpose of the 
study and invite them to participate. A follow-up phone call will be scheduled one 
week after the first phone call to address questions and determine if patients are 
willing to participate.
Table 1. Inclusion and exclusion criteria TIRED study
INCLUSION CRITERIA
(1) Age ≥ 18 years.
(2) Able to read, speak and write the Dutch language.
(3) Diagnosis of incurable cancer (i.e. breast, colorectal, prostate, renal cell, bladder, endometrial, ovarian, cervical, bone and soft 
tissue cancer, or melanoma).
(4) Scheduled for or receiving systemic cancer treatment with palliative intent (i.e., chemotherapy, and/or hormone therapy, and/or 
targeted therapy, and/or immunotherapy, possibly combined with surgery and/or radiotherapy).
(5) Cancer treatment plan based on an expected survival of ≥ 6 months as judged by their oncologist. 
(6) Severely fatigued (CIS-fatigue score ≥ 35).
EXCLUSION CRITERIA
(1) Treatable somatic cause that could explain the presence of severe fatigue (other than the underlying disease and the cancer 
treatment itself ).
(2) Karnofsky Performance Status < 70.
(3) Symptomatic brain metastases.
(4) Severe cognitive problems.
(5) Not able to walk at least 6 minutes successively.
(6) Contra-indication for physical exercise.
(7) Current treatment by a psychiatrist or psychologist for a psychiatric disorder.
Procedure
Eligible patients willing to participate in the study will be asked to sign informed 
consent upon which they will be invited by a research assistant to complete the 
baseline assessment (T0) at their own hospital. Upon completion of T0, the research 
assistant will use a central web-based randomisation service to randomly allocate a 
participant to one of the three study arms: (1) GET in addition to UC; (2) CBT in addition 
to UC; or (3) control group receiving UC (see Figure 1). Participants assigned to GET 
or CBT will start the intervention approximately two weeks after T0. Both interventions 
will be delivered at or near their own hospital over a period of 12 weeks. Participants 
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assigned to CBT will complete a set of additional questionnaires to determine relevant 
intervention modules prior to the first intervention session. Participants assigned to 
GET will complete an additional submaximal test to determine physical fitness during 
the first intervention session. At 14 weeks, participants are invited by the research 
assistant to complete the post-intervention assessment (T1) at the hospital. Follow-
up assessments at 18 weeks (T2) and 26 weeks (T3) are entirely web-based and will 
be completed at home. For participants that do not have Internet access, a paper 
version of the follow-up questionnaires will be send to their home address, which can 
be returned in a self-addressed, pre-stamped envelope.
Figure 1. Flowchart of the TIRED study
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Randomisation
A central web-based randomisation service provided by an independent statistician 
will be used. Randomisation will be stratified by centre. We will use block randomisation 
to reach the same number of participants in all study arms. The ordering of blocks 
and their respective size will be unknown for the research assistants and coordinating 
researcher. When possible, minimisation on gender will be performed in order to 
balance the gender distribution in all study arms. If block randomisation restricts the 
choice to two or only one study arm, minimisation will always be overruled by block 
randomisation. A research assistant will perform allocation upon completion of T0 in 
the presence of the participant. 
Interventions
Graded Exercise Therapy
Participants assigned to the GET group will receive a 12-week supervised exercise 
programme in addition to UC. The treatment protocol ‘GET for fatigue in incurable 
cancer patients’ was developed by the study investigators in cooperation with a 
physiologist (MH) and physical therapist (RN) experienced in exercise programmes 
for cancer patients. The treatment protocol was based on the protocol for a previous 
pilot-study in patients with incurable cancer [20]. Physical therapists affiliated with 
the participating hospitals or from local physical therapy centres will deliver the GET. 
All therapists will be instructed about the treatment protocol and use of registration 
forms before enrolment of participants. Throughout the study, supervision will be 
provided upon request by a physical therapist (RN).
GET will be given by physical therapists individually or in small groups with a maximum 
of 5 participants, depending on the accrual rate. During the intake session, the 
physical therapist will collect information about a participant’s physical fitness level 
(by means of a submaximal test) and physical limitations. Participants will formulate 
treatment goals in activities of daily living together with the physical therapist, 
such as performing activities or leisure interests in the foreseeable future that are 
currently difficult to perform because of a lack of muscle strength or cardiopulmonary 
fitness. After the intake session, participants will receive weekly two-hour sessions 
of individually graded training supported by a physical therapist and adjusted to 
their abilities. In order to adjust the training to an individual participant, their heart 
rate reserve (HRR) and muscle strength (by means of one-repetition maximum [1RM] 
tests) will be determined during first session and after every three sessions. The two-
hour GET sessions will include a warming up (10 min), high intensity aerobic interval 
training (35 min), a break (15 min), resistance training (35 min), and a cooling down 
(10 min). Additionally, there are 15 minutes available for evaluation of the GET session. 
In addition to this supervised session, participants are offered to practise in a second 
weekly session. After every three sessions, training progress will be evaluated and 
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the programme will be adjusted by means of the newly determined HRR and 1RM and 
discussion of formulated treatment goals.
Aerobic training. The aerobic training will consist of cycling on an interval basis prior 
to the resistance training. Intervals will include alternated bicycling for four minutes at 
60% (increasing to 80%) of participants’ HRR with three minutes on 35% (increasing 
to 50%) of HRR. Heart rate will be monitored during the aerobic training using a 
Polar® breast band (Polar T31 Breast Band, 2008, Polar Electro, Finland). We will 
use the Borg Scale of Perceived Exertion after each cycling interval to gauge the 
perceived intensity of the aerobic training [34]. 
Resistance training. The resistance program will include a circuit of seven exercises 
targeting large muscle groups important for activities of daily living. The following 
exercises will be executed: (1) leg press; (2) lunge; (3) vertical row; (4) lateral pull down; 
(5) abdominal crunch; (6) pull over; and (7) bench press. Exercises will be executed at 
60-80% of participants’ 1RM and will consist of 3 sets of 8 to 12 repetitions. Some 
exercises will be performed more often based on the participants’ difficulties in this 
area and his or her goals in activities of daily living. Progression will be conducted by 
the graded activity principle, which states that the focus is on successes and positive 
experiences and that negative experiences will be prevented as much as possible 
[35]. 
Cognitive Behaviour Therapy
Participants in the CBT group will receive ‘CBT for fatigue in incurable cancer patients’ 
in addition to UC. This intervention was developed by the study investigators based 
on the evidence-based protocol of CBT for post-cancer fatigue [23, 26]. Adaptations 
were done for application with our new target population. This adapted CBT will 
consist of a maximum of ten sessions over a period of 12 weeks (i.e., one assessment 
session and maximum nine individual one-hour face-to-face treatment sessions). 
Qualified and trained psychologists will deliver CBT for fatigue. Prior to intervention 
delivery, all therapists will receive a three-day training provided by two experienced 
clinical psychologists (HK and TB). This training will provide background and 
rationale for each of the intervention modules and involves role-playing to practise 
the intervention components. An experienced clinical psychologist (HK) will provide 
on-going supervision to CBT therapists throughout the study.
CBT for fatigue in incurable cancer patients includes several modules aimed at 
fatigue-perpetuating cognitions and behaviours. Participants randomised to CBT 
will complete a set of additional questionnaires prior to the first intervention session 
to assess potential perpetuating factors (see Table 2). During the first intervention 
session it will be determined by the therapist which factors are applicable for the 
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particular patient, which leads to a tailored-made intervention as only the relevant 
treatment modules will be selected. The goal of CBT is reduction of severe fatigue 
and fatigue-related disability. All participants will start with setting their treatment 
goals. Participants will be helped to formulate concrete goals in behavioural terms, 
such as resuming activities or leisure interests in the foreseeable future that are 
discontinued because of being severely fatigued. Then, therapists and participants 
will work on adjusting the fatigue-perpetuating factors that are applicable to the 
individual participant: (1) sleep problems and deregulated sleep-wake cycle; (2) 
dysfunctional cognitions regarding cancer (prognosis) and cancer treatment; (3) 
dysfunctional fatigue-related cognitions; (4) deregulated activity pattern; (5) negative 
social interactions and low perceived social support. Each of these perpetuating 
factors corresponds to a treatment module: 
Module 1: Regulation of sleep-wake cycle and improving sleep hygiene. The patient 
will be explained how the ‘biological clock’ can be reset, in order to establish a 
consistent sleep-wake pattern with regular bed and wake-up times and no day-time 
napping. If necessary, advice with respect to sleep hygiene will be given. 
Module 2: Reformulate dysfunctional cognitions regarding cancer and cancer 
treatment. This module aims to help the patient formulate more helpful beliefs to 
improve his or her coping with the fact of having incurable cancer, including fear of 
the future, and experiencing side effects of cancer treatment. Dysfunctional beliefs 
will be discussed and restructured. 
Module 3: Reformulate dysfunctional cognitions regarding fatigue. The goal is to 
increase self-efficacy with respect to fatigue, reduce fatigue catastrophising, and 
help the patient to focus less on fatigue. 
Module 4: Regulation of activity. Two activity patterns will be distinguished on the 
basis of actigraphy (see ‘Outcomes’): relatively active or low active. Some severely 
fatigued patients have a persistent low level of physical activity, while others have 
a more fluctuating activity pattern with bursts of activities followed by periods of 
inactivity (‘all-or-nothing behaviour’). Both activity patterns can perpetuate fatigue. 
Relatively active participants are helped to spread their physical, mental, and social 
activities more evenly over the day and week. Subsequently, participants will gradually 
increase their physical activity level by means of a daily walking or cycling program 
of their choice. The chosen activity will be gradually and systematically increased. 
Low active participants will be motivated to immediately start with the graded activity 
program. By increasing physical activity, participants’ self-efficacy with respect to 
physical activity and fatigue will often change positively. Eventually, participants will 
also increase mental and social activities.
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Table 2. Instruments to assess which CBT modules are indicated
CBT MODULE INSTRUMENT RATING (RANGE) CUT-OFF VALUE
Sleep problems and 
deregulated sleep-wake 
cycle
Sleep-wake diary Bedtimes and wake up times of 
12 consecutive days and nights
Visual inspection of bedtimes 
and wake up times
Sickness Impact Profile [41]: 
subscale Sleep and Rest
Number and type of items 
endorsed, weighted according to 
a standardised weighting scheme Score ≥ 60
Symptom Checklist-90 [52]: 
subscale Sleeping Problems 5-point Likert scale (3-15) Score ≥ 6
Dysfunctional cognitions 
regarding cancer 
(prognosis) and cancer 
treatment
Impact of Event Scale [53]: 
subscale Intrusion
subscale Avoidance
4-point Likert scale (7-28) 
4-point Likert scale (8-32)
Score ≥ 10
Score ≥ 10
Pictorial Representation of Illness and 
Self Measure [54]
Self-illness separation 
(SIS) in cm
Self-fatigue separation 
(SFS) in cm
Fatigue-related suffering: 
SIS > SFS
Illness-related suffering: 
SFS > SIS
Illness Cognition Questionnaire 
[55, 56]:
subscale Acceptance
subscale Helplessness
4-point Likert scale (6-24)
4-point Likert scale (6-24)
Score ≤ 12
Score > 14
Beck Depression Inventory-II 
Primary Care [57] 4-point Likert scale (0-21) Score ≥ 4
Hospital Anxiety and 
Depression Scale [58]:
subscale Anxiety
subscale Depression
4-point Likert scale (0-21) 
4-point Likert scale (0-21)
Score ≥ 9 
Score ≥ 9 
Dysfunctional fatigue-
related cognitions
Fatigue Catastrophising Scale [45] 5-point Likert scale (10-50) Score ≥ 16 
Self-Efficacy Scale [26, 59] 4-point Likert scale (7-28) Score ≤ 19
Illness Management 
Questionnaire-factor III [60] 6-point Likert scale (9-54) Score ≥ 30
Anxiety for Fatigue 4-point Likert scale (8-32) Score ≥ 14
Deregulated activity 
pattern
Actigraphy during 12 consecutive days Number of days with a 
mean physical activity 
level > 66 
Low-active: 0-1
Relatively-active: ≥ 2
Sickness Impact Profile [41]: 
subscale Social Interactions
Number and type of items 
endorsed, weighted according to 
a standardised weighting scheme Score ≥ 100
Checklist Individual Strength 
[33]: subscale Concentration 7-point Likert scale (5-35) Score ≥ 18
Negative social 
interactions and low 
perceived social support
Van Sonderen Social 
Support Inventory [61] 
(shortened version): 
subscale Negative Interactions 
subscale Discrepancies
4-point Likert scale (7-28)
4-point Likert scale (8-32)
Score ≥ 10
Score ≥ 14
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Module 5: Improve social support and change unhelpful social expectations. This 
module is directed at modifying the patients’ unhelpful cognitions regarding their 
social environment, as they can maintain fatigue. Unrealistic expectations towards 
others are detected and disputed. Patients will practise with exercises in order to 
change these unhelpful cognitions and are encouraged to involve their partner in this 
module. Also, coping strategies in contact with others, such as family, friends, and/
or colleagues, will be discussed. 
After addressing the perpetuating factors of fatigue, patients will gradually work 
towards realising the treatment goals formulated at the start of the intervention. At 
the end of the intervention it is discussed how to deal with new episodes of fatigue, 
that may be induced when starting further lines of systemic cancer treatment.   
Usual care and use of co-intervention
All participants will be treated for incurable cancer in concordance with national 
and regional cancer clinical practice guidelines of the Dutch Comprehensive Cancer 
Centres [36]. Participants assigned to the control group have no access to one of the 
two study interventions, but may be referred by their oncologist or general practitioner 
to physical therapists or psychologists as part of UC. Participants assigned to CBT 
will be asked not to follow an exercise programme as part of UC simultaneously, and 
participants assigned to GET will be asked not to follow a psychological intervention 
as part of UC simultaneously. We will collect information on whether participants have 
engaged in exercise programmes or psychological interventions as part of UC at all 
three post-randomisation assessments (T1, T2, and T3).
Adverse events
All adverse events (AEs) and serious adverse events (SAEs) reported spontaneously 
by the participants or observed by the GET or CBT therapists will be recorded. All 
reported AEs will be followed until they have aborted, or until a stable situation has 
been reached. SAEs are defined as any medical occurrence that results in death, is 
life threatening, requires hospitalisation, results in persistent or significant disability or 
incapacity, or a new event of the study likely to affect the safety of participants. SAEs 
will be reported to the Research Ethics Committee of the University-affiliated hospital 
that approved the study protocol. At post-intervention assessment (T1), patients will 
be asked whether they think they currently experience or have experienced AEs as a 
result of the intervention (GET or CBT) they have received. In case of an affirmative 
answer, patients will be asked to specify these AEs.
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Adherence and treatment integrity
Data will be collected with respect to participants’ attendance of GET or CBT 
sessions, dropout from the intervention (< 2 sessions attended), and therapists’ 
adherence to the protocol. Adherence to GET and CBT intervention protocols will be 
determined by means of evaluating the registration forms completed by therapists, 
including components of the intervention protocol that have been addressed during 
each session. In addition, with permission of participants, all CBT sessions will be 
audio taped and upon study completion a random sample of 5% will be analysed to 
determine treatment integrity. 
Refusal of study participation and study dropout
The researcher will record the reasons why patients do not participate, why participants 
dropout from the intervention, and why study assessments are not completed (T1, T2, 
or T3). Upon completion of the study, these reasons will be categorised, scored and 
analysed to gain insight into the generalisability of the findings.
Outcomes
Outcome measures and data collection time points are listed in Table 3. The 
primary endpoint of this study is the post-intervention assessment (T1), 14 weeks 
after randomisation. Primary and secondary outcomes will be measured at baseline 
(T0), post-intervention (T1) and follow-up (T2, T3). Proposed mediators will only be 
assessed at T0 and T1.
Primary outcome
Fatigue severity will be measured using the subscale fatigue severity (8 items, 7-point 
Likert scale) of the Checklist Individual Strength (CIS-fatigue) [37]. Scores range from 
8 to 56. A score of 35 points or higher is an indication for severe fatigue. The CIS-
fatigue has been used in previous intervention studies aimed at CRF and proved to be 
sensitive to change [23, 27]. The CIS-fatigue has good reliability (Cronbach’s alpha = 
0.88) and discriminative validity [33]. 
Secondary outcomes
Fatigue will also be assessed with the symptom scale fatigue (3 items, 4-point 
Likert scale) of the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30, version 3.0). The EORTC QLQ-C30 
is developed for use in clinical trials in cancer patients [38]. This instrument consists 
of five functional and three symptom scales in addition to a scale on global health 
related quality of life (HRQoL), and a number of single items assessing additional 
symptoms [38, 39]. Total scores on each subscale are linearly converted to a 0 to 100 
scale. Higher scores represent more fatigue. 
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Table 3. Data collection time point of all outcome measures and proposed mediators
CONCEPT QUESTIONNAIRE MEASUREMENT TIME POINTS
T0 T1 T2 T3
Socio-demographics Self-report questionnaire X
Medical characteristics Medical chart review X X
Primary outcome:
Fatigue severity CIS fatigue severity X X X X
Secondary outcomes:
Fatigue EORTC QLQ-C30 fatigue X X X X
Quality of life EORTC QLQ-C30 global health status X X X X
Functional impairments SIP X X X X
EORTC QLQ-C30 emotional functioning X X X X
EORTC QLQ-C30 physical functioning X X X X
Proposed mediators:
Physical activity Actigraphy during 12 consecutive days X X
Physical fitness 6MWT X X
Self-efficacy SES X X
Fatigue catastrophizing FCS X X
T0 = baseline (pre-intervention); T1 = post-intervention/UC (14 weeks post-randomisation); T2 = first follow-up assessment 
(18-weeks post-randomisation); T3 = second follow-up assessment (26-weeks post-randomisation).
The subscale global health status/QoL (2 items, 7-point Likert Scale) of the EORTC 
QLQ-C30 will be used to measure quality of life. A high score indicates good HRQoL. 
The EORTC QLQ-C30 is one of the most commonly used HRQoL instruments [40] and 
is known to be a reliable and valid measure of the quality of life of cancer patients [38].
Functional impairments will be assessed with two instruments. We will include seven 
subscales of the Sickness Impact Profile (SIP) to assess the level of functional 
impairments [41]. This questionnaire measures the influence of complaints in different 
areas of daily functioning. The following subscales will be used: alertness behaviour, 
sleep, homemaking, leisure activities, mobility, social interactions, and ambulation. 
High scores reflect high levels of functional impairments. The SIP is known to be a 
reliable instrument with sufficient content validity [42]. In addition to the SIP, functional 
impairments will also be assessed by the subscales emotional functioning (4 items, 
4-point Likert scale) and physical functioning (5 items, 4-point Likert scale) of the 
EORTC QLQ-C30. Raw scores for both subscales are convertible to a score of 0 to 
100. A high score represents a high level of functioning.
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Proposed mediators
Change scores (T1-T0) for each proposed mediator will be calculated and used for 
multiple mediation analysis. The following proposed mediators will be assessed at 
T0 and T1.
Physical activity. The level of physical activity will be assessed with actigraphy. 
Participants will be wearing an actometer around the ankle for twelve consecutive 
days and nights following T0 and T1. This actometer is a motion-sensing device 
based on a piezo-electric sensor recording the number of movement at five-minute 
intervals and with highly reproducible readings [43]. The mean daily physical activity 
score over twelve days can be calculated as a measure of physical activity.
Physical fitness. We will assess the level of physical fitness with the Six-Minute Walk 
Test (6-MWT). This is an easy to perform and practical submaximal exercise test 
that has been increasingly used across various patient populations. The 6-MWT will 
be conducted in an indoor corridor on a pre-measured test-course of 20 meters. 
Participants will be instructed to walk from one end to the other while attempting to 
cover as much distance as possible during the allotted time. Patients who normally 
use walking aids will be allowed to use them during the test. The total walking distance 
covered in six minutes provides an indirect measure of aerobic functional fitness [44].
Self-efficacy with respect to fatigue. The seven-item self-efficacy scale (SES) will 
be used to measure the amount of experienced control over fatigue [26]. All items 
are scored on a 4-point Likert scale. Higher scores are indicative for more sense of 
control.
Fatigue catastrophising. We will use the ten-item Fatigue Catastrophizing Scale to 
measure catastrophising in response to fatigue [45]. All items are scored on a 5-point 
Likert scale. Higher total scores indicate more fatigue catastrophising.
Sample size calculation
Based on the primary outcome measure of the TIRED study, efficacy of one or both 
interventions is demonstrated when mean fatigue severity (CIS-fatigue) in participants 
assigned to GET and/or CBT is significantly lower at T1 compared to participants 
assigned to UC. A clinically relevant difference between the intervention arms and 
the UC arm of at least 6 points is expected for the primary outcome (CIS-fatigue). 
Per arm, a minimum number of 51 evaluable participants at T1 would be needed for 
a t-test with a power of 0.80 and a two-sided alpha of 0.025 (corrected to account 
for the two comparisons: GET versus UC and CBT versus UC). According to Borm et 
al. (2007) [46], using analysis of covariance (ANCOVA) instead of a t-test to analyse 
treatment effects on a continuous outcome measure (CIS-fatigue) increases the 
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power and reduces the needed sample size in RCTs. This proposed ‘design factor’ 
for ANCOVA can be calculated by multiplying the number of participants needed 
for the t-test by 1 – p2, where p is the correlation between the outcome measure at 
T0 and T1.  Since no data on the correlation of the CIS-fatigue from earlier trials in 
this particular patient group were available, we used a conservative approach by 
assuming a weak correlation (1 – 0.102 = 0.99) and thus the number of participants 
needed was not reduced. Anticipating an attrition rate of 30%, we aim to recruit a 
target sample size of 219 participants at T0 (73 participants per arm).
Statistical analyses
The statistician who will perform data analyses will be blinded for intervention allocation. 
To test the efficacy of both interventions compared to UC, an ANCOVA will be performed 
for each intervention with fatigue severity (CIS-fatigue) at T1 as dependent measure, 
condition as fixed factor and CIS-fatigue screening score as covariate [47]. Missing data 
is a common problem in palliative care research and is also anticipated in our study as 
a result of deteriorating health or because the patient has died. Data will be primarily 
analysed on complete case basis, i.e. only data from evaluable participants with a T1 
assessment will be used. The p-level is adjusted to 0.025 to account for the two primary 
analyses, i.e. GET versus UC and CBT versus UC. When statistically significant differences 
between GET versus UC and/or CBT versus UC are found, additional sensitivity analysis 
accounting for all randomised participants will be done to explore the impact of missing 
data. Several methods of imputation are available and the choice will depend on the 
actual circumstances of missing data. We will record the causes of missing data and 
careful considerations will be given to which imputation procedure should be used.
In addition, ANCOVA will be performed for the secondary outcomes (fatigue, quality of 
life, and functional impairments), with baseline score (T0) on the dependent measure 
as covariate. In these exploratory analyses a p-level of 0.05 will be used. Longer-term 
follow-up effects at T2 and T3 will also be tested using ANCOVA, with baseline score (T0) 
on the dependent measure as covariate. Again, in these explorative analyses a p-level of 
0.05 will be used. No sensitivity analysis will be done, as the power for follow-up analyses 
will be limited due to the expected significant amount of attrition. 
Mediation analysis will be conducted to explore the possible underlying mechanisms 
of the expected reduction in fatigue severity (CIS-fatigue) brought on by GET and CBT 
at T1. Following recommendations of Preacher and Hayes (2008) [48], we will perform 
multiple mediation analysis using bootstrapping to test the mediating effect of four 
potential mediators (i.e. changes in physical activity, physical fitness, self-efficacy with 
respect to fatigue, and catastrophising in response to fatigue). We will only perform 
multiple mediation analysis when there is a significant effect of one or both interventions 
compared to UC. 
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Ethical approval
The study protocol has been reviewed and approved by the Research Ethics Committee 
of our University-affiliated hospital (CMO Arnhem-Nijmegen, reference no. 2012/240) 
and the local Ethics Committees of the participating hospitals (Hospital Gelderse 
Vallei, Máxima Medical Center, Isala Hospital, Canisius-Wilhelmina Hospital, Hospital 
Pantein, Jeroen Bosch Hospital, VieCuri Medical Center, and Academic Medical 
Center). The study is registered in the Dutch Trial Registry (reference no. NTR3812, 
date registered: January 23, 2013).
DISCUSSION
Fatigue is one of the most prevalent symptoms compromising quality of life of 
incurable cancer patients receiving systemic treatment with palliative intent. Graded 
exercise and cognitive behavioural interventions seem promising in reducing fatigue 
severity based on their effectiveness in disease-free cancer patients and patients 
receiving cancer treatment with curative intent. To our knowledge, the TIRED study 
will be the first RCT determining the efficacy of GET and CBT compared to UC in 
reducing severe fatigue in incurable cancer patients receiving systemic treatment 
with palliative intent. 
Recruitment of participants started in January 2013. Thus far, identifying potential 
study participants via nurses and oncologists for this palliative care RCT has been 
challenging. One common barrier for recruitment in palliative care research known 
from the literature is professional gatekeeping [49]. A recent systematic review by 
Kars et al. (2015) explored reasons for gatekeeping in palliative care research, the 
professionals’ perception that study participation would be too burdensome for 
the patients was the most reported reason [50]. Yet, we recently demonstrated that 
93% of incurable cancer patients that completed a fatigue-screening questionnaire 
during cancer treatment with palliative intent wanted to be informed by a researcher 
about available interventional studies for fatigue [51]. Other important reasons for 
gatekeeping reported by Kars et al. (2015) included health carers’ lack of time, 
complicated study procedures, or study procedures that interrupt usual care 
processes [50]. These issues have also been observed in our study and as a result 
we have simplified our study procedures. For example, we originally aimed to screen 
for the presence of severe fatigue during a nursing consultation before the first line 
of systemic treatment with palliative intent began. However, nurses indicated that 
patients often raise several important time-consuming treatment-related questions, 
which hampered nurses from administering the fatigue screening. Therefore, we 
amended the study protocol by also allowing patients to be screened for fatigue at 
consultations further on during treatment. Moreover, we initially aimed to include a 
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homogeneous sample of patients with incurable breast or colorectal cancer. Then 
again, poor recruitment rates during the first year made us broaden our inclusion 
criterion regarding cancer type. Finally, we have extended our research collaboration 
with three hospitals to nine hospitals in total. All study protocol amendments have 
been reviewed and approved by the Research Ethics Committee of our University-
affiliated hospital and the local Ethics Committees of the participating hospitals. 
In conclusion, the TIRED study will provide information on the efficacy of GET and 
CBT compared to UC in reducing severe fatigue in incurable cancer patients, as well 
as on the mediators of any observed intervention effects. Other important outcome 
measures will include quality of life and functional impairments. If proven efficacious, 
one or both interventions might be offered as part of UC for this often overlooked and 
understudied patient group.
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TIME TO PRACTICE WHAT WE PREACH? 
APPRECIATING THE AUTONOMY OF 
CANCER PATIENTS ON DECIDING WHETHER 
THEY WANT TO BE INFORMED ABOUT 
INTERVENTIONAL STUDIES FOR FATIGUE
Hanneke Poort, Marlies Peters, Stans Verhagen, 
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BACKGROUND
Fatigue is a prevalent and burdensome symptom for patients with advanced cancer. 
The long-term use of pharmacological interventions for fatigue is not supported by 
evidence [1]; though, non-pharmacological and behavioural interventions are promising 
approaches to reducing fatigue based on their effectiveness in early-stage cancer patients 
[2]. Behavioural factors, like sleeping problems and being less physically active, can 
also contribute to fatigue in advanced cancer patients [3]. Interventional studies for the 
management of fatigue in advanced cancer patients are needed. However, it is a notorious 
challenge to identify patients for interventional studies aimed at fatigue or symptom 
control while patients are undergoing cancer treatment with palliative intent. One of the 
barriers to successful identification of these patients is professional gatekeeping, due 
to the care professionals’ perception that study participation might be too burdensome 
for the patient [4, 5]. Although gatekeeping is done in order to prevent additional burden 
for patients who are seriously ill, it also limits access for patients to potentially effective 
interventions for fatigue and makes it difficult to develop evidence-based interventions 
for fatigue in advanced cancer patients. More importantly, gatekeeping assumes that 
patients are either not capable to decide for themselves if they want to be informed 
about an intervention study or do not want to be informed. We aimed to investigate to 
what extent patients receiving cancer treatment with curative or palliative intent would 
be willing to be contacted by a researcher about possible interventional studies aimed at 
fatigue once they were screened for the presence of fatigue in routine clinical practice. 
An ongoing interventional study addressing fatigue in patients receiving treatment with 
palliative intent for breast or colon cancer was available at the time of this quality project 
(TIRED study, Netherlands Trial Registry, NTR3812).
METHODS
At the Radboud university medical center, we conducted a quality project aimed at 
screening for the presence of severe fatigue in cancer patients prior to starting (a new line 
of) systemic treatment. Oncology nurses were instructed to introduce the assessment 
of fatigue to all patients via handing out a pre-printed information letter together with 
a multi-dimensional fatigue questionnaire. Patients completed the Checklist Individual 
Strength (CIS) questionnaire directly at the outpatient clinic or at home. The subscale 
fatigue severity (8 items, 7-point Likert scale) of the CIS was used as a measure of fatigue, 
a validated cut-off score of ≥ 35 points indicates the presence of severe fatigue [6]. In 
addition, patients were asked the following question: “Fatigue is an important symptom 
that influences quality of life during cancer treatment. If this questionnaire shows that 
fatigue is also an important symptom for you and a treatment is available, do you agree 
that a researcher contacts you?” Possible answers were ‘yes’ or ‘no’ and in case of an 
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affirmative answer patients had to provide their contact information. Eligible patients for 
an ongoing interventional study addressing fatigue in advanced cancer patients receiving 
treatment with palliative intent for breast or colon cancer were then contacted by a 
researcher. Oncology nurses provided data on age of the patient, gender, type of cancer, 
and treatment intent (curative vs. palliative).
RESULTS
A total of 229 patients completed the fatigue-screening questionnaire between January 
and December 2013. In all, 53% (n=121) were female; mean patient age was 58 years 
(range 25 to 78). The most common types of cancer were gastro-intestinal cancer (32%) 
and breast cancer (19%). Other diagnoses included gynecological cancer, skin cancer, 
head-neck cancer, urogenital cancer, sarcoma, brain tumors, or other. Information about 
treatment intent was available for 214 patients, 49.5% (n=108) received curative treatment 
and 50.5% (n=106) received palliative treatment.
In all, 93% (n=212) of patients agreed with being approached by a researcher to be 
informed about interventional studies for severe fatigue. Of interest, agreement did 
not differ significantly between patients receiving treatment with curative (91%) versus 
palliative intent (93%). The prevalence of severe fatigue in patients receiving treatment 
with palliative intent was 36% (n=38) and 90% (n=34) of those severely fatigued advanced 
cancer patients agreed to being contacted by a researcher.
CONCLUSIONS
Overall, cancer patients who completed a fatigue-screening questionnaire also wanted to 
be informed by a researcher about available interventional studies for fatigue, regardless 
of treatment intent. Even in severely fatigued advanced cancer patients, 90% of patients 
wanted to be informed. Our findings accord with a survey study performed in advanced 
cancer patients, in which almost 90% of patients were interested in studies of symptom 
control, though the concept of randomisation was a deterrent in 40% of patients [7]. In 
light of the new era of patient participation in health care, advanced cancer patients should 
not only be involved in decisions about medical treatment, but also in deciding whether 
they want to be informed about studies targeting symptoms and quality of life. Thus, there 
is no need for well-meant protection of patients receiving treatment with palliative intent 
by withholding from them information about fatigue interventional studies. Researchers 
developing evidence-based interventions for fatigue in advanced cancer patients may 
use our findings to convince health care professionals to actively refer these patients for 
information about interventional studies, including randomised controlled trials. 
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ABSTRACT
Background
The present study investigated the difficulties in recruitment of patients for a still 
ongoing three-armed multicentre randomised controlled trial (RCT) comparing a 
cognitive behavioural or exercise intervention with usual care for severely fatigued 
patients with incurable cancer.
Methods
Figures on the availability of potential study candidates were derived from two out of 
the eight participating hospitals. Recruitment rate per hospital was calculated. T-tests 
and Chi2 tests were used to examine differences between participants and non-
participants in age, gender, and fatigue. Reasons for non-participation were recorded 
and other recruitment barriers were discussed in frequent study team meetings.
Results
Based on the estimated number of patients needed for identification and the national 
cancer incidence and 5-year survival and mortality rates in the Netherlands, we argue 
that sufficient potential candidates were available for identification. From January 2013 
to December 2016, 201 eligible patients were identified. In total, 122 participants were 
randomised (61%). Doctors and nurses missed potential candidates for identification 
and screening. The inclusion rate between centres varied largely (2-10 patients/
year). Engagement of research nurses proved to be vital in successfully identifying 
patients. Participants did not differ from non-participants in age (p = .775) or fatigue 
(p = .719) but male patients were more likely to participate compared to females 
(p = .01). The primary reason for non-participation was ‘participation perceived as too 
burdensome‘ (n=41; 52%). Both inclusion criteria and study procedures appeared to 
be too complicated, preventing quick identification of potential candidates by often 
busy nurses and oncologists. 
Conclusion
We identified several difficulties with recruitment for our RCT (doctor and nurse 
level, patient level, organisational level). Sharing these lessons learned may help 
other investigators interested in improving patient recruitment in similar palliative or 
supportive care RCTs.
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INTRODUCTION
Patients with incurable cancer experience substantial physical and psychological 
symptoms that compromise quality of life. The goal of palliative care is to improve the 
quality of life of patients who have a serious or life-threatening disease by treating as 
early as possible the symptoms of a disease or the side effects caused by its treatment. 
Cancer-related fatigue (CRF) is one of the most common symptoms experienced by 
patients being treated for cancer and is associated with poorer quality of life [1, 2]. 
Randomised controlled trials (RCTs) are essential to the advancement of intervention 
research and clinical practice in the area of CRF in patients with incurable cancer. 
Yet, difficulties in recruitment of sufficient participants into palliative care RCTs have 
been described before [3, 4] and it continues to be a huge challenge today. A recent 
Cochrane review investigating the effects of psychosocial interventions for CRF 
in patients with incurable cancer identified 14 studies involving 3077 randomised 
patients in total [5, 6]. Eight of the 14 studies had a mixed sample of patients with 
incurable and potentially curable cancer. The 12 studies included in the subset meta-
analysis involved only 535 patients with incurable cancer. The study with the largest 
sample size randomised 53 and 57 patients to the intervention and control arm, 
respectively [7]. Problems with recruitment are not unique to palliative care RCTs 
with psychosocial interventions. Rinck et al. (1997) found that 10 out of 11 studies 
included in their review on palliative care (excluding sole psychosocial interventions) 
experienced difficulties with recruitment of participants [8]. In two studies, these 
difficulties were so severe that the RCTs had to be stopped without achieving the 
planned sample size [9, 10]. 
In January 2013, we started patient recruitment for the still ongoing Dutch Cancer 
Society-funded TIRED study (KUN2011-5259). This RCT is focused on the efficacy 
of two supportive care interventions (exercise intervention or cognitive-behavioural 
intervention compared to usual care) in reducing severe CRF in patients with incurable 
cancer [11]. Due to the disappointing recruitment rate in the first year of the study, we 
undertook several important actions to improve recruitment. First, we extended our 
research collaboration from three initial study centres to a total of eight study centres. 
Second, although we originally intended to collect data from a homogenous study 
sample of patients diagnosed with incurable breast or colorectal cancer starting first-
line systemic therapy, disappointing recruitment rates urged us to include a broader 
sample of cancer types (i.e. incurable prostate, renal cell, bladder, ovarian, or cervical 
cancer, and sarcoma or melanoma) and further lines of anticancer therapy. In addition, 
the recruitment period was intended to last for 33 months, but in December 2016, 
after 48 months of recruitment and the taken actions, we achieved still only 76% of 
our recruitment goal. Although we are confident that we will eventually successfully 
reach our recruitment goal, it is important to share the main barriers and challenges 
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that we encountered. Lessons learned from our trial could serve future researchers 
interested in designing and undertaking similar supportive care RCTs within this 
fragile cancer population. Therefore, the purpose of this paper is not to present an 
analysis of the effectiveness data since the TIRED study is still ongoing. Instead, we 
discuss and report on some of the challenges associated with patient identification 
and recruitment for the trial and provide practical solutions. 
There are many reasons why recruitment for RCTs investigating supportive care 
interventions in patients with incurable cancer is so difficult. First of all, there may 
not be sufficient potential candidates available for the research study. A well-known 
phenomenon in clinical trials, known as Lasagna’s Law and already described in 
1970, states that investigators overestimate the number of patients available for a 
research study [12]. Also, overly strict inclusion criteria may reduce the number of 
potential candidates. Therefore, our first aim was to determine whether difficulties 
in recruitment for our RCT originated from the unavailability of sufficient potential 
candidates. However, if sufficient potential candidates should be available, several 
other barriers can still influence recruitment. These barriers can be found at different 
levels: doctor and nurse level, patient level, and organisational level. For example, 
doctors and nurses might be reluctant to recruit seriously ill patients for participation 
in supportive care RCTs based on attitudes of defeatism, other priorities, and limited 
consultation time. On the other hand, patients might also refuse to participate for 
various reasons. For example, the efforts and burden for study participants might 
reduce the motivation of patients to participate. We aimed to explore the barriers and 
determine whether participants and non-participants differed in specific characteristics 
such as age or fatigue severity. In addition, our last aim was to determine the reasons 
for non-participation. It is important to get insight in these barriers and challenges, 
in order to enable investigators to take these problems into account in designing 
future trials. This could facilitate recruitment rates, which would help to determine the 
efficacy of interventions during cancer treatment with palliative intent.
METHODS
TIRED study
The rationale and design for this trial have been described in detail elsewhere [11]. 
In short, we aimed to recruit participants diagnosed with incurable cancer (i.e. 
advanced or metastatic) and reporting clinically significant levels of CRF while on 
first-line systemic therapy with palliative intent. Doctors and nurses from eight Dutch 
hospitals initially screen potential study participants to check the eligibility criteria. 
All eligible patients were contacted by phone by the coordinating researcher (HP) 
who explained study procedures and invited patients to participate. Eligible patients 
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willing to participate are randomised to one of three study arms including two 
intervention arms (cognitive behaviour therapy; CBT or graded exercise therapy; GET) 
and a control arm (usual care). Participants randomised to one of the two intervention 
arms receive 12 weeks of weekly CBT or GET in addition to usual care. Sample size 
was estimated to be 51 evaluable patients in each arm at post-intervention; that is, 
recruitment should be continued until we reached a sample size of 219 participants, 
taking an expected attrition rate of 30% into account. Our recruitment period was 
originally planned between January 2013 and September 2015 (33 months). Doctors 
and nurses received a financial compensation of €50 per enrolled patient. The Medical 
Ethics Committees of all participating centres granted approval to conduct the study. 
Written informed consent was obtained from all participants. 
Data and methods of present analysis
Data collected on identification and recruitment of participants from the opening of 
the trial in January 2013 until December 2016 are presented in this paper. During this 
period, the study team met weekly to monitor patient recruitment, discuss barriers 
and challenges, as well as propose, test, and evaluate interventions to overcome 
these difficulties.
In two hospitals, research nurses were involved in the study and recorded data 
regarding identification and screening of all potential candidates during 31 months 
(Hospital A) and 12 months (Hospital G), respectively. Data collected in these two 
example periods enabled us retrospectively examine whether sufficient potential 
candidates were available by estimating how many patients needed to be available in 
order to recruit our target sample size. This estimate was put into perspective using 
data from the Netherlands Cancer Registry on the national incidence (2012-2015) and 
5-year survival and mortality rates (2008-2012) of our selected cancers (all disease 
stages) (http://www.dutchcancerfigures.nl). 
We used process data collected by the coordinating researcher (HP) to describe the 
recruitment rate per study centre. A description of the main barriers and challenges 
involved in the study was based on information from progress reports and minutes of 
the study team meetings. We categorised these barriers into three levels: doctor and 
nurse level, patient level, and organisational level.
Baseline data provided by potential study participants were used and included age, 
gender, and fatigue severity. Fatigue severity was assessed with the fatigue severity 
subscale of the Checklist Individual Strength (CIS-fatigue). The CIS-fatigue consists 
of 8 items scored on a 7-point Likert Scale. Total scores range between 8 and 56, and 
a score of ≥ 35 is considered to be an indication of the presence of severe CRF [13]. 
Descriptive statistics were used to characterize the sample. Independent samples 
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t-tests and Chi2 tests were used to examine differences between participants and 
non-participants in age, gender, and fatigue severity. 
The coordinating researcher (HP) scheduled a follow-up phone call with eligible 
patients one week after informing them about the study. Free text was used to 
document the reasons why eligible patients did not wish to participate. These reasons 
were sorted into one of 5 categories: (1) too much distance to study centre and/or the 
need for travel arrangements; (2) study participation too burdensome; (3) disliked the 
aspect of randomisation (because they preferred a particular intervention or UC); (4) 
not or no longer interested in study participation; or (5) no reasons given. 
RESULTS
Availability of potential candidates during the study period
From January 2013 to December 2016, 201 eligible patients were identified by nurses 
and doctors and contacted by the coordinating researcher to participate in the TIRED 
study. In total, 122 participants were randomised (61% participation rate). Originally, 
we envisioned enrolling an average of 6-7 participants per month from three study 
centres resulting in a recruitment period of 33 months. Instead, we enrolled an 
average of only 2-3 participants per month from eight study centres in a recruitment 
period of 48 months. Fortunately, attrition was much lower than anticipated (5% 
instead of 30%), which allowed us to adjust our required sample size from 219 to 161 
participants. 
Figure 1 displays a detailed flowchart for patient identification during a 12-month 
example period at the primary study centre. During the example period at Hospital A, 
a total of 278 patients were identified for screening of which 9 patients were eventually 
randomised (3%). In Hospital G, a total of 160 patients were identified for screening 
during a period of 31 months of which 27 patients were eventually randomised (17%). 
Based on this example, an estimated 954 to 4973 patients needed to be available for 
identification to eventually randomise the adapted sample size of 161 participants 
(i.e. (161/27)*160 and (161/9)*278, respectively). 
The national incidence of our selected cancers (all disease stages) between January 
2012 and December 2015 was n=213.054 (see Table 1A). Assuming an average 
mortality of 32% of patients with our selected cancers (± n=68.177, see Table 1B), 
we would still have enough potential candidates available in the eight participating 
hospitals (i.e. ± n=5993) out of a total of 91 hospitals in the Netherlands.
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Figure 1. Flowchart of a 12-month patient identification and recruitment period for the TIRED study (November 2015 to October 
2016, Radboudumc)
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Table 1A. National incidence per selected cancer type per year from January 2012 until December 2015
Cancer type 2012 2013 2014 2015 Total
Breast 14.338 14.494 14.720 14.523 58.075
Colorectal 13.239 13.136 15.166 15.549 57.090
Prostate 11.294 10.977 9986 10.497 42.754
Melanoma (skin) 5316 5566 5642 5926 22.450
Bladder 2991 2946 3001 3135 12.073
Renal 2244 2327 2323 2343 9237
Ovarian 1302 1270 1260 1259 5091
Cervix 731 658 729 715 2833
Soft tissue sarcoma 871 767 866 947 3451
Total 54.338 54.154 55.707 56.909 213.054
Table 1B. National 5-year survival and mortality per selected cancer type from January 2008 until December 2012
Cancer type Survival Mortality
Breast 87% 13%
Colorectal 63% 37%
Prostate 88% 12%
Melanoma (skin) 89% 11%
Bladder 53% 47%
Renal 63% 37%
Ovarian 38% 62%
Cervix 66% 34%
Soft tissue sarcoma 63% 37%
Average 68% 32%
Main barriers and challenges associated with patient identification and 
recruitment
Doctor and nurse level
Given the calculation presented in the previous section, doctors and nurses must have 
missed patients for identification and screening. Despite the acknowledged importance 
of intervention research for CRF in patients with incurable cancer and initial enthusiasm 
of doctors and nurses, we experienced several barriers at this level shortly after initiating 
the study. First, doctors and nurses had limited time available in medical consultations 
and as CRF was neither the primary goal nor the expertise of the oncology team it often 
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hampered them from discussing the study. Second, we compensated efforts of the 
health care research team on a fee-for-performance basis (i.e. €50 per enrolled patient). 
In retrospect, in spite of intrinsic motivation of doctors and nurses, this compensation 
model cannot compete with the compensation for studies led by pharmaceutical 
companies. Third, unawareness of the study despite frequent didactic activities (including 
presentations and newsletters) and forgetfulness in discussing available studies with 
patients was observed in doctors and nurses from all study centres. 
There was a large variation in the inclusion rate between the eight participating 
centres ranging from an average inclusion of 2 to 10 participants per year (Table 2). 
The two hospitals with the highest inclusion rate per month (Hospital A: 10.45 p/y and 
Hospital G: 7.08 p/y) were the two study centres where we could engage research nurses 
in patient identification for the study. In the other centres there were no research nurses 
available for our study. We learned that these dedicated research nurses played a vital 
role in identifying and screening patients. Together, these two centres contributed to half 
of our current study sample, accounting respectively for 28% (n=34; Hospital A) and 22% 
(n=27; Hospital G) of our total recruitment.
Table 2. Recruitment per study centre between January 2013 and December 2016
Study centre Start of recruitment Recruitment period Total inclusion Average inclusion rate Total no. of bedsa
Hospital A Jan, 2013 48 mos. 34 7.08 p/y 953
Hospital B May, 2013 44 mos. 11 3.00 p/y 510
Hospital C June, 2013 43 mos. 11 3.07 p/y 543
Hospital D July, 2013 42 mos. 17 4.86 p/y 663
Hospital E Oct, 2013 39 mos. 7 2.15 p/y 715
Hospital F Nov, 2013 38 mos. 11 3.47 p/y 994
Hospital G June, 2014 31 mos. 27 10.45 p/y 474
Hospital H June, 2014 31 mos. 4 1.55 p/y 190
316 mos. 122 5042
a Total number of hospital beds in 2013 (Annual Health Report, Dutch Ministry of Health, Welfare and Sports available online at 
http://www.desan.nl/net/DoSearch/Search.aspx)
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Table 3. Characteristics participants and non-participants (n=201)
Participants
(n=122, 61%)
Non-participants
(n=79, 39%)
P-value
Age (yr.), mean (SD) a 63.03 (9.19) 62.61 (10.65) .775
Gender
n female (%)
n male (%)
70 (57%)
53 (43%)
59 (75%)
20 (25%)
.01
CIS fatigue a 45.71 (6.71) 45.34 (6.36) .719
a Information available for n=195 patients. b Information available for n=181 patients.
Patient level
Table 3 shows the characteristics of participants and non-participants from the 
identified patient group fulfilling the inclusion criteria. Participants did not differ 
significantly from non-participants in age (p = .775) or fatigue severity score (p = 
.719). However, male patients were significantly more likely to participate compared 
to females (p = .01). Table 4 lists the reasons for non-participation. The three most 
frequently reported reasons for non-participation were (1) study participation too 
burdensome (52%); (2) not or no longer interested in study participation (22%); and 
(3) too much distance between patients’ home and the study centre and the need for 
associated travel arrangements (15%). Non-participants refusing because of the latter 
reason often indicated that they would be willing to participate if they could receive 
the study intervention closer to their homes. This would enable them to participate 
without the burden of additional hospital visits and travel arrangements.
Table 4. Reasons for non-participation (n=79)
Reason  %
(1) Study participation too burdensome (n=41)
(2) Not or no longer interested in study participation (n=17)
(3) Too much distance between patients’ home and study centre (n=12)
(4) Disliked the aspect of randomisation (n=3)
(5) No reason given (n=6)
52%
22%
15%
4%
8%
Organizational level
Ethical rules and regulations in the Netherlands warrant that a member of the medical 
team (e.g. nurse or doctor) approaches suitable patients for potential trial participation 
when recruitment is performed within the hospital. Although the underlying ethical 
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principle is important, for non-pharmacological research this is often a challenge 
because researchers involved in these studies (e.g. behavioural scientists) usually do 
not belong to the medical team and have to rely on the willingness of often-busy clinical 
nurses and oncologists to identify eligible patients. Consequently, in our study, this 
resulted in tension between the ethical requirement to rely on patient identification by 
clinical nurses and oncologists and the methodological necessity for approaching all 
patients who may be suitable. We tried to overcome this barrier by involving dedicated 
research nurses in patient recruitment for the study, as described above.
In addition, the primary eligibility criteria for our study were overly strict and study 
procedures were too complicated. For example, the study protocol required that 
screening for severe fatigue should be completed before the first cycle of treatment 
in the original study design. However, this was not feasible in clinical practice as 
other more urgent topics often needed to be discussed in the consultation prior to 
administration of the first cycle of treatment. To overcome these and other difficulties, 
we amended our eligibility criteria and study procedures during the study with approval 
of the funder of the study and the Medical Ethics Committee. Unfortunately, this was 
a lengthy process taking up to 12 months during which time we had to adhere to the 
original criteria and procedures. More procedures were adjusted and simplified such 
as inclusion of additional cancer types and more lines of anticancer therapy in order 
to widen the inclusion gate.
DISCUSSION
In the present paper, we evaluated patient recruitment for the Dutch TIRED study. 
During a period of 4 years, health care professionals from eight participating 
hospitals identified a total of 201 eligible patients of which the majority agreed to 
participate (n=122; 61% participation rate). Although this overall participation rate 
was satisfactory compared to other supportive care RCTs [14, 15], the total number 
of identified eligible patients was much lower than anticipated and it is likely that 
potential candidates have been missed.
Due to the slow recruitment for our trial, broadening of the original inclusion criteria, 
increase of participating centres and extension of our still ongoing recruitment 
period was necessary. This is in line with reports from other RCTs in patients with 
incurable cancer [3, 4]. Many investigators are struggling with challenges regarding 
the recruitment of study participants for RCTs and these issues are not limited to trials 
with incurable cancer patients. Briel et al. (2016) recently reported that one quarter 
of RCTs in general are discontinued with poor recruitment being the most frequently 
reported reason [16]. The most often mentioned reasons for recruitment failure were 
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overestimation of eligible patients and prejudiced views against effectiveness of trial 
interventions by recruiters and participants. We also encountered prejudiced views 
by doctors and nurses; mostly thinking study participation would be too burdensome 
for these seriously ill patients. In addition, defeatism about the prognosis and 
therefore not feeling that such supportive care studies could be of added value was 
also observed. Yet, in a previous study, we demonstrated that 93% of patients being 
treated for incurable cancer at least want to be informed about fatigue interventional 
studies and they did not differ in their preference from patients being treated with 
curative intent [17]. 
We experienced a substantial variation in the recruitment rate between study centres. 
Also, doctors and nurses indicated that screening potential candidates was often not 
possible because it required too much time. In part, this was caused by overly complex 
eligibility criteria and study procedures, demonstrating a need to more globally define 
eligibility criteria and better align study procedures with clinical practice. However, 
after amending these, limited time still remained a main barrier for doctors and nurses 
to identify patients. These findings seem to underline the importance of having 
dedicated local coordinators, such as research nurses, available on site in multicentre 
studies. Unfortunately, this was not foreseen in our study budget and thus we had 
insufficient funding available to hire dedicated research nurses at all sites.
The main reason for identified patients not accepting our study (39% of eligible 
patients) was that participation was perceived as too much of a burden. Indeed, the 
interventions offered in our study involved weekly hospital visits and associated travel 
arrangements over a period of 12 weeks coinciding with systemic cancer treatment. 
Several patients expressed concerns about burdening family members or friends for 
travel arrangements and preferred using their services for medical appointments. In 
some instances, we were able to offer taxi services or a financial compensation for 
friends or family members willing to shuttle patients to the hospital, which facilitated 
participation. For future trials, we recommend allocating resources for these types 
of services into study budgets. Alternatively, the emergence of e-Health and the 
development of self-management or home-based interventions offer the potential to 
reduce the intensity of the intervention as well as overcome the burden of distance 
for these patients.
We adopted a three-armed study design in line with our desire to test both the effects 
of CBT and GET compared to usual care. In hindsight, although three-armed studies 
are ambitious, we believe this might have been a bridge too far. Especially, taking into 
account that only a few two-armed RCTs focusing on supportive care interventions 
for CRF in a homogeneous sample of patients with incurable cancer have been 
conducted. However, the growing pressure and ongoing competition in obtaining 
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research funding is associated with an incentive to propose ambitious and novel 
research. Moreover, in the Netherlands, funding for feasibility or pilot intervention 
studies in cancer research was very limited when we developed our study plans. 
Fortunately, in 2016, the Dutch Cancer Society launched a new way of funding in which 
they provide funding for so called ‘unique high risk’ projects offering the possibility 
to perform short-term preparatory work to determine whether these early-stage ideas 
offer viable opportunities for further large-scale studies (https://www.kwf.nl/english/
poi-english/). We believe that many of the barriers and challenges experienced in our 
study, would have been encountered in piloting the planned recruitment strategies.
Despite sharing valuable lessons learned from patient identification for our RCT in 
patients with incurable cancer, our findings have limitations that should be noted. 
We retrospectively calculated the number of patients that needed to be available 
for identification to eventually randomise the adapted sample size. In relation to 
the estimated total number of potentially eligible patients during the recruitment 
period, this number seemed feasible. However, we could only perform an indirect 
comparison, since specific information on the incidence of metastatic disease per 
participating hospital was not available. Ideally, investigators should obtain specific 
information regarding the number of patients that would meet their eligibility criteria 
for each hospital in the year prior to the start of intended patient recruitment. In 
addition, we shared lessons learned from a single Dutch study but the findings might 
not necessarily pertain to other countries with different rules, regulations and local 
situations, thus limiting the generalisability of our findings. Notwithstanding these 
differences, recruitment challenges are widespread and the findings from our study, 
particularly on the patient level and doctor and nurse level, may therefore also be 
important for researchers in other countries.
The present paper presented important lessons learned from the still ongoing Dutch 
TIRED study. In cancer research we are often focused too much on the output of 
RCTs and not enough on the processes by which the study was done. We learned that 
we need studies with less complicated procedures that are better aligned with routine 
clinical practice, with more globally formulated eligibility criteria, and examining less 
burdensome interventions delivered closer to or at the patients’ home, preferably. 
Also, we need more effective education preparing doctors and nurses involved in 
patient recruitment for these trials. Given their pivotal role in successful recruitment 
of participants, dedicated research nurses should be employed at each study centre. 
Accordingly, study budgets must include allocation of sufficient financial resources 
to adequately compensate research nurses for time spent on patient identification. 
Finally, we encourage other investigators to also share their valuable lessons learned.
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SUMMARY AND GENERAL DISCUSSION
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This thesis focused on cancer-related fatigue (CRF) with an emphasis on understudied 
cancer populations in psychosocial oncology, ranging from patients with a rare cancer 
diagnosis to patients with incurable disease. In this final chapter the previous chapters 
are summarised and discussed. Practical implications along with recommendations 
for future research are formulated. 
SUMMARY
In Chapter 1 a general introduction on CRF research is provided. Despite the fact 
that CRF is a common symptom in patients with cancer, it is still underreported, 
underrecognized and undertreated. In particular, research on the prevalence, impact 
and management of severe fatigue in patients with a rare cancer diagnosis or incurable 
disease is scarce. 
PART I: FATIGUE IN PATIENTS WITH RARE CANCER
Chapter 2 focused on the prevalence, impact, and correlates of severe fatigue in 
patients diagnosed with cancer during adolescence and young adulthood (AYA). 
Compared to older adults, a diagnosis of cancer between the ages of 18 and 35 
years is rare. Severe fatigue based on a validated cut-off for severe fatigue occurred 
in 48% (n=40/83) of participating AYAs with cancer visiting a specialised AYA 
outpatient clinic. This proportion is significantly higher compared to the proportion 
of severely fatigued matched population-based controls, in which only 20% of 249 
controls scored above the cut-off. We demonstrated that severely fatigued AYAs 
with cancer reported significantly lower quality of life on physical, psychological, 
social, and spiritual domains. Fatigue severity was associated with female gender, 
being unemployed (or not studying), late stage cancer at diagnosis, receiving active 
treatment at the time of study participation, palliative intent of treatment, and having 
had radiotherapy as part of cancer treatment. In addition, more fear of cancer 
recurrence and higher psychological distress were associated with higher CRF 
scores. The findings of this study emphasize the importance of careful attention for 
fatigue in AYAs with cancer. Screening for the presence of severe fatigue at regular 
intervals as well as the identification of treatable contributing factors (e.g. anemia, 
hypothyroidism, psychological distress, and sleep disorders) is warranted not only 
during cancer treatment but also after completion of treatment.
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Chapter 3 described the results of a study on CRF conducted in patients with rare 
gastro-intestinal stromal tumors (GISTs). We used a validated cut-off for severe 
fatigue to assess the prevalence of CRF among a sample of 89 patients with GIST. 
The sample included patients with localized as well as metastatic disease. Sixty-one 
patients (69%) received treatment with tyrosine kinase inhibitors (TKIs) at the time of 
study participation. Severe fatigue occurred in 30% (n=27/89) of patients with GIST 
and in 33% (n=20/61) of patients with GIST on a TKI. The prevalence of severe fatigue 
was significantly higher in patients with GIST compared to the matched population-
based controls. Severely fatigued patients with GIST reported poorer quality of life and 
were significantly more impaired on physical, role, emotional, cognitive, and social 
functioning compared to non-severely fatigued patients with GIST. The severity of 
fatigue was associated with the use of a TKI, more psychological distress, and lower 
self-reported physical functioning. Discontinuation of treatment with a TKI because 
of severe CRF is generally not an option, however, the other associated factors 
(i.e. psychological distress and lowered physical functioning) can be addressed by 
psychosocial and exercise interventions. Doctors could play a crucial role in informing 
severely fatigued patients about these psychosocial and behavioural factors that 
deserve appropriate management and may refer patients to existing evidence-based 
interventions for CRF that aim to address these factors.
We focused on CRF in patients with a rare diagnosis of chronic myeloid leukemia 
(CML) in Chapter 4. This once-fatal cancer has become a chronic disease leading to 
a normal life span in the majority of patients as a result of the introduction of TKIs. 
Yet, patients may need to take TKIs indefinitely and many of them suffer from TKI-
related fatigue. Building upon an evidence-based intervention for fatigue in disease-
free cancer survivors, i.e. cognitive behaviour therapy, we adapted this intervention 
to the specific needs of patients with CML receiving chronic TKI treatment. Guided 
by an adaptation framework, we used a series of systematic steps and adaptation 
methodologies, including semi-structured interviews with CML patients and health 
care providers, and feedback from topical experts. We aimed to gauge reactions 
to existing intervention content and a new delivery format. Furthermore, with the 
emergence of e-Health and to reduce travel burden, the adaptation also involved 
moving from a clinic-based face-to-face delivery to an Internet-assisted delivery 
format using video telephony and tablet computer technology (FaceTime using 
iPads). We found that patients were receptive to existing content topics and the 
Internet-assisted delivery format was acceptable. A key theme reflected the need 
for a new customized psycho-educational module about CML as a disease and its 
treatment. The results from this study have set the stage for the pilot RCT that is 
currently evaluating the usability, feasibility, and efficacy of the adapted CBT for TKI-
related fatigue.
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PART II: FATIGUE IN PATIENTS WITH INCURABLE DISEASE
Chapter 5 focused on dyadic agreement between patients with incurable cancer and 
their informal caregivers regarding patients’ fatigue severity during cancer treatment 
with palliative intent. In a longitudinal study, we examined to what extent patients and 
informal caregivers agreed on patients’ fatigue severity both on a continuous level as 
well as on the presence of severe fatigue based on a validated cut-off. A sample of 
107 patients and their informal caregivers completed questionnaires at baseline and 
69 dyads completed questionnaires six months later. At baseline, informal caregivers 
significantly overestimated patients’ fatigue severity with a moderate amount of 
bias. In 76% of the dyads there was agreement about the presence or absence of 
severe fatigue. On a group level, agreement did not change over time. However, on a 
dyad level, there was a tendency to either remain in agreement or reach agreement. 
In addition to baseline agreement, informal caregivers’ own fatigue severity and 
caregiver strain predicted their ratings of patients’ fatigue. For consultations where 
important treatment decisions are to be made, a second rating of patients’ fatigue 
by the informal caregiver may provide oncologists with a more complete reflection 
of patients’ fatigue and facilitate discussing how well patients are holding up with 
treatment. It is however important to take into account informal caregivers’ affective 
state when asking for judgements about patients’ fatigue, as their response is likely 
to be affected if the informal caregiver is fatigued or feeling strained.
Chapter 6 described the results of a Cochrane systematic review and meta-analysis, 
in which we included randomised controlled trials (RCTs) that investigated the effects 
of psychosocial interventions in patients with incurable cancer receiving systemic 
treatment with palliative intent and had fatigue as an outcome of interest. We included 
data from 12 studies (n=535) in the subset meta-analysis. Findings did not support 
the effectiveness of psychosocial interventions for reducing fatigue post-intervention. 
There were sources of potential bias, including a lack of description of methods of 
blinding and allocation concealment and small size of the study populations. We 
considered the overall quality of evidence to be very low. As such, the true effect is 
likely to be substantially different from the estimate of the effect. At present, there is a 
lack of evidence around the benefits of psychosocial interventions to reduce fatigue 
in patients with incurable cancer receiving cancer treatment with palliative intent. 
Additional studies with larger samples are required. In addition, studies should expand 
their focus beyond patients with metastatic breast cancer, as it is unknown whether 
findings from this most widely studied patient group generalize to patients with other 
cancer diagnoses. Multicentre studies investigating short interventions delivered over 
a period of several weeks or months, with follow-up assessment following shortly 
after intervention delivery are recommended. 
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As a result of the longer-term treatment of patients with incurable cancer, aspects 
regarding quality of life and symptom management become even more important. 
Fatigue is one of the most commonly reported symptoms during systemic cancer 
treatment for incurable cancer but there is a lack of evidence around the benefits 
of psychosocial and exercise interventions in this specific population. Chapter 7 
described the design and rationale for a multicentre three-armed RCT randomising 
patients with incurable cancer to either graded exercise therapy (GET), cognitive 
behaviour therapy (CBT) for severe fatigue or usual care (UC). GET and CBT for 
severe fatigue are delivered over 12 weeks in addition to UC. UC included treatment 
in concordance with national and regional cancer clinical practice guidelines. The 
primary outcome is fatigue severity. Secondary outcomes included functional 
impairments and quality of life. Outcomes will be assessed at baseline, post-
intervention (14 weeks), and at follow-up 18 and 26 weeks post-randomisation. 
Outcomes at post-intervention of either treatment arm will be compared to those of 
UC participants. We aim to randomise a total of 219 severely fatigued patients from 
nine hospitals throughout the Netherlands.
Shortly after initiating the multicentre three-armed RCT described in Chapter 7, 
we experienced major difficulties in recruiting study participants. One of the main 
barriers to successful identification and enrolment of study participants for palliative 
or supportive care RCTs is professional gatekeeping. This gatekeeping is often 
related to the health care professionals’ perception that study participation might 
be too burdensome for the patient. In Chapter 8 we examined whether professional 
gatekeeping of patients with incurable cancer from the aforementioned fatigue 
interventional study was justified from the patients’ perspective. In total, 229 patients 
completed a fatigue-screening questionnaire as part of routine care prior to the start 
of (a new line of) systemic treatment. In addition, patients were asked whether they 
agreed with being contacted by a researcher if their answers indicated the presence 
of severe CRF. In all, 93% (n=212) of patients agreed with being approached by a 
researcher to be informed about fatigue interventional studies. Of interest, agreement 
to be informed did not differ significantly between patients receiving treatment with 
curative (n=108) or palliative intent (n=106). In addition, 90% of those severely fatigued 
patients receiving systemic treatment with palliative intent agreed to being contacted 
by a researcher. Thus, the majority of patients who completed a fatigue-screening 
questionnaire also wanted to be informed by a researcher about available fatigue 
interventional studies, regardless of treatment intent. Our findings imply that there is 
no need for well-meant protection of patients receiving cancer treatment with palliative 
intent by withholding from them information about fatigue interventional studies.
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Chapter 9 described lessons learned in patient identification and recruitment for the 
multicentre three-armed RCT described in Chapter 7. Although sufficient potential 
candidates were available for identification, we experienced a slow recruitment rate. 
Consequently, this resulted in the need to broaden our original inclusion criteria, 
extend the number of participating centres as well as the duration of the recruitment 
period. Barriers and challenges were faced at the doctor and nurse level, the patient 
level and the organisational level. Between January 2013 and December 2016, a total 
of 201 eligible patients were identified of which 122 were randomized. The inclusion 
rate varied largely between centers. The most frequently mentioned reason for non-
participation of eligible patients was that study participation was perceived as ‘too 
burdensome’ (52%; n=41/79). Ethical rules and regulations necessitate that a member 
of the medical team, such as a doctor or nurse, introduces the study to potential 
candidates before a researcher informs them. Yet, these health care professionals 
were often too busy to screen patients for eligibility and introduce the study. The 
overly strict primary eligibility criteria and complicated study procedures further 
impeded doctors and nurses in introducing the study to patients.  Engagement of 
dedicated local coordinators, especially research nurses who have time allotted to 
identify potential candidates, was essential in successfully identifying patients.
GENERAL DISCUSSION
Fatigue in patients with a rare cancer diagnosis or incurable disease
The studies presented in this thesis focused on patients primarily characterized by a 
rare cancer diagnosis and patients diagnosed with incurable disease. These patient 
populations are largely understudied in psychosocial oncology. In addition, more and 
more patients from these groups are living longer with cancer as treatments have 
become more effective over time. For example, the introduction of targeted agents 
as a new class of cancer drugs have changed the therapeutic landscape for patients 
with CML and GIST in which they are used as the main systemic treatment nowadays. 
Targeted agents alongside immunotherapy are currently the focus of novel systemic 
treatment developments and form a cornerstone of personalised medicine. For an 
increasing number of patients, their disease may be controlled as long as patients are 
receiving cancer treatment but their cancer is not cured. Living with cancer is different 
from living after cancer. Next to prolonging patients’ lives, it is equally important to 
continue to live with the best possible quality of life. CRF is one of the symptoms that 
compromises patients’ quality of life and as such deserves more attention in both 
research and clinical practice.
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Fatigue in patients with a rare cancer diagnosis versus patients with 
more common cancers
The first two studies presented in this thesis demonstrated that a considerable 
proportion of patients with a diagnosis of cancer at an uncommon age (AYA) and 
with a rare diagnosis of GIST experience severe fatigue during and after cancer 
treatment. In line with previous research in patients with more common cancers 
[1-5], the presence of severe fatigue significantly impaired all domains of patients’ 
quality of life. Because of the high prevalence and profound impact on quality of 
life, systematically screening of patients for the presence of severe fatigue at regular 
intervals is warranted. It should be the first step to increase awareness for fatigue 
by health care professionals and has been suggested before [6]. In agreement with 
previous studies on CRF in more common cancer populations [7-9], we found that 
several cognitive and behavioural factors were related to fatigue severity, such as 
psychological distress, fear of cancer recurrence, and lower self-reported physical 
functioning. Traditionally, CRF has often been attributed solely to the disease itself and 
its treatments. Yet, the studies in AYA cancer patients and GIST patients presented 
in this thesis demonstrated that these disease- and treatment-related factors are not 
the only factors associated with fatigue severity, which is also the case in patients 
with more common cancer types. In fact, strong correlations were found between 
psychological distress and self-reported physical functioning and fatigue severity in 
AYAs with cancer and patients with GIST. In contrast to disease- and treatment-related 
variables, these factors can actually be altered. A recent meta-analysis compared the 
four most commonly recommended interventions for CRF [10]. Exercise (i.e. aerobic, 
anaerobic, or both), psychological (i.e. cognitive behavioral or psycho-educational 
therapies), and exercise plus psychological interventions improved CRF during and 
after primary cancer treatment, whereas pharmacological interventions did not. The 
authors advised clinicians to prescribe exercise or psychological therapies as first-
line interventions for CRF. AYA cancer patients and GIST patients suffering from 
severe fatigue might also benefit from these interventions that target behavioural and 
cognitive factors. 
Targeted therapy-related fatigue
The transition from conventional chemotherapy to molecularly targeted cancer drugs 
has resulted in an increasing number of successful treatments that have impacted 
many cancer patients’ lives [11]. In addition to GIST and CML, TKIs are now also 
indicated in the treatment of many common cancers such as breast and lung cancer 
[12]. Despite the unprecedented clinical success of TKIs in the treatment of cancer, 
these targeted cancer drugs are associated with side effects that can impact patients’ 
quality of life [12]. As described in this thesis, CRF is a known side effect of TKI 
treatment in patients with GIST. In patients with CML on a TKI, chronic fatigue is the 
most important factor that limits patients’ quality of life [13]. However, the majority 
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of CRF research has been conducted in patients receiving more conventional cancer 
treatments such as chemotherapy, radiotherapy, and hormone therapy. With the 
increasingly common use of TKIs in the treatment of cancer, more knowledge on the 
prevalence, impact, course, and associated factors of TKI-related fatigue is needed. 
In addition, it remains to be examined whether existing evidence-based interventions 
addressing CRF that have been developed for and tested in patients receiving 
conventional treatments could also be applied in fatigued patients with extended TKI 
treatment.
Adapting existing evidence-based interventions for new target 
populations
Existing evidence-based interventions aimed at behavioural and cognitive factors that 
maintain fatigue have not been specifically examined in patients with a rare cancer 
diagnosis or incurable disease. One way to facilitate the translation of evidence-
based interventions for CRF into clinical practice is to adapt existing interventions 
for application in new target populations. Our study in patients with CML treated 
with TKIs demonstrated that it is feasible to adapt an existing fatigue intervention 
to a new target population without changing the internal logic and core components 
of the intervention. Although results on efficacy from the ongoing pilot RCT are not 
yet available, the preliminary findings are promising (Jim et al., conference abstract 
submitted). This adaptation process could also be applied to other cancer populations 
in which fatigue interventions have not been examined extensively. For example, 
specific tailoring of the content and delivery of the intervention to the needs and 
age-specific situation of AYAs with cancer might increase efficacy of the intervention 
in this unique patient group. Finally, the adapted intervention for targeted therapy-
related fatigue in CML might also be appropriate for patients being treated with TKIs 
for GIST, as these two patient groups are both receiving treatment with TKIs for an 
extended period.
Proxy rating of patients’ fatigue severity by informal caregivers
We found that informal caregivers, partners in most instances, are able to give a 
meaningful and accurate proxy rating of patients’ fatigue severity during cancer 
treatment with palliative intent. Accuracy was better for dichotomous ratings on the 
presence or absence of severe fatigue, than on a continuous level. The accuracy was 
influenced by caregivers own fatigue severity and strain. Previous research already 
demonstrated that almost a quarter of the informal caregivers suffered from severe 
fatigue and their mean fatigue severity score was higher compared to a healthy 
reference group [14]. Yet, proxy ratings of patients’ fatigue may add to the richness of 
available information that the doctor, patient and caregiver will need to collect when 
decisions on current and continuing further systemic treatment are to be made. This 
seems even more important with the availability of sequential novel cancer treatments 
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and the need to often continue treatment for an extended period of time in order 
to control the disease for as long as possible. Because CRF affects not only the 
patient, but also the informal caregiver, careful consideration of the severity of CRF by 
including both the patient and the proxy rating seems a rational approach for clinical 
practice. However, it should be kept in mind that caregivers’ own fatigue severity and 
strain influence these ratings and thus doctors should also address these aspects in 
their consultation to put these ratings into perspective.
Difficulties in recruiting participants for fatigue interventional studies
Conducting fatigue interventional studies in patients with a rare cancer diagnosis or 
incurable disease is challenging. The most challenging aspect in both populations is 
recruitment of large enough samples. However, the reasons for the difficulties in patient 
recruitment differ. In patients with a rare cancer diagnosis, only a limited number 
of patients per year are being diagnosed with the condition even though the total 
incidence accounts for 24% of the total cancer prevalence in Europe [15]. For studies 
in these patients, it is critically important to collaborate with multiple institutions and 
establish (inter)national networks that participate in testing interventions in trials or 
to develop alternative designs for clinical experiments in these patients. For patients 
with a diagnosis of incurable cancer it is not the rarity of the disease but other 
aspects such as the seriousness of the condition or professional gatekeeping and 
attitudes of defeatism that impact the possibility to recruit sufficient sample sizes. 
In the Cochrane systematic review presented in this thesis, 14 RCTs were identified 
in which at least part of the patients were diagnosed with incurable disease. The 12 
studies able to provide data for the subset meta-analysis including only patients with 
incurable disease had a limited total of 535 participants of interest to the review. 
Unfortunately, recruitment of severely fatigued incurable cancer patients for the RCT 
of which the design and rationale were presented in this thesis also proved to be 
challenging. Despite continued efforts of involved study personnel and the frequent 
discussions within the multidisciplinary study team, in which we tried to overcome 
barriers and challenges for patient identification, we did not reach our sample size 
within the envisioned and already extended recruitment period. The disappointing 
recruitment rate required a substantial extension of the recruitment period as well as 
inclusion of many more study centers and broadening of our original eligibility criteria 
on cancer types and treatment lines. We learned that future studies should be better 
aligned with routine clinical practice, have more globally formulated eligibility criteria, 
and should examine less burdensome interventions, delivered closer to the patients’ 
home. In addition, study budgets should include sufficient financial resources to hire 
dedicated local coordinators at each study site in multicentre trials.
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DIRECTIONS FOR FUTURE RESEARCH
The aim of this thesis was to address CRF in patients with rare cancer or incurable 
disease. A consistent theme throughout the studies was the difficulty with recruiting 
large enough samples to assess fatigue and test the efficacy of interventions for 
fatigue. In the following paragraphs, directions for future research have been 
formulated based on several observations that were made in conducting the research 
presented in this thesis. 
Single-case intervention research
One possibility to overcome some of the challenges in patient recruitment might be the 
use of alternative study designs, such as replicated experimental single-case studies. 
A single-case experimental (SCE) study is a rigorous, scientific methodology used 
to define basic principles of behaviour [16]. Because they document experimental 
control, it is an approach, like the golden standard RCT, that may be used to establish 
evidence-based practices. The SCE design has specific advantages compared to 
the RCT as they are comparatively quick, inexpensive, and easy to perform. Most 
importantly, the power is derived from the number of observations performed 
within each individual and thus this design is particularly useful for studying small-n 
populations or populations in which a full-scale traditional RCT is not feasible. We 
piloted this SCE methodology to examine the efficacy of our adapted CBT intervention 
for targeted therapy-related fatigue in five CML patients receiving treatment at the 
Radboud university medical center. The results of this study are expected at the end 
of 2017, but preliminary findings demonstrated the feasibility and acceptability of this 
design [17].
Improved assessment of CRF during cancer treatment
At present, enrolment of participants for RCTs often relies on identification of potential 
candidates by often-busy health care professionals. The study protocol for our RCT 
required that patients should be screened for the presence of severe fatigue prior 
to or during systemic cancer treatment with palliative intent. Due to ethical rules 
and regulations, a member of the patients’ medical team had to perform this fatigue 
screening. However, screening for severe fatigue by the nurse or doctor is not often a 
priority when several other medical topics need to be discussed during consultations. 
Including routine assessment of CRF during the course of cancer treatment using 
patient-reported outcomes (PROs) may be a viable strategy to enhance fatigue 
screening. To save time during consultations, patients could complete brief and 
electronic fatigue screening questionnaires prior to clinic visits and their data are 
automatically scored and available in reports to be viewed when the clinician meets the 
patient [18, 19]. Bennett et al. (2012) described the use and advantages of electronic 
PRO systems in oncology clinical practice [20]. The authors describe that the rapid 
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expansion and use of mobile devices facilitates the clinical use of electronic PRO 
systems. Data can be automatically transferred in real time to a computer server and 
data entry or calculation of a total score by staff is not required. Adding results to the 
patient’s electronic medical record allows for generation of alerts to notify clinicians 
when patients score above a clinical relevant threshold for fatigue. In addition, it 
enables clinicians to review patients’ CRF over time. The electronic system could 
then alert clinicians to current trials or existing evidence-based interventions when 
CRF persists over time within a patient. It would be interesting to examine whether 
these methods also facilitate improved patient identification and recruitment for 
fatigue interventional studies.
Patient involvement in intervention research
Another way to facilitate patient recruitment would be to collaborate more intensively 
with patients and patient organisations in intervention research. In addition to the 
limited time available in consultations, another well-known barrier to successful 
patient recruitment is professional gatekeeping resulting predominantly from the 
professionals’ perception that study participation might be too burdensome [21]. 
While this might be true for some patients, this cannot be generalized to the entire 
population. In fact, in one of the studies presented in this thesis we clearly demonstrated 
that gatekeeping is not justified from the patients’ perspective, with 93% of patients 
receiving cancer treatment with palliative intent agreeing to at least be informed about 
fatigue interventional studies. Unfortunately, we also experienced gatekeeping in the 
TIRED study. In addition, attitudes of defeatism were observed within clinicians, such 
as undermining that CRF is a symptom that can be effectively treated also in patients 
with incurable cancer. Indeed, the optimal approach for addressing CRF in patients 
receiving cancer treatment with palliative intent is yet to be determined, but there 
is substantial evidence from patients during and after adjuvant treatment for more 
common cancers [10, 22, 23] that CRF can be effectively treated. In light of the new 
era of patient-centred health care, it seems only reasonable to enable patients to also 
take a more active role in making their own decisions on participating in supportive 
care research. Consequently, participants for the previously described experimental 
SCE study in patients with CML were not only recruited by haematologists but also 
directly via an online platform for patients and health care professionals (http://www.
cmylife.nl). Furthermore, a recently completed trial on the efficacy of a web-based 
version of CBT for severe fatigue in disease-free breast cancer survivors included both 
clinician-referred as well as self-referred patients. Self-referrals were successfully 
recruited via announcements on social media (i.e. Facebook and Twitter), on websites 
of the participating hospitals, and in local newspapers. In total, 42% (n=56/132) of the 
entire study sample consisted of self-referred patients (Abrahams et al., submitted 
for publication). We believe that efforts to promote patient-centredness should not be 
restricted to clinical care. Instead, intervention research should also be respectful of 
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and responsive to patient preferences, needs, and values. Therefore, it is suggested 
to place individual patients at the centre of what we do by informing all patients 
about available supportive care trials, e.g. by using social media, brochures in 
waiting rooms, websites, and newspapers. If patients are interested they can decide 
to discuss study participation with their health care provider instead of the other 
way round. This may also overcome the possibility of selection bias resulting from 
professional gatekeeping or attitudes of defeatism in health care providers.
Home-based, e-Health, and technology-enhanced interventions
Although the overall participation rate of identified and eligible patients (61%; 
n=122/201) was satisfactory, one of the main reasons for refusal of participation in 
the TIRED study was that participation was perceived as too burdensome. The two 
interventions under examination were delivered at or near the hospital where the 
patient was undergoing cancer treatment and involved weekly sessions in a period of 
12 weeks. For future trials, we recommend researchers to consider transitioning from 
traditional clinic-based intervention delivery to home-based delivery using e-Health 
technologies. The World Health Organization defined e-Health as “the transfer 
of health resources and health care by electronic means” [24]. There are specific 
advantages to the use of Internet-based interventions in addressing CRF in patients 
with incurable cancer. First and foremost, it allows patients to receive the intervention 
at their own environment reducing travel burden and creating more efficient and 
convenient delivery of the intervention. As a result, health care professionals might 
also be more likely to refer patients for participation in these studies because the 
burden of participation is limited. Potential disadvantages of home-based Internet-
assisted delivery also need to be acknowledged, such as getting participants to use 
the technologies at a high enough frequency over a specified duration to receive 
the desired dose of the intervention. Evidently, before transitioning to home-based 
or e-Health interventions, the first step for researchers would be to gauge how this 
patient population feels about these new ways of intervention delivery and what 
expectations and wishes they have. In addition to the Internet-assisted delivery 
channel of the intervention, one might also consider incorporating more technology 
in fatigue interventions itself. For example, as part of CBT for fatigue, cancer patients 
will often be advised to go to bed and wake at the same time each day to reduce 
bed and wake time variability and reset the biological clock. Smart phone technology 
may assist patients by alerting them 15 minutes prior to the scheduled bedtime 
and set automated alarms in the morning. Furthermore, wearable technologies 
such as smart watches or activity trackers provide both monitoring and real-time 
feedback applications and may facilitate the implementation of home-based exercise 
interventions. In addition, the use of automated responses in cognitive behavioral and 
exercise interventions might be a practical solution to reduce the amount of therapist 
time needed to deliver the intervention. For example, feedback on the sleep-wake 
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pattern or the distribution of activities in CBT for fatigue could be delivered by using 
automated responses based on predefined algorithms.
CONCLUDING REMARKS
To conclude, this thesis added to a better understanding of the prevalence, impact, 
and associated factors of CRF in patients with a rare cancer diagnosis. Research on 
severe fatigue in this population is scarce but our studies suggested that, despite the 
somewhat higher prevalence of severe fatigue, the impact and associated factors do 
not differ from patients with more common cancer diagnoses. This implies that these 
patients might also benefit from existing (adapted) evidence-based interventions for 
CRF. In addition, patients with incurable cancer have been relatively understudied in 
the area of CRF intervention research. Conducting high quality intervention research 
in this population by using a ‘golden standard’ RCT is particularly challenging. There 
is currently a lack of evidence around the benefits of exercise and psychosocial 
interventions for CRF in these patients. In the near future, we will complete a multicentre 
three-armed RCT that has the potential to significantly add to our knowledge on how 
to best address CRF in the growing population of patients living with a diagnosis of 
incurable cancer that are increasingly receiving life-extending cancer treatment. 
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Appendix
SAMENVATTING
Dit proefschrift is gericht op aan kanker gerelateerde vermoeidheid met bijzondere 
aandacht voor populaties die weinig bestudeerd zijn binnen de psychosociale 
oncologie, namelijk patiënten met een zeldzame kanker diagnose en patiënten 
met ongeneeslijke kanker. Hierna worden de verschillende hoofdstukken van het 
proefschrift samengevat en praktische implicaties en aanbevelingen voor toekomstig 
onderzoek voorgesteld.
Hoofdstuk 1 geeft een algemene inleiding over onderzoek naar aan kanker gerelateerde 
vermoeidheid. Ondanks het feit dat vermoeidheid een veelvoorkomend symptoom is 
bij patiënten met kanker, wordt het nog steeds te weinig gerapporteerd door patiënten, 
wordt het onvoldoende herkend en onvoldoende behandeld. Met name het onderzoek 
naar de prevalentie, gevolgen en behandeling van ernstige vermoeidheid bij patiënten 
met een zeldzame of ongeneeslijke vorm van kanker is schaars.
DEEL I: VERMOEIDHEID BIJ PATIËNTEN MET EEN 
ZELDZAME VORM VAN KANKER
Hoofdstuk 2 richt zich op het vaststellen van de prevalentie van ernstige vermoeidheid 
bij patiënten waarbij kanker tijdens de adolescentie en jong volwassenheid (AYA) 
werd gediagnosticeerd. Tevens wordt onderzocht wat de impact is van ernstige 
vermoeidheid en welke factoren hieraan bijdragen. Een diagnose van kanker op 
de leeftijd van 18 tot 35 jaar is zeldzaam. Ernstige vermoeidheid op basis van een 
gevalideerde afkapwaarde kwam voor bij 48% (n=40/83) van de deelnemende AYA’s 
met kanker die een gespecialiseerde AYA polikliniek bezochten. Dit percentage is 
aanzienlijk hoger dan de prevalentie in de algemene populatie, waarin slechts 20% 
van de op leeftijd en geslacht gematchte groep ernstig vermoeid is. Ernstig vermoeide 
AYA’s met kanker hebben een aanzienlijk lagere kwaliteit van leven, zowel op fysieke, 
psychologische, sociale als spirituele domeinen. De ernst van de vermoeidheid was 
geassocieerd met geslacht (vrouw), werkeloosheid (of niet studerend), een gevorderd 
stadium van kanker bij diagnose, actieve behandeling ten tijde van het invullen van de 
vragenlijst, palliatieve intentie van de behandeling en eerdere radiotherapie. Daarnaast 
waren ook angst voor terugkeer van de kanker en psychische distress geassocieerd 
met hogere vermoeidheidsscores. De bevindingen van deze studie benadrukken het 
belang van zorgvuldige aandacht voor vermoeidheid bij AYA’s met kanker. Op grond 
van de resultaten is het aan te bevelen met regelmaat te screenen op de aanwezigheid 
van ernstige vermoeidheid en om behandelbare factoren te identificeren (bijvoorbeeld 
psychische klachten en slaapstoornissen), niet alleen tijdens de behandeling, maar 
ook na afronding van de behandeling.
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Hoofdstuk 3 beschrijft de resultaten van een studie over aan kanker gerelateerde 
vermoeidheid bij patiënten met zeldzame gastro-intestinale stroma tumoren (GIST). 
We gebruikten een gevalideerde afkapwaarde voor ernstige vermoeidheid om de 
prevalentie van vermoeidheid in een steekproef van 89 patiënten met GIST te bepalen. 
De steekproef omvatte patiënten met zowel gelokaliseerde als gemetastaseerde 
ziekte die op de polikliniek medische oncologie en chirurgische oncologie behandeld 
werden. Eenenzestig patiënten (69%) werden op het moment van deelname aan het 
onderzoek behandeld met tyrosine kinase remmers (TKIs). Ernstige vermoeidheid 
kwam voor bij 30% (n=27/89) van de patiënten met GIST en bij 33% (n=20/61) van de 
patiënten met GIST die met een TKI behandeld werden. De prevalentie van ernstige 
vermoeidheid was significant hoger bij patiënten met GIST in vergelijking met de 
controlepersonen uit de algemene populatie, die gematched waren op geslacht en 
leeftijd. Ernstig vermoeide patiënten met GIST rapporteerden een lagere kwaliteit van 
leven en waren significant meer beperkt op het gebied van lichamelijk, emotioneel, 
cognitief en sociaal functioneren in vergelijking met niet vermoeide patiënten met 
GIST. De ernst van de vermoeidheid was geassocieerd met het gebruik van een TKI, 
meer psychische distress en verminderd lichamelijk functioneren. Het staken van de 
behandeling met een TKI vanwege ernstige vermoeidheid is in het algemeen geen 
optie, maar voor de andere geassocieerde factoren (psychische klachten en verlaagd 
fysiek functioneren) kunnen psychosociale interventies en interventies gericht op 
lichamelijke activiteit een nuttige aanpak zijn. Artsen kunnen een cruciale rol spelen 
door ernstig vermoeide patiënten te informeren over de bijdrage van psychosociale 
en gedragsmatige factoren aan de vermoeidheid en door hen te verwijzen naar hierop 
gerichte en bewezen effectieve interventies.
Hoofdstuk 4 richt zich op vermoeidheid bij patiënten met een andere zeldzame 
vorm van kanker, chronische myeloide leukemie (CML). Deze tot het begin van dit 
millennium dodelijke vorm van kanker heeft zich als gevolg van de introductie van 
TKIs ontwikkeld tot een chronische ziekte met een levensverwachting die voor de 
meeste patiënten niet van de algemene populatie verschilt. Patiënten moeten de TKIs 
echter voor onbepaalde tijd gebruiken en velen van hen lijden aan TKI gerelateerde 
vermoeidheid. Wij hebben een bewezen effectieve interventie voor vermoeidheid bij 
patiënten genezen van kanker, namelijk cognitieve gedragstherapie (CGT), toegespitst 
op de specifieke behoeften van patiënten met CML die chronische behandeling met 
TKIs krijgen. De interventie werd geanalyseerd volgens een in de literatuur beschreven 
model. Door middel van semi-gestructureerde interviews met CML patiënten en 
zorgverleners werden de reacties op de bestaande inhoud en vorm van de interventie 
gepeild. In aanvulling op de inbreng van patiënten en zorgverleners werd ook 
feedback gevraagd aan deskundigen op het gebied van vermoeidheidsinterventies. 
Mede om de reisbelasting te verminderen, werd de overgang van een face-to-face 
interventie naar een interventie via het internet op basis van video-telefonie (Face-
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time) via iPads voorgesteld. De resultaten lieten zien dat patiënten open stonden 
voor het gebruik van de op CML toegespitste interventie en positief waren over het 
volgen van de interventie via Internet. Het bleek nodig een nieuwe psycho-educatieve 
module over de ziekte CML en de behandeling ervan toe te voegen aan de bestaande 
inhoud. De resultaten van deze studie vormden de basis voor een onderzoek dat 
de bruikbaarheid, haalbaarheid en effectiviteit van deze toegespitste CGT voor TKI 
gerelateerde vermoeidheid bij CML onderzoekt. Deze studie loopt momenteel in de 
Verenigde Staten.
DEEL II: VERMOEIDHEID BIJ PATIËNTEN MET 
ONGENEESLIJKE KANKER
In Hoofdstuk 5 hebben we gekeken naar de overeenstemming tussen patiënten 
met ongeneeslijke kanker en hun mantelzorgers met betrekking tot de ernst van 
de vermoeidheid van de patiënt tijdens de behandeling van kanker met palliatieve 
intentie. In een longitudinale studie hebben we onderzocht in hoeverre patiënten en 
mantelzorgers overeenstemming hadden over de ernst van de vermoeidheid van de 
patiënt. De ernst van de vermoeidheid werd gemeten met een totaalscore en op basis 
van een gevalideerde afkapwaarde. Honderdzeven patiënten en hun mantelzorgers 
vulden vragenlijsten in bij aanvang van het onderzoek, waarvan 69 koppels zes 
maanden later de vragenlijsten opnieuw invulden. Bij aanvang van het onderzoek 
overschatten mantelzorgers de ernst van de vermoeidheid van patiënten. Tegelijkertijd 
was er in 76% van de koppels overeenstemming over de aanwezigheid of afwezigheid 
van ernstige vermoeidheid. Op groepsniveau veranderde de overeenstemming niet 
in zes maanden. Echter, binnen koppels was er een tendens om ofwel het eens te 
zijn ofwel het eens te worden over de ernst van de vermoeidheid van de patiënt. 
Naast de overeenstemming bij aanvang, waren de ernst van de eigen vermoeidheid 
en de belasting van de mantelzorger voorspellers van hun beoordeling van de ernst 
van de vermoeidheid van patiënten. Tijdens consulten waarin belangrijke besluiten 
over de medische behandeling moeten worden genomen kan een beoordeling van de 
vermoeidheid van patiënten door mantelzorgers, oncologen voorzien van een vollediger 
beeld van de vermoeidheid van de patiënt. Dit kan tevens het gesprek faciliteren over 
hoe goed patiënten de medische behandeling verdragen. Het is echter van belang om 
rekening te houden met de vermoeidheid en belasting van de mantelzorger wanneer 
zij uitspraken doen over de ernst van de vermoeidheid van de patiënt, aangezien de 
reactie van de mantelzorgers gekleurd kan zijn door de eigen mate van vermoeidheid.
Hoofdstuk 6 beschrijft de resultaten van een Cochrane systematische review en 
meta-analyse van gerandomiseerde en gecontroleerde studies die het effect van 
psychosociale interventies op vermoeidheid bij patiënten met ongeneeslijke kanker 
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tijdens systemische behandeling met palliatieve intentie hebben onderzocht. In de 
subgroep meta-analyse konden we gegevens opnemen uit 12 studies (n=535). De 
bevindingen bieden geen ondersteuning voor de effectiviteit van psychosociale 
interventies voor het verminderen van vermoeidheid direct na de interventie. Er waren 
bronnen van potentiële bias, waaronder een gebrek aan beschrijving van de methoden 
van blindering bij toewijzing van een interventie aan deelnemers en blindering ná 
toewijzing, alsmede de kleine omvang van de steekproef. De algehele kwaliteit van 
het bewijs wordt als zeer laag beschouwd. Hierdoor verschilt het werkelijke effect 
waarschijnlijk aanzienlijk van de schatting van het effect. Op dit moment is er 
onvoldoende bewijs dat psychosociale interventies de vermoeidheid van patiënten 
met ongeneeslijke kanker, die behandeld worden met palliatieve intentie, kunnen doen 
verminderen. Aanvullende studies met een grotere steekproef zijn nodig. Bovendien 
dienen studies hun focus te verbreden door zich niet alleen te richten op patiënten met 
uitgezaaide borstkanker, aangezien niet bekend is of de bevindingen uit deze meest 
bestudeerde patiëntengroep ook gelden voor patiënten met andere kankerdiagnoses. 
Op grond van het voorgaande wordt aanbevolen om multicenter studies te initiëren die 
kortdurende interventies over een periode van enkele weken of maanden onderzoeken 
en die een follow-up evaluatie hebben kort na afloop van de interventie.
Als gevolg van de steeds langduriger behandeling van patiënten met ongeneeslijke 
kanker zijn aspecten van kwaliteit van leven en symptoombestrijding nog belangrijker 
geworden. Vermoeidheid is een van de meest voorkomende symptomen tijdens de 
systemische behandeling van ongeneeslijke kanker, maar er is onvoldoende bewijs 
dat psychosociale interventies en interventies gericht op fysieke activiteit voor 
vermoeidheid in deze specifieke populatie effectief zijn. Hoofdstuk 7 beschrijft de 
opzet en rationale voor een multicenter driearmige, gerandomiseerde en gecontroleerde 
interventiestudie bij patiënten met ongeneeslijke kanker waarin het effect van graded 
exercise therapie (GET; therapie gericht op een verbetering van de lichamelijke conditie 
door stapsgewijze toename van lichamelijke activiteit) of cognitieve gedragstherapie 
(CGT; therapie gericht op het veranderen van gedachten en gedrag die de vermoeidheid 
in stand houden) vergeleken wordt met gebruikelijke zorg. GET en CGT worden 
gegeven gedurende 12 weken in aanvulling op gebruikelijke zorg. Gebruikelijke zorg 
omvat behandeling in overeenstemming met de nationale en regionale oncologische 
richtlijnen voor de klinische praktijk. De primaire uitkomstmaat in de studie is ernst van 
de vermoeidheid. Secundaire uitkomstmaten zijn functionele beperkingen en kwaliteit 
van leven. De effecten van beide interventies zullen worden gemeten op baseline, 
direct na de interventie (14 weken) en bij follow-up 18 en 26 weken na randomisatie. 
De uitkomsten direct na de interventie worden voor iedere interventie apart vergeleken 
met de uitkomsten van de deelnemers die alleen gebruikelijke zorg hebben gekregen. 
We streven naar het randomiseren van in totaal 219 ernstig vermoeide patiënten uit 
negen ziekenhuizen.
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Kort na de start van het interventieonderzoek beschreven in hoofdstuk 7 ondervonden 
wij problemen met het werven van deelnemers voor de studie. Eén van de belangrijkste 
belemmeringen voor succesvolle identificatie en inclusie van deelnemers voor 
studies gericht op palliatieve of ondersteunende zorg is professionele gatekeeping. 
Deze gatekeeping is vaak gerelateerd aan de perceptie van de zorgprofessional dat 
deelname aan de studie te belastend voor de patiënt is. In Hoofdstuk 8 hebben 
we onderzocht of professionele gatekeeping van patiënten met ongeneeslijke kanker 
voor een interventiestudie gericht op ernstige vermoeidheid gerechtvaardigd was 
vanuit het perspectief van de patiënt. In totaal hebben 229 patiënten in het kader van 
reguliere zorg een screeningsvragenlijst voor vermoeidheid ingevuld voor aanvang 
van (een nieuwe lijn) systemische behandeling. Daarnaast werd patiënten gevraagd 
of zij akkoord gingen met benadering door een onderzoeker indien er sprake was 
van ernstige vermoeidheid. In totaal stemde 93% (n=212) van de patiënten in met 
benadering door een onderzoeker om geïnformeerd te worden over de interventiestudie 
gericht op ernstige vermoeidheid. Er werd geen verschil gezien tussen patiënten die 
behandeld werden met curatieve (n=108) of palliatieve intentie (n=106), ten aanzien 
van hun instemming om geïnformeerd te worden (91% versus 93%). Bovendien 
stemde 90% van de ernstig vermoeide patiënten die systemische behandeling met 
palliatieve intentie kregen in met benadering door een onderzoeker. De meerderheid 
van de patiënten die een screeningsvragenlijst voor vermoeidheid invulde, wilde dus 
ook geïnformeerd worden door een onderzoeker over beschikbare interventiestudies 
voor ernstige vermoeidheid, ongeacht de intentie van de behandeling. Onze 
bevindingen impliceren dat er geen noodzaak is voor goed bedoelde bescherming 
van patiënten die behandeling met palliatieve intentie krijgen door hen informatie over 
interventiestudies voor vermoeidheid te onthouden.
Hoofdstuk 9 beschrijft de lessen die geleerd zijn ten aanzien van de identificatie 
en werving van patiënten voor het interventieonderzoek beschreven in hoofdstuk 7. 
Hoewel voldoende potentiële kandidaten beschikbaar waren, was de inclusie lager 
dan verwacht. Als gevolg hiervan was het noodzakelijk om onze oorspronkelijke 
inclusiecriteria aan te passen, het aantal deelnemende centra uit te breiden en de 
duur van de wervingsperiode te verlengen. Er waren belemmerende factoren voor 
de werving bij de arts en verpleegkundige, op het niveau van de patiënt en de 
ziekenhuisorganisatie. Tussen januari 2013 en december 2016 werden in totaal 201 
patiënten geïdentificeerd die in aanmerking zouden kunnen komen voor deelname aan 
de studie waarvan er uiteindelijk 122 werden gerandomiseerd. De inclusiesnelheid 
varieerde sterk tussen de centra. De meest genoemde reden voor het weigeren van 
deelname door patiënten was dat studiedeelname door hen als te belastend werd 
beschouwd (52%; n=41/79). Ethische regels en voorschriften vereisen dat een lid van 
het behandelteam, zoals een arts of verpleegkundige, de studie bij een potentiële 
kandidaat introduceert voordat de onderzoeker hen informeert. Deze zorgprofessionals 
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zijn echter vaak te druk om patiënten te screenen op geschiktheid en de studie te 
introduceren. De zeer strikte oorspronkelijke inclusiecriteria en studieprocedures 
belemmerden artsen en verpleegkundigen verder in het introduceren van de studie 
aan patiënten. Het betrekken van toegewijde lokale coördinatoren, in het bijzonder 
researchverpleegkundigen die tijd hebben om potentiële kandidaten te identificeren, 
blijkt van essentieel belang in het succesvol identificeren van patiënten.
In Hoofdstuk 10 worden de praktische implicaties van de bevindingen beschreven en 
aanbevelingen voor toekomstig onderzoek voorgesteld. Het proefschrift heeft geleid 
tot een beter begrip over de prevalentie van aan kanker gerelateerde vermoeidheid 
bij patiënten met een zeldzame kanker diagnose. Daarnaast heeft het inzicht gegeven 
in wat de impact is van ernstige vermoeidheid en welke factoren hieraan bijdragen. 
Onderzoek naar ernstige vermoeidheid in deze populatie is schaars. De studies die zijn 
beschreven in dit proefschrift laten zien dat ondanks de ietwat hogere prevalentie van 
ernstige vermoeidheid bij patiënten met een zeldzame kanker diagnose, de impact en 
de factoren die hieraan bijdragen niet verschillen ten opzichte van patiënten met meer 
voorkomende kanker diagnoses. Hieruit volgt dat patiënten met zeldzame kanker 
diagnoses mogelijk ook kunnen profiteren van bestaande (aangepaste) bewezen 
effectieve interventies voor aan kanker gerelateerde vermoeidheid. Vermoeidheid 
bij patiënten met een ongeneeslijke vorm van kanker wordt eveneens relatief weinig 
bestudeerd. Dit geldt in het bijzonder voor interventieonderzoek naar aan kanker 
gerelateerde vermoeidheid. Het uitvoeren van gerandomiseerde en gecontroleerde 
studies, de ‘gouden standaard’ voor interventieonderzoek, is niet eenvoudig. 
Er is op dit moment onvoldoende bewijs dat met interventies gericht op fysieke 
activiteit of met psychosociale interventies de vermoeidheid van deze patiënten 
verminderd kan worden. In de nabije toekomst zullen wij een uniek en grootschalig 
interventieonderzoek afronden dat in belangrijke mate zal bijdragen aan de kennis 
over hoe aan kanker gerelateerde vermoeidheid het best aangepakt kan worden in 
de steeds groter wordende populatie van patiënten die leven met een diagnose van 
ongeneeslijke kanker en daarvoor steeds meer en langduriger behandeld worden.
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mooi mens, maar ook een fantastisch medisch oncoloog in spé.
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Lieve Bart en Mirte, mijn grote broer en schone zus, er was vanuit jullie nooit 
een tekort aan steun, afleiding en aanmoediging, waarvoor mijn grote dank. De 
gezamenlijke weekenden in Brabant, Texel of Italië deden mij altijd goed en ik kijk er 
nu al naar uit jullie in Boston te ontvangen. We vinden elkaar in een passie voor het 
goede leven, zijn echte familiemensen en hebben aan ambitie geen gebrek. Ik ben 
ontzettend trots op alles wat jullie zo ‘meesterlijk’ hebben bereikt. Liefste Femke en 
Siem, jullie zorgden er met jullie vrolijke energie vaak genoeg voor dat ik even vergat 
dat ik een proefschrift moest afronden. Ik ben een apetrotse tanti.
Lieve Papa en Mama, jullie kennen de ups en downs van mijn promotietraject. Maar 
hoe zwaarder de storm, hoe mooier de regenboog. Die ervaring hebben we als familie 
al eerder opgedaan. Jullie zijn er onvoorwaardelijk en altijd voor mij, op afstand of 
dichtbij en in praktische of emotionele zin. Dank voor de goede basis en het juiste 
moreel kompas dat jullie mij hebben meegegeven. Niets dan liefde! ♥
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